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ABSTRACT  
The integrity of blood vessels is critical to vascular homeostasis. The present study 
investigates how microRNAs (miRNA) and fluid shear stress (FSS) impact on 
vascular integrity. 
In the first part of this thesis, the roles of miR-23a and miR-23b were investigated. I 
have demonstrated they differently regulate vascular permeability and angiogenesis 
both in vitro and in vivo. These differences were caused by that miR-23a and miR-23b 
preferentially regulates junctional adhesion molecule C and zonula occludens protein 
2, respectively. The difference in potency was attributed to differences in a single 
nucleotide outside the seed sequence. This study demonstrates a concept not hitherto 
appreciated, that miRNAs paralogues can have profoundly different effects on 
endothelial cell (EC) function due at least partially to selective effects on target 
proteins.  
In the second part of this thesis, the role of miR-27a was investigated in cerebral 
cavernous malformations (CCM). CCM lesions are characterised by disruptive EC 
junctions, with changes in the expression and location of vascular endothelial cadherin 
(VE-cadherin). I demonstrated that miR-27a was increased in EC islolated from the 
brains of the mice with CCM. BlockmiR CD5-2 specifically blocks the interaction of 
miR-27a with its target, VE-cadherin. CD5-2 rescued key CCM downstream 
signalling including RhoA activity, the inflammatory response and disruptive EC 
junctions in cultured EC. In CCM neonatal animal models, it markedly reduced CCM 
lesions in the hindbrain and retina.  
CCM lesions only develop in regions where blood velocity is low. The third part of 
this thesis was focussed on investigations into how FSS affects CCM downstream 
signalling in cultured EC. I demonstrated that key CCM downstream signalling 
	 xiv	
pathways were deregulated under low FSS but not high FSS. Furthermore, CCM-
silence-induced disruptive EC-EC junction, inflammatory response and increased 
RhoA activity were rescued by high FSS. These data establish that FSS acts as a key 
regulator for CCM gene function and may determine CCM lesion sites. 
Collectively, these studies demonstrated the novel role of miRNA and FSS in the 
regulation of vascular integrity. MiRNA-based drug targeting VE-cadherin may have 
therapeutical potential for the treatment of vascular malformations such as CCM. 
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INTRODUCTION 
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1.1 VASCULAR INTEGRITY 
The vascular system is comprised of an extremely large number of vessels, including 
blood and lymph vessels, which carry blood and lymph to and from all parts of the 
body1-3. The vessels function to carry blood to deliver oxygen and nutrients to the 
body tissues and remove cellular and metabolic waste products4-6. The lymph vessels 
carry lymphatic fluid and white blood cells through the lymphatic system, which helps 
protect and maintain the fluid environment of the body2.  
The term “vascular integrity” is usually used to refer to the capacity of the blood 
vessels to properly exert all its normal functions, including retaining and passage of 
components of blood and regulation of blood flow7, 8. Therefore vascular integrity is 
critical to vascular homeostasis.  
The vasculatures vary from normal to diseases, from organ to organ and even from rest 
and active conditions. Therefore, the maintenance of vascular integrity is not a static 
but rather dynamic process, which is constantly and tightly regulated by many factors9. 
Despite enormous progress to understand the vessel formation and maintenance, we 
are still a long way from a complete elucidation of how vascular integrity is regulated. 
This is particularly important for the development of novel therapeutic strategies for 
vascular dysfunction associated diseases, where changes in vascular integrity are 
hallmarks of the pathology. Such diseases include some of the most life-threatening 
diseases like cardiovascular and cerebrovascular diseases, cancer and diabetes10-15. 
1.1.1 CLASSIFICATION OF VASCULAR SEGMENTS 
There are three major types of blood vessels namely artery, capillary, and vein (Figure 
1.1). Each of them has distinct structures and physiological functions. 
1.1.1.1 Arteries 
CHAPTER 1 
	 3	
 The Arterial system can be classified into systemic arteries (muscular and elastic 
arteries) and pulmonary arteries. Systemic arteries deliver blood to the arterioles, and 
then to the capillaries. They can be classified as elastic arteries, muscular arteries and 
arterioles. Elastic arteries are majorly the large vessels such as aorta and the 
pulmonary artery. The aorta is the largest artery in the body16. It begins at the top of 
the left ventricle, where the heart pumps the blood. 
The pulmonary artery transports blood containing a low oxygen content from the right 
ventricle to the lungs and back to the left atrium17, 18. Muscular arteries continue from 
elastic arteries and control the distribution of blood throughout the tissues of the body.  
Arterioles are the smallest of the vessels, which range in diameter from about 5 to 100 
µm, carrying blood away from the heart and direct blood into capillaries19, 20.  
1.1.1.2 Capillaries 
Capillaries, the smallest and most numerous of the blood vessels, form the connections 
between the vessels that carry blood away from the heart (arteries) and the vessels that 
return blood to the heart (veins)21, 22. The primary function of capillaries is the rapid 
exchange of materials like gases and solutes between the blood and the target tissues23. 
There are three types of capillaries: continuous capillary, fenestrated capillary, and 
sinusoid capillary, each have a distinct structure to fulfil its physiological function. 
Capillary networks drain into postcapillary venules24. 
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Figure 1.1 Classification of blood vessels. Arteries are in red. They can branch 
repeatedly into very small branches called arterioles. Veins are in blue. Very small 
branches that collect the blood from the various tissues are called venules. Capillaries 
are thin-walled vessels that connect the arterioles and venules. Modified from 
https://www.britannica.com/science/blood-vessel 
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1.1.1.3 Veins 
After blood passes through the capillaries, it enters the smallest veins, called venules. 
These smallest and most porous of the venules are involved in solute and gas exchange 
in the tissues along with the capillary networks25. Postcapillary venules are also where 
white blood cells extravasate from the blood stream into the surrounding tissue in 
response to inflammation or infection. As blood moves into the venules, it flows 
progressively through the venous system until it returns to the heart.  
1.1.2 STRUCTURE OF BLOOD VESSELS 
The structure of the arteries, veins, and capillaries is vital for the vascular system to 
function properly. Blood vessels vary in structure to fulfil their distinctive biological 
roles. 
For example, the walls of arteries and arterioles are thicker than that of veins in order 
to keep gases and solutes in the bloodstream until they arrive at the target tissue. The 
thicker walls also help arteries to deal with constant changes in blood pressure with 
heart contractions. Capillaries are even thinner than veins to allow faster exchange of 
either small or larger molecules between tissue and the blood.  
Despite the difference between vessels, they do exhibit some homology especially for 
the large vessels like artery and vein. In general, most of the large blood vessels 
consist of three tunics as follows26: 
tunica adventitia is outermost layer of the blood vessel. It contains connective tissue 
and surrounded by an external elastic lamina to anchor vessels with surrounding 
tissues and cells like macrophages, mast cells and fibroblast. It may also include some 
nerves27.  
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tunica media is the middle layer of blood vessel wall majorly consisting  of smooth 
muscle cells and elastin fibres (external elastic lamina and collagen fibres). This layer 
is much thicker in arteries than in veins, which contain fewer elastic fibres. 
tunica intima is the innermost and thinnest layer of the blood vessel wall.  It comprises 
the endothelium and supported by subendothelial connective tissue, comprised of 
internal elastic lamina, and supportive cells.  
In contrast to large blood vessels, capillaries only consist of tunica intima with a single 
layer of endothelium and associated connective tissue. 
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1.1.3 VASCULAR PERMEABILITY 
Maintenance of vascular integrity has been conventionally regarded as a passive 
process that is largely dependent on continuous blood flow. The endothelium 
constitutes the inner cellular lining of blood vessels, and directly senses blood flow 
and regulates exchanges between the bloodstream and the surrounding tissues28-30. It is 
therefore recognized as a predominant player in the control of vascular integrity and 
vascular function, including blood fluid filtration, blood vessel homeostasis and 
vascular tone31. It is also considered as a major player in the regulation of 
inflammatory and immunological responses, another critical function of blood 
vessels32. 
There is a close relationship between the control of permeability and vascular 
integrity. Indeed, alteration of vascular permeability, which is predominately regulated 
by endothelium intactness, is one of the early hallmarks of dysfunctional vascular 
integrity8, 33. The endothelium consists of a monolayer of endothelial cells (EC), which 
adhere to each another to control proper endothelial permeability34.  
There are two types of vascular permeability, paracellular permeability and 
transcellular permeability35. The former refers to the transfer of substances, like solute, 
small molecules and cells, across an endothelium by passing through the 
interendothelial junctions between the cells. In contrast, the latter involves the travel of 
substances cross the cell, mediated by mean of transcytosis primarily through 
caveolae36. These two routes can work independently, but also work together to 
control the passage of fluids, nutrients, membrane protein and certain types of cells.  
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Figure 1.2 Transcellular and paracellular pathways in EC. The transfer of substances 
across the endothelial barrier can occur through transcellular or paracellular pathways. 
The figure was modified from citation37. 
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Paracellular permeability is regulated by a set of structural proteins such as vascular 
endothelial cadherin (VE-cadherin), zonula occludens-1 (ZO-1), junctional adhesion 
molecule C (JAM-C) and	semaphorin-6A (SEMA6A). These proteins are involved in 
homophilic or heterophilic interactions between attractive (e.g. VE-cadherin, ZO1) 
and repulsive (e.g. JAM-C, SEMA6A)38 membrane molecules and associated 
signalling pathways.  
Transcellular permeability is mediated by caveolae, vesiculo-vacuolar organelles 
(VVOs), and fenestrae39. Under basal conditions, the transcellular vesicular pathway is 
responsible for the active transport of macromolecules such as albumin40.  
1.1.4 ENDOTHELIAL CELL-CELL JUNCTIONS 
Increased permeability is often a result of disruptive junctional adhesions, caused by 
destabilization EC junction or reorganization of the actin cytoskeleton41, 42. There are 
three types of interendothelial junctions: adherens junctions (AJ), tight junctions (TJ) 
and gap junctions (GJ). Each is formed by different junctional molecules and control 
different features of vascular homeostasis, although they also share some functions in 
common.  
AJs and TJs maintain the endothelial barrier, whereas gap junctions form channels 
between neighboring cells that pass H2O and other small molecules, including 
signalling molecules between cells. Although GJ proteins exist in the EC junction 
area, only AJ and TJ contribute to the structural integrity of the endothelium43. In both 
types of junctions, adhesion is mediated by the clustering of transmembrane proteins 
through homophilic interactions. As a result, they form a zipper-like structure along 
the cell border. Although AJs and TJs have different functions and molecular 
components, there is cross-talk between them43. Indeed, AJs are formed at early stages 
of intercellular contacts prior to formation of TJ organization and TJ formation is 
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dependent on AJ formation44. Therefore AJs influence TJ organization45.  
Junctional proteins of both AJs and TJs also are linked to cytoskeletal proteins through 
their intracellular tails43. This association is required for stabilization and dynamic 
regulation of opening and closing of the junctions44. In addition junctional proteins act 
as signalling proteins, interpreting the extracellular milieu, and transfering signals to 
intracellularly45. 
1.1.4.1 Adherens junctions (AJ) 
In ECs, AJs initiate cell-cell contacts and promote their maturation and 
maintenance46.The principle component of the AJs is VE-cadherin and its associated 
binding partners47. Deletion VE-cadherin leads to early embryonic lethality indicating 
it is critical for the organization of a stable vascular system in development48. In 
adults, it controls vascular permeability and angiogenesis47.  
VE-cadherin consists of an ectodomain region composed of five extracellular repeat 
domain, a single transmembrane domain, and a short cytoplasmic domain49, 50. The 
extracellular region of VE-cadherin mediates homophilic interactions via cis- and 
trans-associations51. The transmembrane domain of VE-cadherin binds to VEGFR2 
and VEGFR3 to facilitate the response to external stimuli such as fluid shear stress 
(FSS)52. The cytoplasmic tail binds to a number of partners, including p120-catenin, β-
catenin, and plakoglobin53, 54. The binding is critical to the maintenance of vascular 
integrity. p120-catenin binds to the transmembrane adjacent domain of VE-cadherin to 
reduce endocytosis36, 55. β-catenin links VE-cadherin and actin cytoskeleton to 
stabilize VE-cadherin trans-interaction56. Further, VE–cadherin may associate with the 
vimentin cytoskeleton mediated by plakoglobin57. VE-cadherin is also linked to a large 
set of actin binding proteins including α-catenin, vinculin, α-actinin and eplin to 
regulate cytoskeleton58-60. 
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1.1.4.2 Tight junctions (TJ) 
TJs are the areas where lateral membranes between adjacent ECs were fused. TJs 
regulate the passage of ions and solutes through the paracellular route. TJs are 
particularly enriched in the vessels where permeability is strictly controlled such as in 
the brain microcirculation. TJs account for about 20% of the total junctional proteins 
in ECs. The most important components of TJs that promote cell-cell adhesion are 
members of the claudin family especially claudin-5, which is an EC-specific 
transmembrane adhesion protein61, 62. 
Structurally TJs are variable among different segments of the vascular tree. Arteries 
consist of two to seven well-developed TJs between EC, whereas in venular parts, 
there is only one to three discontinuous TJs63. The functions of TJs include the barrier 
(or gate) function, controlling the passage of ions, water, and various macromolecules, 
and the fence function, maintaining cell polarity43. TJs are particularly enriched in the 
central nervous system (CNS) and play an important role in regulation of blood–brain 
barrier (BBB) and the blood retinal barrier (BRB)64. TJs are composed of both 
transmembrane (e.g. occludins, claudins and junctional adhesion molecules (JAMs)) 
and intracellular molecules (e.g. zonula occludens (ZOs)). Claudin family members 
are the major TJ transmembrane constituents. They bind to each other in a homotypic 
and heterotypic manner through their extracellular domains65, 66.  
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Figure 1.3 Transmembrane adhesive proteins at endothelial junctions. There are 2 
types of EC junctions. In the tight junctions, adhesion is mediated by claudins, 
occludin and JAMs. At adherens junctions, adhesion is mostly promoted by VE-
Cadherin, which, through its extracellular domain, is associated with vascular 
endothelial protein tyrosine phosphatase (VE-PTP). Outside these junctional 
structures, platelet endothelial cell adhesion molecule (PECAM) is also a major 
contributor to endothelial cell–cell adhesion43 34. Figure was modified from citation33. 
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regulated by cell-cell junctions whereas the transcellular pathway acts through specialised transport 
systems such as fenestrae and vaso-vesicular organelles (Dvorak et al., 1995). This grant focuses 
only on the regulation of the paracellular pathway.  
 
Endothelial cell junctions are organized by molecules grouped within tight junctions (TJ) (claudins, 
occludins, nectin, JAMS) (Furuse and Tsukita, 2006, Tsukita et al., 2001, Hirase et al., 1997) 
(Taddei et al., 2008, Mandicourt et al., 2007), adherens junctions (AJ) (VE cadherin, VE-PTP) 
(Nawroth et al., 2002) (Harris and Nelson, 2010) together with other cell-cell molecules such 
PECAM (Dejana, 2004). We can further add to this the angiomotin family which localize to TJ (Yi 
et al., 2011) and cerebral cavernous malformation proteins (CCM) which localize to the AJ and 
bind beta catenin (Glading et al., 2007, Kleaveland et al., 2009). The junctional molecules are not 
only structural but also transmit extracellular cues to the internal of the cell (Dejana et al., 2009a) 
through other intermediate signaling molecules such as the zonula occludens (ZO-1 and 2) 
(Traweger et al., 2008, Fischer et al., 2002) and IQGAP1 (Yamaoka-Tojo et al., 2006) (Yamaoka-
Tojo et al., 2004), all of which are also required in order to establish stable cell-cell contacts. Many 
of these proteins are linked directly or indirectly to the actin cytoskeleton and microtubules, through 
which they regulate cell behavior (Figure1). 
Fig1 
The control of EC permeability generally falls 
into two classes: one the stimuli, like 
thrombin, histamine, vascular endothelial 
growth factor (VEGF), that induce leakiness ( 
(Dvorak et al., 1995, Li et al., 2004, Bates, 
2010). The other, class of molecules like 
angiopoetin-1, sphingosine kinase and 
sphingosine-1-phosphate (Gamble et al., 2000, 
Li et al., 2008, Garcia et al., 2001) that exert a 
tonic effect on sustaining the status quo. 
Ultimately these two influences converge on 
the cell-cell junctional molecules such as VE-
cadherin and PECAM, to regulate junctional 
structure and downstream signaling events 
(Dejana et al., 2009c).  
Our contribution to this area has been to 
define cell junctions as a major regulator of 
EC function ((Litwin et al., 1997)), the initial molecular description of angiopoietin 1 as a 
junctional stabilisor (Gamble et al., 2000), the action of sphingosine kinase (Li et al., 2008) and 
JAM C (Li et al., 2009) to regulate junctions, and identification of PKCz as a signaling molecule in 
control of permeability (Li et al., 2004) ).  
 
Although many miRNAs target the overall process of angiogenesis (Suarez and Sessa, 2009, Fish et 
al., 2008, Wang et al., 2008, Anand e  al., 2010, Bonauer et al., 2009) and indirectly can affect 
permeability, there have been no reports of a miRNA that targets the specific aspect of vascular 
leak, through targeting junctional proteins. Given the critical nature of EC junctions to the 
maintenance of vascular integrity we screened for miRNA that specifically influence this aspect of 
EC biology a d h v  identified the miR-23a~27 ~24-2 cluster as important in vascular integrity. 
miR-23a~27a~24-2 cluster: 
miR-23a, miR-27a and miR-24 are derived from the intergenic cluster miR-23a~27a~24-2 located 
on chromosome 19. This cluster has attracted considerable attention recently since its expression is 
altered in many diseases including cancer and cardiac hypertrophy. Further it has effects on the 
regulation of osteogenesis, skeletal muscle development and on the regulation of the DNA damage 
response in haematopoietic cells (Lin et al., 2009a, Lin et al., 2009b). This cluster also has a role in 
angiogenesis. MiR-23a and miR-27a together regulate angiogenesis at least partially through effects 
EC# EC#
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Among the 24-members of the claudin family, claudin-5 is a key regulator of TJs 
assembly in ECs. Lower expression in claudin-5 results in decreased BBB function67, 
68. JAMs are single-pass transmembrane adhesive proteins belonging to the 
immunoglobulin (Ig) superfamily. JAMs include JAM-A (JAM-1), JAM-B (JAM-2) 
and JAM-C (JAM-3), which share 30%–40% sequence homology69. JAM-C is a 
repulsive EC junctional molecule70. Localization of JAM-C in the interendothelial 
junctions increases permeability71, 72 JAMs also have a role in lymphocyte 
transmigration via its binding to the leukocyte integrin73. 
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1.2 REGULATION OF VASCULAR INTEGRITY 
Vascular integrity is tightly controlled by endothelial barrier function responding to a 
complex set of extracellular stimuli, such as growth factors and inflammatory 
mediators33. In addition, the endothelium is continuously exposed to hemodynamic 
stimuli such as blood flow induced shear stress and diameter change in vessel tone74. 
Therefore, vascular integrity is determined by two major factors: endothelial barrier 
function and blood flow75. Consequently, these factors initiate a complex intracellular 
signalling to regulate endothelial cell-cell junction, the cell cytoskeleton, or the 
interaction between EC and other types of cells and extracellular matrix.  
1.2.1 EXTRACELLULAR STIMULI AND MEDIATORS  
Growth factors, cytokines, extracellular matrix and transcription factors are involved 
in the maintenance of vascular integrity37. Most of the effects are reversible once the 
stimuli are removed, although some agents act more rapidly than others53.  
Permeability-increasing mediators include pro-inflammatory agents such as thrombin 
and histamine, and pro-angiogenic agents such as angiopoietin-2 (Ang2) and vascular 
endothelial growth factor (VEGF)76-79. Histamine or thrombin can increase vascular 
permeability almost immediately. In contrast, VEGF or some inflammatory cytokines 
like interleukin-4, interleukin-8 may take hours to elevate permeability80-82. This 
suggests different agents may regulate vascular permeability through different 
mechanisms. The increase in permeability may or may not be through opening of 
intercellular gaps. 
Permeability-decreasing mediators include fibroblast growth factor (FGF)83, 
sphingosin-1-phosphate (S1P)84, angiopoietin-1  (Ang1)85, 86 and interleukin-10 (IL-
10)87, 88. The inhibition of FGF signalling dissociates VE-cadherin/p120-catenin 
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complex and disassembly of adherens and tight junctions, leading to severe 
impairment of the endothelial barrier function83. S1P, an endogenous bioactive lipid, 
regulates endothelial barrier function by activation of its G-protein coupled receptor 
Sphingosine-1-phosphate receptor 1 (S1PR1), resulting in subsequent downstream 
activation of the Rho family of small GTPases, cytoskeletal reorganization, AJs and 
TJs assembly89. Ang1 is a potent proangiogenic factor, acting through the endothelial 
cell-specific tyrosine kinase receptor Tie286. Unlike VEGF, which causes vascular 
permeability, Ang1 stabilizes blood vessels86, 90. Indeed, Ang1 can prevents VEGF-
induced endothelial permeability90.  
1.2.2 INTRACELLUAR PATHWAYS  
The “basic” organization of AJs is that VE-cadherin links to p120-catenin and β-
catenin or plakoglobin through its cytoplasmic domain. In response to physiological or 
pathological cues, endothelial junctions, especially AJs, affect endothelial permeability 
through phosphorylation, cleavage and internalization of VE-cadherin and its binding 
partners. 
1.2.2.1 Phosphorylation of AJ components 
As the major AJ component, VE-cadherin plays an important role in the control of 
vascular permeability and integrity. In response to extracellular stimuli, VE-cadherin 
adapts to trigger intracellular signalling through phosphorylation in its cytoplasmic 
tail91. Multiple phosphorylation sites have been reported including Y645, Y658, Y731, 
Y733, Y685 and S66592-95. Among them, phosphorylation of Tyr658 or Tyr731 are 
involved in the binding with p120-catenin and β-catenin, rescpectively93. Csk, a Src 
antagonist, has been shown to bind to Y685 of VE-cadherin95. Further studies revealed 
that Tyr685 regulates vascular permeability and Tyr731 regulates leukocyte diapedesis 
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in vivo96. Indeed, VE-cadherin is phosphorylated on Tyr658 and Tyr731 in vivo in 
veins but not in arteries under resting conditions. This difference is due to shear stress-
induced junctional Src activation in veins91.  
VEGF-A induces VEGFR2 dimerization and Src-dependent phosphorylation of the 
guanine nucleotide exchange factor Vav2, followed by activation of Rac and p21 
activated kinases (PAKs). This results in the serine phosphorylation at S665 of VE-
cadherin92. VEGF-A can also trigger the tyrosine phosphorylation of VE-cadherin at 
Y658 to dissociate VE-cadherin and its binding partner p12097, leading to loss of cell-
cell contacts and increase in endothelial permeability55. Other permeability increasing 
agents such as histamine can also induce tyrosine phosphorylation of VE-cadherin to 
alters its link to catenins and vimentin75, 98. Intriguingly, histamine only increases VE-
cadherin phosphorylation in long-confluent ECs but not in recently-confluent cells 98. 
Tumour necrosis factor α (TNFα)-induced endothelial permeability is also associated 
with tyrosine phosphorylation of VE cadherin99. 
The phosphorylation of VE-cadherin and other AJs are directly or indirectly affected 
by a range of kinases (c-Src, csk, and others) and phosphatases (protein-tyrosine 
phosphatase 1B (PTP1B), VE-PTP, Src-homology 2 domain-containing phosphatase 2 
(SHP2))42.  For example, c-Src is responsible for VEGF, thrombin and TNFα induced 
phosphorylation95, 100-106.  Csk binds via its SH2 domain to the phosphorylated tyrosine 
685 of VE-cadherin107.  
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Figure 1.4  Signalling pathways of key permeability associated factors. VEGF-A 
stimulation induces VEGFR2 dimerization and Src-dependent phosphorylation of VE-
cadherin at Y68592. Phosphorylation of VE-cadherin leads to dissociation of VE-
cadherin and its binding partners, p120 and β-catenin, which link VE-cadherin to the  
cytoskeletal actins108. VEGF-A also causes the dissociation of VE-PTP/VE-cadherin 
and triggers loss of adhesion and increase in permeability109. Ang1 activates and 
phosphorylates its cognate receptor, Tie2 at Y992, which binds and sequesters SRC 
preventing VEGFR2-SRC complexes induced by VEGFA. Consequently, it hinders 
VEGF-A signalling and VE-cadherin internalization90. In contrast, Ang2 acts as an 
apparent antagonist of Ang1110.  
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Fer or Fyn phosphorylates β-catenin at Tyr142 to destruct the formation of β-
catenin/α-catenin complex, followed by detachment of VE-cadherin from actin 
cytoskeleton111.  Protein tyrosine phosphatases can stablise the cadherin-catenin 
complex against kinase activities, which are often barrier-disruptive42. For examples, 
PTP1B prevents the dissociation of β-catenin from AJs through dephosphorylating β-
catenin at Tyr654112. PTP1B can also stabilize VE-cadherin-mediated cell-cell 
adhesions by reducing VE-cadherin tyrosine phosphorylation. Knockdown of PTP1B 
by small interfering RNA increased endothelial permeability113. VE-PTP is an 
endothelial-specific vascular endothelial protein tyrosine phosphatase.  It associates 
with VE-cadherin via both their membrane-proximal extracellular domains, 
independently of their cytoplasmic tails114. In addition, VE-PTP reduces VE-cadherin 
phosphorylation and increases the cell monolayer barrier function115. Dissociation of 
VE-PTP from VE-cadherin is also required for leukocyte extravasation and for VEGF-
induced vascular permeability115. In contrast, VE-PTP also negatively regulates Tie-2 
activation through dephosphorylation of Tie-2, leading to destabilization of endothelial 
junctions. In the absence of Tie-2, inhibition of VE-PTP destabilizes endothelial 
barrier integrity 116. Therefore VE-PTP regulates vascular integrity through a balance 
of tie-2 and VE-cadherin activities. 
1.2.2.2 Cleavage and internalization of VE-cadherin 
The amount and location of VE-cadherin also affect vascular permeability117-119. VE-
cadherin can be degraded by proteases120, 121, metalloproteases122-124, microRNAs125, 126 
and microparticles127. Elastase and cathepsin G secreted by leukocytes have also been 
reported to cleave VE-cadherin extracellular domain in haemodialysis patients128. In 
systemic inflammation, ADAM10 is involved in VE-cadherin cleavage129. Indeed, 
circulating VE-cadherin RNA and soluble VE-cadherin is linked with endothelial 
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barrier breakdown, and can be used as a biomarker for sepsis and tumour 
angiogenesis129, 130. Maintenance of VE-cadherin in the cell membrane, especially in 
the cell-cell junction area, is critical for the maintenance of vascular integrity. The 
binding with p120-catenin is critical for VE-cadherin expression by preventing its 
endocytosis and degradation108.  
1.2.3 BLOOD FLOW INDUCED SHEAR STRESS  
The vascular endothelium is under constant mechanical stimuli principally pressure 
and shear stress in the blood flow. Therefore FSS act as central regulator of vascular 
function and related to many vascular diseases. For example, the endothelium in 
straight parts of the aorta tree is exposed to pulsatile FSS with a uniformed direction, 
conferring protective effects. In contrast, disturbed or oscillatory FSS at arterial 
bifurcations, branch ostia and curvatures results in endothelial dysfunction, causing 
atherosclerosis131, 132. ECs transduce the extracellular force from blood flow into 
intracellular biochemical signalling that regulate gene expression and cell function 
through specialized mechanisms and pathways48, 123,124 
ECs sense FSS through mechanosensors, which the primary cellular structure or 
protein that senses a physical force, setting off downstream biochemical signalling 
pathways. There are a few menchanosensors have been reported in ECs to sense FSS 
(Figure 1.5). These sensors, according to their location in EC, can be grouped into 
junctional, luminal, and basal menchanosensors. 
1.2.3.1 Junctional mechanosensors 
One of the best-studied mechanosensors is a complex of proteins localized at 
endothelial cell-cell junctions, consisting of PECAM-1, VE-cadherin, VEGFR2 and, 
more recently, VEGFR352, 133. FSS increases tension of PECAM-1 via an unknown 
upstream pathway that leads to association of PECAM-1 with the vimentin 
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cytoskeleton, thereby transmitting force from myosin to PECAM-1134. The change on 
the tension on PECAM-1 activates c-Src kinase to activate VEGF receptor 2 and 
subsequently phosphorylate the p85 subunit of Phosphatidylinositol-3-OH kinase 
(PI3K) and endothelial NOS (eNOS), which has been shown to induce vasodilation134, 
135. PI(3)K inhibitors completely block integrin activation suggesting PI(3)K also 
mediates integrin activation, which is responsible for both the alignment of ECs in 
laminar shear and the activation of inflammatory signalling in response to changes in 
shear134. VE-cadherin, functioning as an adapter, associates with VEGFR2 and 
VEGFR3 through their respective transmembrane domains to mediate VEGFR 
transactivation and downstream signalling in flow133,52. In addition, VE-cadherin 
phosphorylation at cytoplasmic tyrosine Y658 can be induced by low shear stress in 
vitro and in vivo91. Indeed, phosphorylation of a small pool of VE-cadherin on Y658 is 
essential for flow sensing through dissociation of p120-catenin and binding of the 
polarity protein LGN136.  
1.2.3.2 Luminal mechanosensors 
FSS can initiate EC response through deformation of molecules on the luminal 
surface. Two of surface structures have drawn great interest: primary cilia and the 
endothelial glycocalyx (EG) and 137-142.  
Primary cilia are antennal-like structure on cell surface and were noted in 
atherosclerotic lesions back to 30 years ago143. They are more prevalent in regions of 
low and disturbed blood flow144. FSS elicits ciliary bending and disassembles their 
structure to trigger a immediate biochemical-signallling cascade that involves 
activation of polycystin proteins, followed by intracellular calcium flux and expression 
of eNOS 145, 146. Longer expose to FSS results in cytoskeleton rearrangements, leading 
to vessel remodeling147. Indeed, defects in endothelial primary cilia result in 
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inappropriate blood flow-induced responses and are associated with many vascular 
diseases, including atherosclerosis, hypertension, and aneurysms148.  
EC without primary cilia can still detect FSS though EG and transmits the force 
through the cytoskeleton146. The EG is a highly charged, glycoprotein-rich extension 
of the cell surface with a thickness of between 0.5 to 4.5 m137, 149. Inactivation of EG 
completely blocked flow-induced NO, suggesting its role in mechanosensing150, 151.  
1.2.3.3 Basal mechanosensors 
Basal mechanosensors are mainly integrins, which are membrane-associated 
glycoproteins composed of  and  subunits. The extracellular domain of these 
subunits binds directly to extracellular matrix (ECM) protein such as fibronectin, 
vitronection and collagen.	The cytoplasmic domains of both the subunits interact with 
cytoskeletal protein and other intracellular signalling molecules in the focal adhesion 
sites such as focal adhesion kinase (FAK) and c-Src the to regulate cell behavior152. 
After application of FSS on ECs, integrins are activated within 1 min, as indicated by 
their clustering, and lasts for more than 6 h153, 154. Activation of integrins then activate 
kinases in focal adhesion sites, RhoGTPases and the cytoskeletal proteins155. Blocking 
integrins attenuates the shear stress-induced signalling such as activation of  ERK, c-
Jun N-terminal kinase (JNK),  the IB complex, sterol regulatory element– binding 
proteins (SREBPs) and the attendant changes in cellular functions156. These suggest 
integrins are involved in the mechanotransductions in ECs157-159. However, the 
evidence supporting integrins as direct mechanosensors in EC is not strong. For 
example, FSS does not directly active integrin but via by PI3 kinase. More 
importantly, the amount of force applied by FSS onto integrins is much less lower than 
tration forces on integrins, suggesting integrins are not directly active by FSS. 
However, integrins could act as mechansensitive protein to sense minute FSS160, 161.  
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Figure 1.5 Mechanotransduction in EC. Blood flow induced shear stress activates ion 
channels, actin filaments, caveolae, the glycocalyx, tyrosin kinase receptors and 
adherens junction proteins152, 162-164. A mechanosensory complex, consisting PECAM-
1, VE-cadherin and VEGFR2, is the best-studied mechanotransducer in ECs9. Shear 
stress influences activation of EC  through multiple mechanisms, leading to a range of 
biological responses, such as inflammation165, cell migration166 and proliferation167. 
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investigation into blood flow patterns in lesions and the effect of 
CCM mutations and pathways on flow sensing are warranted.
Conclusions
Vascular development and remodeling are morphogenetic pro-
cesses that depend on many genes but are guided by mechanical 
forces from blood flow. This feature very likely reflects the need 
to optimize vessel morphology to carry blood with maximum effi-
ciency. Sensing of FSS by ECs is a key element of these processes. 
Our understanding of FSS sign ling, though largely incomplete, 
has reached a stage in which connections to disease are coming 
into focus. We proposed that atherosclerosis and vascular mal-
formations are, in essence, diseases of morphogenesis. That is, 
normal morphogenetic programs have gone awry, resulting in the 
generation of vessels with abnormal characteristics (summarized 
in Figure 1). Atherosclerosis may be seen as a form of futile vascular 
remodeling that occurs in an inflammatory environment at regions 
of disturbed shear. CCMs may be seen as the result of genetic 
mutations that disrupt normal homeostasis, of which flow sensing 
is a key component. Future research is likely to benefit from walk-
ing this two-way street, in which genes and processes involved in 
of flow-dependent pathways (117). Indeed, more recent data show 
that loss of the CCM complex induces flow-independent integrin 
activation (118) and that i tegrins are required for KLF2 induction 
(119). These data are again consistent with the general idea that 
loss of CCM proteins results in constitutive activation of a pathway 
that is normally regulated by flow. In this regard, it is also interest-
ing that CCMs have now been linked to EndMT (115). This transi-
tion required upregulation of BMP6, which occurred specifically 
in brain vasculature, perhaps explaining the specificity of CCMs 
for this location. On on  hand, disturbed flow can induce EndMT 
(86, 87). Conversely, downregulation of EC-specific proteins such 
as VE-cadherin and PECAM-1, which participate in flow signal-
ing, would be expected to reduce flow responsiveness. There are 
a number of different ways in which these observations might be 
related. Either low flow or low sensitivity to flow in malformations 
might sensitize the endothelium to the action of BMP6 or other-
wise contribute to EndMT. EndMT might also contribute to loss of 
flow sensitivity. In either case, the critical role of flow in regulation 
of vascular morphogenesis, including both vessel diameter and 
stabilization, suggests multiple mechanisms by which flow inde-
pendence could contribute to vascular malformations. Further 
Figure 1. Fluid shear stress sensing in physiological and pathological vascular remodeling. FSS acts on mechanosensors including the junctional mecha-
nosensory complex consisting of PECAM-1, VEGFRs, and VE-cadherin (VE-Cad), with the latter also linked to the CCM complex (CCM1, CCM2, and CCM3). 
Left: Changes in flow due to growth or exercise that result in sustained deviation from the set point result in changes in the activation state of flow- 
dependent pathways, which mediate physiological remodeling to restore normal shear stress levels. Center: Mutations in CCM genes results in abnormal 
flow sensing and pathological remodeling, with subsequent formation of abnormal, low-flow vessels. Right: Regions of disturbed flow, in the presence of 
systemic risk factors, result in pathological remodeling to form atherosclerotic plaque. β-cat, β-catenin; HEG, heart-of-glass.
Downloaded from http://www.jci.org on March  1, 2016.   http://dx.doi.org/10.1172/JCI83083
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1.3 MICRORNA in VASCULAR INTEGRITY 
MicroRNAs (miRNA) are generally considered as a negative regulator of gene 
expression. They are also emerging as an important regulator of vascular integrity168-
170. MiRNAs are a highly conserved class of endogenous small non-coding RNAs (20-
25 nucleotides), which regulate genes at the post-transcriptional stage of expression. 
The first miRNA, lin-4, was discovered in C.elegans as a negative regulator of LIN-14 
protein more than 20 years ago171. This finding exposed a new mechanism of gene 
regulation during development. Since then, approximately 2500 mature miRNAs 
(miRBase 21) have been identified in human alone, regulating more than 30% of all 
proteins expressed. 
1.3.1 miRNA BIOGENESIS 
MiRNA genes exist in animals, plants, protists and viruses. They can be either 
intergenic or intronic172, 173.  MiRNAs are processed from the introns of their hosting 
transcription units and hence share common regulatory mechanisms and expression 
patterns with its host gene. The intergenic miRNAs are transcribed as independent 
transcription units (TU) by their own promoter.  Around 50% of all mammalian 
miRNA located within other TUs174-176. These clustered miRNAs are transcribed from 
a single polycistronic transcription unit (TU), although there may be exceptional cases 
in which individual miRNAs are derived from separate gene promoters177. Some 
miRNAs are generated from non-coding TUs, whereas others are encoded in protein-
coding TUs. Approximately 40% of miRNA loci are located in the intronic region of 
non-coding transcripts, whereas approximately 10% are placed in the exonic region of 
non-coding TUs178.  
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Figure 1.6 MiRNA biogenesis pathway. The miRNA gene is transcribed to generate a 
primary miRNA (pri-miRNA), then to a precursor miRNA (pre-miRNA), which is 
further cleaved to create a miRNA duplex. The duplex unwinds and the mature 
miRNA assembles into RISC, where the miRNA base-pairs with target mRNA to 
direct gene silencing 13-16. The endogenous miRNA expression can be manipulated by 
either synthetic miRNA mimic to increase or miRNA inhibitors to suppress the 
expression of miRNAs of interest179. Figure was modified from citation180.   
In animals (Figure 1.6), miRNA genes are transcribed by RNA polymerase II to pri-
miRNAs181, which are then processed into pre-miRNAs in the nucleus by the 
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Microprocessor complex (comprising Drosha and DGCR8). Following Drosha 
processing, pre-miRNAs are exported to the cytoplasm by exportin-5 (EXP5). In the 
cytoplasm, pre-miRNAs are further cleaved by Dicer into a small, imperfect double-
stranded RNA duplex including guide strand (miRNA) and passenger strand 
(miRNA*)182. The RNA duplex is then released and subsequently loaded onto 
Argonaute (AGO) protein to form an effector complex named RNA-induced silencing 
complex (RISC)183. In humans, there are 8 AGO family members. However, only 
Argonaute2 was associated with cleavage of target mRNAs.  
Once miRNA duplex is loaded, the passenger strand is quickly excluded from RISC 
and degraded rapidly, leading to a strong preference towards the guide stand in the 
pool of mature miRNA. The thermodynamic stability of the 5’ ends of the two ends of 
the small RNA duplex is usually different. The mature strand is preferentially derived 
from the strand with a less stable terminus at the 5’ side184. In addition, AGO proteins 
also prefer to choose the strands with a U at nucleotide position 1 as guide strand185.  
However, the selection of strand is not strict. In some cases, the guide strand and 
passenger strand have similar 5’side stability, resulting to similar loading frequencies 
to RISC186, 187. Both miRNA and miRNA* are active in silencing, although one may 
be less potent than the other. This potency is usually determined by the abundance of 
the miRNA strands, which may vary from tissue to tissue. The canonical pathway of 
animal miRNA biogenesis is shown in Figure 1.7. Unlike their animal counterparts, 
plant miRNA processing is completed in the nucleus, although the pri-miRNAs are 
also transcribed by RNA polymerase II.  
1.3.2 FUNCTION OF MIRNA 
MiRNAs are post-transcriptional regulators of gene expression that have been 
implicated in diverse cellular processes such as development, proliferation, 
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differentiation and apoptosis188, 189. They function via either mRNA cleavage or 
translational repression. The first miRNA, lin-4, negatively regulates its target, lin-14, 
through repressing its translation. The mature miRNA is further manipulated to 
interact with a miRNA-protein complex, incorporating one strand of the duplex which 
acts to guide the complex to partially complementary sequences within the 3’ 
untranslated region (UTR) of target mRNAs, resulting in destabilisation or inhibition 
of translation. The miRNA recognises and binds to the target mRNA via the seed 
region; a sequence of 6 contiguous nucleotides found from position 2 -7 at the 5’-end 
of the molecule. However, it has been proposed that ancillary nucleotides at the 3’-end 
of the miRNA play an important role in target recognition190, 191. Nevertheless, target 
prediction, which is based solely on complementarity of the seed region with its target 
sequence, has proven to be extremely difficult. While each miRNA may have 
hundreds of potential target genes, it is becoming apparent that there is cell type and 
context specific selection of these targets.  
1.3.3 MIRNA TARGET PREDICTION AND IDENTIFICATION 
MiRNAs act by leading the RISC to their target mRNAs through partial 
complementarity. The seed sequence, which is in the 5’-end of the miRNA, has 
particular importance in determining the interaction with miRNA targets. It initiates 
search for targets by direct Watson-Crick base-pairing with the sequences in the 
3’UTR of mRNA. Therefore the way to identify miRNA targets is often through this 
mechanism to predict miRNA:mRNA interaction. However if consideration is only 
through the seed sequence, which is only 7 nucleotides, there would be many false 
results. Therefore, precise prediction of miRNA target remains a challenge. Over the 
last few years, many prediction tools have been developed. The most frequently used 
prediction tools include TargetScan, miRanda and DIANA microT search for miRNA 
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targets exclusively in mRNA 3’UTR. Each of these tools has been developed with 
different algorithms with different parameters. In general, miRNA sequences, 3’UTR 
of mRNA, the seed region, free energy, accessible energy and supplementary pairing 
between the target and the 3’end of the miRNA are the major parameters needed to 
consider for target prediction. Increasing evidence shows that the complementarity 
between miRNA seed region and 3’UTR of mRNA sites is not always required. Other 
parts such as 5’UTR, the coding sequence and the open reading frames, have also been 
reported as miRNA binding sites. Therefore some prediction tools, e.g. DIANA 
microT v5.0, also include these regions as parameters for prediction. Recently, a new 
approach called MirAncesTar, uses ancestral genome reconstruction to improve the 
accuracy of existing prediction tools, including Targetscan, miRMark and Diana-
microT, for human miRNAs192.  It has also been shown that miRNA regulate 
translation through the pairing between the central region of the miRNA and their 
targets193.  These non-canonical miRNA interactions are much more prevalent than we 
originally thought194. Despite prediction tools being regularly updated to take into 
account more parameters for better prediction, they still produce high rates of false 
positives and, potentially more important, such tools also result in a significant rate of 
false negatives195. In addition, different prediction programs produce different lists of 
predicted targets due to the employment of different parameters and algorithm. This 
leads to the fact that experimental data is required to identify genuine miRNA targets.  
MiRNA target identification often includes experiments in which transcriptional levels 
or more importantly corresponding gene product abundances are measured in response 
to manipulation of endogenous miRNA of interest by either genetic or oligonucleotide 
based methods. These experiments can be high throughput using proteomic or 
transcriptomic analysis. However these measures will not distinguish between direct 
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and indirect regulation. For example, miRNA of interest may target transcription 
factors, which in turn profoundly affect the gene expression that are controlled by 
these transcription factors, instead of miRNA interaction with mRNA targets.   
Luciferase reporter assays have been commonly used to demonstrate a direct binding 
between miRNA and 3’UTR of its targets. Direct binding is shown by inhibition of 
luciferase activity, which can be rescued by mutating miRNA-binding sites. 
Considering the time for cloning and generation of mutants, these methods are quite 
time-consuming and only feasible for identification of a small number of targets. To 
overcome this problem, a luciferase reporter library was set up for screening 
miRNA:mRNA binding. This library consists of 275 human 3’UTRs and identified the 
targets of miR-10b and let-7c. A larger scale of library of 1461 human 3’UTR has also 
been developed. Despite this progress, the scale of library is not sufficiently large and 
the target region is only restricted to the 3’UTR. More recently, another screening 
system using complementary DNAs (cDNAs) from Mammalian Gene Collection 
(MGC) plasmids and the Gateway recombination system was created196. It includes 
4891 full-length cDNAs instead of just the 3’UTR. Using this system, the authors 
identified both known and unknown targets of miR-34a, especially those targets 
directly regulated by miR-34a through coding region. These targets would not have 
been identified if only searched for 3’UTR binding.  
The advance of microarray and next generation sequencing (NGS) approaches has 
opened another opportunity to identify direct interactions between miRNA and its 
targets at much faster speed and larger scale. These methods are based on 
immunoprecipitation of RISC, where miRNA:mRNA bind together, and are then 
isolated by using antibodies targeting Ago197, 198. In these methods, an exogenous, 
epitope-tagged Ago-1 or Ago-2 are expressed in HeLa, human embryonic kidney cells 
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293T (HEK-293T) or other type of cells199-201 together with miRNA of interest, then 
Ago protein is pulled down using an antibody against the epitope tag. Precipitates are 
analysed by deep sequencing.  This allows identification of targets at both the levels of 
degradation and translational repression. However the results can be misleading for the 
artificial interaction between the miRNA and mRNAs, which bind together during cell 
lysis instead of RISC202. In addition, those mRNA targets with weak affinity to 
miRNA will not be sufficiently stable during the immunoprecipitation process. 
Consequently, they will be absent in the following deep sequencing analysis. To 
overcome these problems, high-throughput sequencing of cross-linking 
immunoprecipitation (HITS-CLIP) has been developed. In this method, ultraviolet 
irradiation was employed to crosslink RNA to RISC before immunoprecipitation197.  
However, ultraviolet (UV) 254nm is not sufficiently efficient to crosslink all RNA-
protein. A modified method, termed photoactivatable-ribonucleoside-enhanced 
crosslinking and immunoprecipitation (PAR-CLIP) has been developed to give 
stronger UV crosslinking between RNA and protein. In this method, cells are 
incubated with a photoactivatable nucleoside such as 4-thiouridine (4-SU) and 6-
thioguanosine (6-SG), followed by UV 365nm irradiation to induce efficient 
crosslinking of photoreactive nucleoside-labelled RNA to RISC. This improves RNA 
recovery by 100- to 1000-fold compared to the HITS-CLIP method200, 203.   
1.3.4 miRNA IN VASCULAR DISEASES 
MiRNAs have been shown to be dysregulated and contribute to the initiation and 
development of many vascular diseases.  
1.3.4.1 miR-23~27~24 
The miR-23~27~24 cluster has attracted considerable attention recently since this 
cluster has been shown to be disregulated in many diseased states and members of the 
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cluster cooperate to regulate several processes during health and diseases204-210. 
1.3.4.1.2 Transcriptional regulation of miR-23-27-24 cluster 
There are two copies of this miR cistron in the genome. In human, the intergenic miR-
23a-27a-24-2 cluster is encoded on chromosome 19p13.13. The intronic miR-23b-27b-
24-1 cluster is localized at chromosome 9q22.32. In mouse miR-23a-27a-24-2 is also 
intergenic with its own promoter on chromosome 8 and miR-23b-27b-24-1, being 
located in intron 4 on chromosome 9204. This organization has been highly preserved 
in vertebrates and also in fish, albeit less closely clustered. Mature sequence of miR-
23a/27a differ by just one nucleotide in comparison to miR-23b /27b, while the mature 
sequence of miR-24-1 and miR-24-2 share the identical sequences206, 210. 
1.3.4.1.2 Role of  the miR-23-27-24 cluster in vascular diseases 
miR-23-27-24 cluster have been shown to be involved in regulation of many vascular 
functions like angiogenesis, permeability and apoptosis211-215. Most interestingly, 
bioinformatics analysis has revealed that the EC junction is a target for all three 
miRNAs of this cluster214, 216, again suggesting the inter-relationship between the 
members of the cluster and that although their individual effects may be limited there 
is likely to be a significant co-operative effect204, 206, 208, 209, 217. (Ref. 214 is generated 
from Chapter 2 of this thesis). 
miR-23a/b  
The role of miR-23a in angiogenesis is controversial. On one hand, miR-23a has been 
shown to be pro-angiogesis205.  Expression of miR-23a is significantly upregulated in 
exosomes from lung cancer under hypoxic conditions. In turn, excessive miR-23a 
increase angiogenesis by directly targets SIRT1 in receipt EC or indirectly upregulates 
hypoxia-inducible factor-1 α (HIF-1 α) by suppressing its target prolyl hydroxylase 1 
and 2 (PHD1 and 2)212, 218. On the other hand, some reports have shown that miR-23a 
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is actually anti-angiogenesis219.  In mouse model, inhibition of miR-23 promoted 
blood flow recovery in ischemic limbs of mice220. miR-23a inhibit angiogenesis by 
suppressing EGFR expression and endothelial progenitor cells (EPCs) activities220. 
Expression of miR-23a are higher in patients with	coronary artery disease (CAD) than 
in the normal controls 221. miR-23a also regulates vascular integrity by directly 
targeting tight junction protein ZO-1 to disrupt EC junctions and induce vascular 
permeability212, 214. Furthermore,. miR-23a regulates cardiac hypertrophy through 
targeting the transcription factor nuclear factor of activated T-cells (NFAT)222. 
Overepxression of miR-23a induces telomere shortening by targeting telomeric repeat 
binding factor 2 (TRF2), which plays an important role in telomere maintenance and 
cellular senescence221, 223.  
miR-23b is required to keep EC quiescent224. It is upregulated by pulsatile shear flow, 
which arrests EC growth. Further study shows that elevated miR-23b targets 
transcription factor E2F1 and the phosphorylation of the tumor suppressor protein 
retinoblastoma (Rb), which in turn inhibits EC growth. Indeed, inhibition of miR-23b 
reversed the PS-induced E2F1 reduction and G1/G0 arrest224.  Consistently, miR-23b 
also inhibits inflammation by targeting a range of cytokines and inflammatory factors, 
including CCL7, TAB2, TAB3, IKK-αNF-κB, TNF-α, IL-6, ICAM-1, E-selectin and 
VCAM-1225-227. In addition to its role in EC, miR-23b is also involved in phenotypic 
switch of vascular smooth muscle cells (VSMCs), which is critical for vascular 
diseases such as atherosclerosis and restenosis after coronary intervention228. 
miRNA-27a/b  
miR-27a controls angiogenesis by targeting SEMA6A, VEGFC, SPRY2 and Delta-
like 4 (DLL4)38, 229, 230. It’s also been shown to regulate vascular integrity through 
targeting VE-cadherin125, 231. miR-27a also targets Peroxisome proliferator-activated 
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receptor gamma (PPARγ) to mediate repressive actions in hypoxic pulmonary 
vasculature and LPS-medicated inflammation232,233.  The fact that miR-27a is 
upregulated in the serum of the patients with acute ischemic stroke, suggesting it could 
be used as biomarker for this disease234. 
miR-27b promote angiogenesis by regulating endothelial tip cell fate, branching and 
venous specification through down-regulation of Delta-like ligand 4 (Dll4) and 
Sprouty homologue 2 (Spry2) 205. It also inhibit angiogenesis in tumour by targeting 
vascular endothelial growth factor C (VEGF-C)230.  miR-27b also targets Bcl-2-
associated athanogene 2 (Bag2) in macrophages to modulate inflammation235. 
miR-24  
miR-24 is involved in the deoxyribonucleic acid (DNA) damage response in 
haematopoietic cells and linked with this is its action to regulate the cell cycle. 
Furthermore one of its targets in cardiomyocytes is BIM236, the positive regulator of 
apoptosis and indeed expression of miR-24 in mice reduced cardiac dysfunction after 
MI. MiR-24 limits aortic vascular inflammation and murine abdominal aneurysm 
development via targeting chitinase 3-like 1237. 
1.3.4.2 Other miRNA in vascular diseases 
There are many other miRNA shown to play roles in regulation of vascular pathology. 
For example overexpression of miR-10a can reduce the inflammatory infiltrate 
associated with atherosclerosis238 and miR-208 control of pathological cardiac 
remodelling and obesity239. MiR-210 is induced under hypoxic conditions and 
improves myocardial infarction (MI) through inhibition of apoptosis in 
cardiomyocytes and by stimulation of angiogenesis240. An interesting finding from 
Thum et al. has shown that miR-21 controls cardiac hypertrophy and fibrosis241. MiR-
21 is upregulated in cardiac fibroblasts in response to pathological stresses that 
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promote cardiac fibrosis241. Antagomirs to miR-21 can inhibit fibrosis and restore 
function in severely injured hearts via targeting Sprouty 1 (SPRY1), which acts as an 
inhibitor of mitogen-activated protein kinase (MAPK) signalling (a driver of cardiac 
dysfunction). MiRNAs have also been shown to regulate many of the key aspects of 
angiogenesis. Mir-92a and miR-132 both regulate angiogenesis through regulation of 
integrins in EC. MiR-92a targets α5 integrin signalling and activation of Ras, a 
signalling molecule downstream of integrin activation is controlled by miR-132242, 243. 
  Much work has been done on miR-126, demonstrating that one miRNA can influence 
a phenotypic response in a cell by acting on a number of critical genes244. MiR-126 is 
an EC specific, intragenically-expressed miRNA situated within an intronic region of 
the Egfl7 gene, which encodes the EC-derived secreted angiogenic factor. Thus 
regulation of this gene will also influence levels of miR-126. MiR-126 regulates the 
response of EC to VEGF through regulation of the inhibitor, Sprouty related protein-
1245. Deletion of miR-126 results in loss of vascular integrity and embryonic 
lethality244, 245. Furthermore, miR-126 regulates C-X-C motif chemokine 12 
(CXCL12), an anti-inflammatory cytokine associated with unstable coronary artery 
disease246. CXCL12 also is involved in recruitment of smooth muscle cell progenitors 
to areas of neointimal formation168.  
1.3.5 MIRNA THERAPEUTICS 
The deregulation of miRNAs in many diseases draws substantial interest in exploiting 
miRNAs for therapeutic applications. Depending on the regulation of miRNA in 
diseases, miRNAs can be either replenished by miRNA mimics or inhibited by 
miRNA inhibitors for therapeutic purposes. MiRNA mimics are synthetic chemically 
modified double-stranded small RNA molecules that are processed into single-
stranded miRNAs in cells to mimic the endogenous function of the miRNA of interest. 
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Another way to increase the level of a miRNA is by the use of adenoviral delivery 
methods, such as AAC9, resulting in continuous enhanced expression of miRNAs of 
interest247. For miRNA inhibition, several different approaches have been developed 
including miRNA sponges and anti-miRs. MiRNA sponges are vector containing 
multiple artificial miRNA-binding sites, which can selectively inhibit corresponding 
miRNAs. Anti-miRs are antisense oligonucleotides (ASOs) that target miRNAs 
directly. One of the major challenges for miRNA-based therapeutics is the degradation 
of oligonucleotides by RNases in vivo before they take effects, since unmodified 
miRNA mimics or ASOs are not stable in vivo due to nucleases cleavage. In addition, 
since naked oligonucleotides are negatively charged, they are not able to penetrate cell 
membranes that are also negatively charged. Therefore naked miRNAs mimics or 
ASOs need modification to prevent degradation and increase binding affinity for 
targeted miRNAs. Current efforts have been made from two different strategies 
including chemical modification and design of vehicles for delivery. miRNA mimics 
do not tolerate extensive modification to enhance stability and binding affinity, since 
those modifications will compromise the efficiency in loading of the miRNA into the 
RISC, resulting in the loss of silencing ability. Therefore, designing in vivo delivery 
vehicles becomes an alternative strategy to overcome nuclease cleavage for the 
therapeutic use of miRNA mimics. Considering the similarity between small 
interference RNA (siRNA) and miRNA, many of the delivery methods are adapted 
from siRNA therapeutics, including but not limited to conjugation-based method, 
liposome-based methods, nanoparticle-based method and antibody-based methods. 
MRX34, a lipid nanoparticle encapsulated miRNA mimic targeting miR-34, is the first 
miRNA mimic to reach phase 1 study (NCT01829971) to treat multiple solid 
tumours248. Although it showed significant inhibition of tumour growth without 
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carrier-mediated immune stimulation in animal models of liver, lung and prostate 
cancer, the clinical trial has been terminated due to multiple immune-related severe 
adverse events in patients165. A few other miRNA mimics are in preclinical and phase 
1 study including MRG 201 (miR-29 mimic, phase 2)249, MesomiR-1 (miR-16 mimic, 
multi-centre phase 1)250 and miR-200 (pilot clinical trial)251. 
The majority of chemical modification has been focused on ASOs252, 253. As Figure 1.8 
shows, the modifications are made to two parts of the oligonucleotide: backbone and 
sugar ring. The phosphorothioate modification, which is to replace non-bridging 
oxygens in the phosphate group with sulphur atom, is the most common change to the 
RNA backbone. This modification increased nuclease resistance although with some 
reduction in binding affinity to miRNAs.  In addition, it also improves the 
pharmacokinetics and pharmacodynamics (PK/PD) profile of ASOs in vivo254. The 
modification to sugar ring have been focused at the 2’ position, shown to increase the 
resistance of ASOs to nucleases and enhance their stability. These modifications 
include 2’-O-methyoxyethyl (2’-MOE), 2’-O-methyl(2’-OMe), 2’-fluoro (2’-F) and 
locked nucleic acid (LNA). In LNA, 2’-O-oxygen is bridged to the 4’-position through 
a methylene linker to form a rigid bicycle, locked into a C3’-endo (RNA) sugar 
conformation255. It offers the greatest increase in binding affinity among these 
modifications by raise melting temperature of 2-8 ºC per LNA. However fully LNA-
modified anti-miRs tend to form LNA oligonucleotide dimers due to exceptional 
thermal stability. Therefore DNA-LAN mix, which only incorporated LNA into a few 
DNA nucleotides, are recommended. Recent animal data indicate that LNA based 
miRNA inhibitors are able to bind to their miRNA targets with good stability, affinity 
and specificity256. Miravirsen, a 15-nucleotide phosphorothioated-modified LNA/DNA 
mixmer to miR-122, is one of the most advanced miRNA therapeutics and is currently 
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being tested in a Phase II study in the treatment of hepatitis C virus (HCV)257. 
Inhibition of miR-122 using LNAs significantly reduced the infection load of HCV in 
mice and in chimpanzees. In clinical trials, patients with chronic HCV infections and 
miR-122 LNA treatment had significant lower (2-3 log decrease) in virus loading in 
serum. No sign of serious adverse effects were observed. Other anti-miRs targeting 
miR-103/107 and miR-155 are also in Phase I studies252, 255.   
Individual miRNAs have dozens if not hundreds of potential targets. The ability of 
miRNAs to regulate a wide array of mRNA gives miRNAs unique advantages as drug 
candidates to target complex biological processes, especially when multiple genes are 
within a molecular pathway or the context of a network. However it also raises the 
potential of off-targets. To overcome these drawbacks, ASOs that specifically block 
miRNA interaction with mRNA of interest have been developed125, 231, 258 (Figure 1.8). 
In contrast to anti-miRs that bind to miRNAs, these ASOs, named miR-Mask, target 
site blocker (TSB) or BlockmiRs, bind to the miRNA in the 3’UTR of the target 
mRNA of interest through full complementarity. Consequently, they prevent miRNA 
from gaining access to that site and block the regulation of a specific mRNA. This can 
be highly useful in identifying the importance of a specific miRNA:mRNA interaction 
or developing miRNA therapeutics towards characterised drug targets259-261. 
There are still some limitations of TSB or BlockmiRs. Although the length and 
sequences of TSB are aligned against genome for selection of the antisense with 
minimal off-target and maximum affinity, if similar sequences are present in the 
genome, it is still possible that off-target effects could be observed. In addition, if the 
TSB does not bind stronger enough to target sequence, the regulation of the target 
could be subtle. Furthermore, due to the toxicity of TSB , continuous and high dose of 
treatment of TSB could also cause non-specific effects. 
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Figure 1.7 a Major challenge to develop miRNA therapeutics. MiRNAs can be 
chemically modified to increase stability and improve PK/PD characters. Common 
chemical modifications include sulfur substitution of a non-bridging oxygen to make a 
phosphorothioate linkage between nucleotides, 2’-O-methyl, 2’-O-methoxyethyl, 2’-
fluor and locked nucleic acid262. MiRNAs can also be delivered in vivo using delivery 
systems like lipid nanoparticles. Key challenges in translating these delivery systems 
into the clinic are potential immunostimulatory effects, toxicity and the lack of specific 
targeting of the disease site. Figure is adapted from literature262, 263. 
Key Challenges 
•  Toxicity 
•  Immunostimulatory effect 
•  Off-target 
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Figure 1.8  MiRNA inhibitors and site-specific blocker. MiRNA inhibition leads to 
de-repression of multiple targets. Target site blocker or BlockmiR binds to the binding 
site on mRNA, leading to specific upregulation264.  
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1.4 VASCULAR INTEGRITY DISORDER  
Abnormal vascular integrity is a hallmark to many diseases such as cancer, sepsis, 
inflammation, cerebral cavernous malformation (CCM), adult respiratory distress 
syndrome (ARDS), systemic capillary leak syndrome (SCLS) and compartment 
syndromes.  
1.4.1 CANCER     
Histologic analyses showed increased gap sizes between ECs in tumours, suggesting 
higher vascular permeability265. Tumour vasculature is poorly differentiated and 
organized, supplying nutrients and oxygen for rapid tumour growth. The hypoxic 
tumour microenvironment stimulates tumour cells secretion of VEGF, which induces 
extensive angiogenesis and vascular permeability in the tumour266. Disruption of 
endothelial barrier is also critical for tumour metastasis, since cancer cells need to 
intravasate into and extravasate from blood vessel to engraft at secondary sites267. 
Hypermeability in tumours also increases interstitial fluid pressure268. In normal tissue, 
intravascular pressure is higher than that of interstitial area, whereas in tumours the 
difference in pressure is largely reduced to virtually zero269. This leads to the reduction 
of the capacity to remove excess fluid and transport of macromolecular drugs, which 
are predominantly driven by pressure gradient across vascular wall270.  
1.4.2 INFLAMMATION 
During inflammation, leukocytes have to overcome the endothelium of the blood 
vessel wall to extravasate from the blood steam into the surrounding tissue at the site 
of inflammation. Leukocytes are firstly captured and arrested at the luminal side of the 
endothelium, followed by the transendothelial migration (TEM) step271. Numerous 
endothelial adhesion and junction molecules have been implicated in TEM including 
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VE-cadherin, JAMs, PECAM-1, Endothelial cell–selective adhesion molecule 
(ESAM), Intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion 
molecule 1 (VCAM-1) 272-282. The strong involvement of EC junctional molecules 
suggests TEM is mainly through the paracellular route, where endothelial junctions 
need to open or loosen to facilitate extravascation, leading to induction of vascular 
permeability. Actually in vivo studies show that in the cremaster muscle circulation, at 
least 90% of the transmigration events are paracellular at least for neutrophils283.  
However, increasing evidence also suggests transcellular migration also contributes to 
leukocyte (mainly lymphocyte) TEM284. Therefore, leukocytes cross endothelium via 
both transcellular and paracellular routes285, 286.  
1.4.3 CEREBRAL CAVERNOUS MALFORMATION 
CCMs are vascular malformations (Figure 1.10) characterized by a cluster of dilated 
capillary-like caverns, which have poorly developed endothelium with absence of 
pericytes or astrocytes support. Electron microscopy showed disruptive EC-EC 
junctions in clinical CCM samples287, leading to increased permeability and massive 
vascular leak. CCM lesions restrictively develop in the venous and capillaries in the 
CNS, where the blood flow is much lower than arteries. CCMs can be divided to two 
groups: familial and sporadic forms. The familial form is often more severe with 
multiple lesions and more prone to hemorrhage, although it only accounts for around 
30% of all CCM cases. In contrast, sporadic form consists of a single lesion and grows 
more slowly compared with its counterpart. In addition, it is less likely to be 
symptomatic. 
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Figure 1.9  Appearance and location of CCM lesions. CCM lesions predominantly 
develop in brain and retina. The lesions are mulberry-like dilated and leaky blood 
vessels. CCM lesions can be diagnosed by MRI scan. One of the key features of CCM 
is the existence of gaps between ECs lining lesions288. Figure was modified from 
citation289-291. 
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Familial CCMs are caused by the loss-of-function mutation in either one allele of 
CCM1 (KRIT1), CCM2 or CCM3 (PDCD10) followed by somatic loss of the second 
allele292, 293. Although CCM genes are expressed ubiquitously, only the mutation in 
ECs cause CCM lesion294.  These three CCM genes share no sequence homology; 
form a complex to interact with interendothelial cell junction and cytoskeleton, leading 
to impact on vascular integrity.  Loss of either one of CCM genes disrupts CCM 
complex, activating a range of signalling pathways, which ultimately leads to CCM 
lesion formation (Figure 1.10).  
1.4.3.1 CCM1/KRIT1 
CCM1 is the first gene shown to associate with the familial form of CCMs295.  
Mutation of CCM1 accounts for about 40% of familial CCM cases. CCM1 is a 
scaffold protein to integrin cytoplasmic domain-associated protein-1 (ICAP-1), a 
specific binding protein and negative regulator of integrin β1. Loss of CCM1 
destabilized ICAP-1, leading to activation of integrin β1 and its dependent endothelial 
contractility and fibronectin remodeling296. Activation of integrin β1 also results in 
overexpression of Kruppel like factor 2 (KLF2), which in turn causes an upregulation 
of EGF-like domain-containing protein 7 (EGFL7) and activates VEGF signalling to 
promote angiogenesis297. CCM1 has also been shown to induce DLL4-NOTCH 
signalling to maintain ECs quiescent298. Therefore CCM1 is an anti-angiogenesis 
molecule299. In addition, CCM1 binds to Rap1, a guanosine triphosphatase that 
maintains the integrity of endothelial junctions. Rap1 activity regulated the junctional 
localization of CCM1 and its physical association with junction proteins. However, the 
association of the isolated CCM1 FERM domain was independent of Rap1. Small 
interfering RNA-mediated depletion of CCM1 blocked the ability of Rap1 to stabilize 
endothelial junctions associated with increased actin stress fibers. Thus, Rap1 
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increases CCM1 targeting to endothelial cell-cell junctions where it suppresses stress 
fibers and stabilizes junctional integrity. Loss of CCM1 also activates MAPK/ERK 
kinase kinase 3 (MEKK3), leading to phosphorylation of ERK5 and MEF2, 
consequently increase Kruppel like factor 4 (KLF4) expression. KLF4 promotes 
TGFβ/BMP6 signalling, leading to endothelial-to-mesenchymal transition (EndMT) 
shown to be a causal for CCM formation300.  
1.4.3.2 CCM2 
Mutation of CCM2 accounts for about 20% of familial CCM cases. CCM2 closely 
links to CCM1, and shares some similarity in the downstream pathways. CCM2 is a 
scaffold protein to MEKK3. Loss of CCM2 activates MEKK3, resulting in both 
RhoA–	Rho-associated protein kinase (ROCK)-mediated myosin light-chain activation 
and extracellular-signal-regulated kinase 5 (ERK5) phosphorylation. Increase in RhoA 
activity leads to cytoskeleton reorganization as shown by increase in actin stress fibres, 
which is a key contributor for paracellular permeability41, 301. ERK5 phosphorylation 
activates its downstream target myocyte enhancer factor-2 (MEF2) to upregulate 
KLF2 and KLF4 expression, which have been shown to cause CCM lesion 
formation300, 302.  
1.4.3.3 CCM3 (PDCD10) 
CCM3 mutation causes the earliest onset and most severe symptoms in CCM 
patients303-305, indicating it may function in a different mechanism from CCM1 and 
CCM2303. CCM3 is enriched at the luminal membrane of the germline and the 
contractile ring of dividing cells in the embryo306. Physically, CCM3 directly interacts 
with the CCM2 phosphotyrosine-binding domain (PTB) through its C-terminal focal 
adhesion kinase targeting (FAT)-homology domain307. It also associates with the 
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germinal center kinase III (GCKIII) kinases (including STK24 and STK25) to plays an 
essential role in cardiovascular development. Loss of ccm-3 impairs DLL4-Notch 
signalling and activates EphB4, which in turn leads to aberrant angiogenesis308, 309, 
CCM3 deficiency in ECs also increases the exocytosis310 and secretion of ANGPT2, 
resulting in destabilized EC-EC junctions, enlarged lumen formation and endothelial 
cell-pericyte dissociation311. Activation of β-catenin through a WNT-receptor–
independent pathway also contributes to CCM3 pathology. Inhibition of β-catenin 
transcription activity by sulindac sulfide and sulindac sulfone reduces vascular 
malformations in CCM3-deficient mice312.  
1.4.3.4 Other key signaling pathways  
Endothelial Toll-like receptor 4 (TLR4) and the gut microbiome have recently been 
identified as critical stimulants of CCM formation289. The CCM deletion mouse model, 
with Gram-negative bacteria infection in the gut, was susceptible to CCM lesion 
formation. In contrast, Germ-free mice were resistant to CCM formation. More 
importantly, a single dose of antibiotics rescued CCM susceptibility in mice. When the 
mice received injections of LPS, they formed large number and volume of CCM 
lesions, similar to those produced by bacterial infection. Further study revealed that 
Gram-negative bacteria were able to produce a molecule called lipopolysaccharide 
(LPS) activating innate immune reaction to accelerate CCM formation. Knockout of 
TLR4, a LPS receptor, rescued mice prone to develop CCM lesions. Treatment of 
susceptible CCM mice with TAK-242 (resatorvid), a small-molecule TLR4 antagonist, 
significantly reduced the volume of CCM lesion. Finally, in humans, the increase in 
TLR4 expression was positively associated with the risk of developing CCM lesions.  
However, in healthy individuals, the intestinal microbiota cannot access the 
bloodstream. Some pathogenic bacteria can cross gut epithelium and blood vessels to 
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reach liver, spleen, or other peripheral tissues. In the context of CCM, whether just 
stay in the gut or access the CCM lesion in the brain is not clear. If only the pro-
inflammation molecule such as LPS released from bacterial in the gut enter 
bloodstream to induce a systemic immune response, leading to acceleration of CCM 
lesion development, does Gram-negative bacteria infection in other parts of body also 
contribute to CCM development? In addition, the intestinal barrier is critical to limit 
systemic dissemination of microbes and toxins to access the circulation.  Is there any 
defect in the intestinal barrier in CCM patients? This is especially interesting in the 
context that no defect in gut permeability (mainly epithelium) in the animal with CCM 
diseases has been identified so far. The existence of a gut-vascular barrier could open 
another window to address this issue32.  
Thrombospondin1 (TSP1), encoded by a gene called Thbs1, is a angiogenesis inhibitor, 
functioning through direct effects on EC migration and survival. It may also indirectly 
affect angiogenesis by effects on growth factor mobilization313. It was recently 
uncovered that inhibition of TSP1 contributes to the development of CCMs314. 
Acute loss of brain endothelial KRIT1 caused a markedly reduction in Thbs1 gene 
expression in BMECs (brain microvascular EC).  Reconstitution of TSP1 in vitro 
rescued BMEC, tight junctions and inhibited increased VEGF signalling. In a mouse 
model of CCM1 (Krit1ECKO), administration of 3TSR, an anti-angiogenic TSP1 
fragment, reduced the development of CCM lesions. In contrast, inhibition of TSP1 by 
inactivation of one or two copies of Thbs1 expression accelerated CCM formation. 
These results suggest that 3TSR potentially can serve a target for the development of 
therapeutics for CCMs. 
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Figure 1.10. CCM signalling in EC. CCM1, CCM2 and CCM3 physically bind to 
each other to form a CCM complex. Disruption of this complex increases RhoA–
ROCK kinase activity, causes inflammatory response, upregulates β1 integrin 
activation and activates DLL4–Notch signalling to destabilize adherens junctions and 
tight junctions298, 312, 315, 316.  LPS accelerates CCM formation by activating TLR4–
MEKK3–KLF2/4 signalling289.  
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1.4.3.5 Remaining questions in CCM pathology 
One of the critical unanswered questions in CCM1/CCM2 signalling pathways is the 
downstream of KLF2/4. Increased KLF2 and KLF4 have been shown by several labs 
to be causal for CCM pathogenesis. As widely reported, KLF2 and KLF4 are 
associated with vascular stability and lack of inflammation74, 317-319. It is therefore very 
unclear how increased loss-of-CCM induced elevated KLF2 and KLF4 would result in 
vascular destabilization and inflammatory response in this context. 
The other one of the essential unsolved questions in our understanding of this 
potentially devastating disease is why there is site-specific development of the lesions, 
principally in the brain and eye regions of the CNS. This restricted development 
occurs even though there is loss-of-function mutations of the CCM genes in all EC. 
CNS are regions with sluggish blood flow and low fluid shear stress (LSS). Whether 
blood flow induced FSS contributes to CCM development is largely unknown. This is 
of special interest that CCM1 and CCM2 have been shown to play a role in the sense 
of FSS299, 320, 321. However, no arterial diseases have been linked to the deficiency of 
CCM proteins. 
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1.5 PROJET AIMS 
 The central aims of this thesis were to a) broaden our understanding of miRNA and 
shear stress in the regulation of vascular integrity, and b) to test a novel miRNA-based 
therapeutic for the diseases associated with abnormal vascular integrity. 
1.5.1 AIM 1 
We previously showed that the miR-23-27-24 cluster was down in angiogenesis. miR-
27a, a member of this cluster was shown to target VE-cadherin to regulate vascular 
permeability. The role of other members in this cluster to regulate vascular integrity 
remains unclear. The first hypothesis of this study is that miR-23s, including miR-23a 
and miR-23b, play an important role in the regulation of vascular integrity. To address 
this hypothesis I investigated: 
(1) the targets of miR23a and miR-23b in vitro.  
(2) the function of miR-23a and miR-23b in the regulation of vascular integrity 
including permeability and angiogenesis in vitro and in mouse model. 
(3) the differences between miR-23a and miR-23b in the regulation of vascular 
integrity in vitro.   
(4) the mechanisms underlining the difference between miR-23a and miR-23b in vitro. 
1.5.2 AIM 2 
CCM is a disease with abnormal vascular integrity. There is no effective treatment for 
CCM. VE-cadherin is downregulated and delocalized in the ECs lining CCM lesion. 
We previously developed BlockmiR CD5-2, which blocks the interaction between 
miR-27a and VE-cadherin, leading to an increase in endogenous VE-cadherin 
expression. The second hypothesis of this project is that targeted restoration of VE-
cadherin by BlockmiR CD5-2 can rescue CCM development. To address this 
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hypothesis I investigated:  
(1) BlockmiR CD5-2 action on key signalling in CCM development in vitro. 
(2) BlockmiR CD5-2 action in the regulation of CCM deficiency induced abnormal 
vascular permeability deficiency in vitro and in vivo. 
(3) BlockmiR CD5-2 action to regulate early-stage CCM lesions development in 
neonatal CCM mice. 
(4) BlockmiR CD5-2 action to regulate early-stage CCM lesions development in 
neonatal CCM mice. 
1.5.3 AIM 3 
The development of CCM lesions is restricted to CNS, where blood velocity is low. 
Since FSS is a key regulator of vascular integrity, we hypothesized that low FSS 
mediates cerebral cavernous malformation signalling pathways. To address the third 
hypothesis of this project, I investigated the following questions in vitro: 
(1) whether FSS influences the transcriptome in CCM gene-silenced ECs. 
(2) whether FSS affects key signallings in CCM development. 
(3) whether FSS affects key phenotypes in CCM development. 
(4) The mechanism underlying the role of FSS in CCM development. 
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INTRODUCTION 
MiRNAs are emerging as a new regulator of vascular integrity. We previously showed 
the miR-23-27-24 cluster is downregulated in the early stage of angiogenesis. There 
are two copies of this miRNA cistron in the genome, miR-23a-27a-24 being intergenic 
with its own promoter on chromosome 19 and miR-23b-27b-24, being intronic on 
chromosome 9. Bioinformatic analysis of the potential targets of these miRNAs finds a 
concentration of molecules expressed in adherens and tight junctions, giving rise to the 
possibility that endothelial junctional regulation is a chief function of these co-evolved 
set of miRNAs. Indeed, we demonstrated that miR-27a directly targets VE-cadherin to 
regulate vascular permeability. In this chapter, the role of miR-23, including miR-23a 
and miR-23b, in the regulation of vascular integrity has been explored. 
The data presented in this chapter is published in Mol Ther Nucleic Acids. 2016 Aug 
23;5(8):e354. 
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Introduction
The sustenance of normal vascular permeability is one of the 
chief functions of endothelial cells (ECs) and is achieved mainly 
by the regulation of tightness of endothelial cell–cell junctions. 
Junctional integrity is maintained by a balance of adhesive junc-
tional proteins, such as VE-Cadherin, ZO-1, ZO-2, and repulsive 
proteins such as JAM-C, SEMA-6A, and semaphorin.1–5 The 
coordination of regulation of expression and signaling through 
these proteins is very important to allow transient changes 
as seen in acute inflammation and prevent chronic changes 
evident in almost all inflammatory and degenerative diseases. 
Targeting such junctional proteins is a possible approach for 
development of therapeutics particularly for diseases where 
vascular leak is central to the underlying pathology.
MiRNAs (miRs) are a highly conserved class of endogenous 
small noncoding RNAs (20–25 nucleotides), which regulate 
genes at the post-transcriptional stage of expression.6 MiRs 
have been shown to be dysregulated and contribute to the ini-
tiation and development of many diseases.7,8 MiRs are able to 
inhibit the post-transcriptional expression of multiple genes or 
gene families involved in development or complex cellular func-
tions,9 and are thus well suited to coordinate the function of cell 
junctions.
The complexity and importance of these interactions was 
highlighted by our recent description of miR-27a as a potent 
regulator of the proadhesive protein VE-Cadherin,10 while oth-
ers have demonstrated miR-27 regulation of the antiadhesive 
proteins SEMA-6A and semaphorin.5,11,12 This contrasting 
function led to the development of an RNA-derived drug that 
specifically targets the miR-27a-VE-Cadherin interaction and 
has potent antipermeability properties and has suitable drug 
characteristics.10
MiR-27 is part of a poly-cistronic group of cotranscribed 
miRs, including 23 and 24. There are two copies of this miR 
cistron in the genome, miR-23a-27a-24 being intergenic with 
its own promoter on chromosome 19 and miR-23b-27b-24, 
being intronic on chromosome 9. This organization has been 
highly preserved in vertebrates and also in fish, albeit less 
closely clustered.13,14 Members of the cluster have been 
described to have functions in several organ/developmental 
systems, including in cancer,15 the central nervous system 
16 and vascular organs.17,18 Most recently the cluster has 
been shown to regulate T cell differentiation.19 In the vascular 
system there has been a linkage primarily to angiogenesis, 
cardiac development and apoptosis.5,11,20–22 However bioinfor-
matic analysis of the potential targets of these miRs finds 
a concentration of molecules expressed in adherens and 
tight junctions,13 and in particular, we note representation of 
almost all known members of endothelial cell–cell junctions, 
giving rise to the possibility that endothelial junctional regula-
tion is a chief function of these coevolved set of miRs.
Mature sequences of miR-23a and miR-23b have iden-
tical seed sequences and only differ by one nucleotide 
in the nonseed region. As a result, in silico target analysis 
(Targetscan, DIANA lab, and www.microRNA.org) has sug-
gested they share the same putative target genes and thus 
are likely to have similar biological functions. Despite reports 
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showing distinct function between miRs with the same seed 
sequence, few studies have focused on the possible differ-
ence in the biological effects or the targets of these miRs.23–25  
By using both gain- and loss-of-function approaches, show 
that in ECs, miR-23a and miR-23b do not behave in the 
expected identical manner. Overexpression of miR-23a inhib-
its EC permeability whereas miR-23b increases permeability. 
Moreover, miR-23b but not miR-23a overexpression regulates 
angiogenesis. Importantly, such differences are also seen in 
vivo. Further, we demonstrate that these biological differences 
likely are attributed to the differential regulation of miR-23a 
and miR-23b on EC junctional molecules in either a direct or 
indirect manner. Together our findings provide substantial evi-
dence for the evolution of a vascular permeability miR operon, 
and demonstrate the differing potent effects of miR-23s on 
their target genes and diverse role on EC function. The find-
ings have both physiological and clinical relevance at a time 
where miRNAs and their inhibitors are entering the clinic.
Results
The miR-23-27-24 cistron targets endothelial junctional 
proteins
We examined the predicted targets of the individual mem-
bers of the miR-23-27-24 cistron. 2,517 genes are predicted 
(by TargetScan 6.2) to be targets of at least one member 
of miR-23-27-24 cluster. A gene set enrichment analysis 
(GSEA) revealed that many of the predicted targets (see 
Supplementary Table S1) are involved in the adherens junc-
tions pathway (P = 9.67 e−18) with a highly significant False 
Discovery Rate q-values of 8.01 e−16.
All of the 17 major junctional and 18 downstream signaling 
or junctional regulating proteins (Figure 1a) known to play 
important roles in regulating EC junctions,3,5,26–33 are poten-
tial targets of at least one member of miR-23-27-24 clusters. 
Thus, it is highly likely that the whole cistron has a major role 
in governing endothelial function.
Of the predicted EC junctional targets of miR-23-27-24, 
three (VE-cadherin, SEMA6A, Sprouty2) have been con-
firmed by our group10 and by others.24 Here we focus on 
targets of miR-23 namely the expression of five of the most 
conserved (ZO-1, ZO-2, JAM-C, VE-PTP, and CCM2). Human 
umbilical vein endothelial cells (HUVEC) (Figure 1b) or 
human cerebral microvascular endothelial cell line (hCMEC/
D3) (see Supplementary Figure S1a, b) transfected with 
either locked nucleic acid (LNA) to miR-23 or mimics of miR-
23a or miR-23b. Mimics to miR-23a and miR-23b were able 
to specifically increase miR-23a and miR-23b expression 
respectively (see Supplementary Figure S2a), whereas with 
the LNA, both miR-23a and miR-23b was reduced to a similar 
level (see Supplementary Figure S2b), The manipulation of 
endogeneous miR-23a/b led to appropriate up or down regu-
lation of all five genes, as measured by polymerase chain 
reaction (PCR). Therefore there are at least eight major EC 
junctional molecule targeted, either directly or indirectly, by 
the miR-23-27-24 cistron5,10,11,22,29,34(bold in Figure 1a).
Taken together, these data indicate that miR-23-27-24 tar-
gets are specifically highly enriched in EC tight and adherens 
junctions. We thus propose that the miR-23-27-24 cluster 
serves as a vascular cell–cell junctional operon. It should be 
noted that the miRs target both attractive and repulsive pro-
teins, thus there is likely to be a fine tuning in the release of 
these miRs or access to their respective targets to coordinate 
the opening and closing of cell–cell junctions.
Expression patterns of miR-23a and miR-23b in 
angiogenesis
The miR-23-27-24 cluster was originally identified using 
microarray analysis (GSE50437) and found to be regulated 
in ECs during in vitro 3-dimensional (3D) collagen angiogen-
esis assay. Both miR-23a and miR-23b showed a rapid and 
sustained downregulation in their expression (Figure 2a,b). 
This microarray data for miR23 was validated in the 3D col-
lagen angiogenesis assay by quantitative PCR (Figure 2c). 
The pattern is similar to that we have previously observed 
with miR-27a.10 Since the earliest events in in vitro angiogen-
esis are cell movement and alignment, the rapid decrease in 
miR maybe associated with loss of cell–cell interactions or 
cell migration. To test this we measured miR expression in 
migrating ECs, in a modified “scratch assay”, from a wounded 
edge of a confluent monolayer (Figure 2d). Both miR-23a 
and miR-23b were rapidly down-regulated within 30 minutes 
of wounding and also at times that reflect the migration stage. 
Normal levels of expression of both miRs are achieved by 6 
hours and times thereafter (Figures 2e,f). These data indi-
cate that miR-23a and miR-23b were both down-regulated in 
the early stage of angiogenesis, times associated with loss of 
cell–cell interactions and the induction of migration.
MiR-23a and miR-23b differentially regulate angiogenesis
To test whether the down-regulation of miR-23 family is 
essential to the angiogenic process, we manipulated the lev-
els of the miRs and investigated changes in the early phases 
of an angiogenesis assay.
The knockdown of miR-23a and miR-23b by LNA-23 sig-
nificantly enhanced tube formation on Matrigel, as quantified 
by tube length, tube number and number of branching points 
(Figure 3a). These results indicate that down-regulation of 
miR-23 promotes angiogenesis in vitro. Next, we investigated 
the role of each of the individual miRs in angiogenesis. Since 
LNAs against the individual members could not be designed 
to achieve specificity, we used mimics of each of these trans-
fected into ECs. Cells were seeded onto Matrigel 48 hours 
after transfection. Different cell concentrations were used in 
order to see enhancement or inhibition of tube formation (See 
“Materials and Methods”). Overexpression of miR-23b, but 
not miR-23a significantly impaired the formation of capillary-
like structures in ECs causing a decrease of total tube length, 
total tube numbers, and total branching points  (Figure 3b). 
This was interesting as miR-23a and miR-23b are predicted 
to have the same targets due to their identical seed sequence 
and were similarly downregulated in angiogenesis  (Figure 
2a,b). The difference in the regulation of angiogenesis 
between miR-23a and miR-23b also occurs in vivo. Matrigel 
plugs containing either miR23a, miR-23b or control miR mimic 
were injected into mice and the neovascularization quanti-
fied by total vessel area and average vessel size, as deter-
mined by immunohistochemical analyses of CD31 expression 
 (Figure 3c). MiR-23b containing plugs significantly inhibited 
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the angiogenic response whereas the miR-23a mimic treated 
mice did not show any significant change compared with con-
trol. Taken together, these data indicate that miR-23b but not 
miR-23a regulates angiogenesis.
MiR-23a and miR-23b regulate vascular permeability 
differently
Changes in vascular permeability are associated with patho-
logical angiogenesis.35,36 We investigated whether miR-23a 
and miR-23b impacted on permeability. Since EC junctions 
are directly involved in regulating vascular permeability, we 
first examined the EC junction pattern, as shown by VE-cad-
herin staining, after miR-23 mimics treatment. In a loosely 
packed HUVEC monolayer, the control cells showed open 
zipper–like staining for VE-cadherin, whereas miR-23a 
mimic treated cells showed a smoother and continuous VE-
cadherin staining at both 1.5 nmol/l and 15 nmol/l, indicating 
tightly apposed junctions (Figure 4a). In contrast, more gaps 
and wider zipper-like staining for VE-cadherin between cells 
were observed in miR-23b mimic treated cells particularly in 
the cells that received 15 nmol/l of 23b mimic (Figure 4a, 
white arrows). These data indicate miR-23a and miR-23b 
may have opposite roles in the regulation of cellular junctions 
and hence permeability, where miR-23a may inhibit perme-
ability while miR-23b may promote permeability.
Later, we investigated the effects of miR-23a and miR-23b 
using in vitro permeability assays. HUVEC were transfected 
with miR mimics or LNA-23 and 24 hours later, plated on 
permeable membranes for another 24 hours to allow the 
development of cell junctions. Thrombin was used to induce 
permeability and extent of permeability measured by the pas-
sage of  fluorescein isothiocyanate (FITC)-dextran through 
the monolayer. Basal and thrombin stimulated permeability 
was inhibited by mimic 23a overexpression (Figure 4b). 
The inhibition by miR-23a was independent of the amount 
of mimic transfected since inhibition was seen at both 1.5 
nmol/l and 15 nmol/l (Figure 4c). In contrast miR-23b overex-
pression did not inhibit permeability rather showing a signifi-
cant increase in basal permeability with the higher dose of 15 
nmol/l of mimic 23b (Figure 4d,e). A slight trend to increase 
thrombin-induced permeability was seen in some experi-
ments but was not consistent using mimic 23b transfected 
cells (Figure 4d). These data are consistent with the effect of 
miR-23a and miR-23b on the pattern of EC junctions (Figure 
4a). In comparison, LNA to miR-23 (inhibiting both 23a and b) 
did not significantly change either basal nor thrombin (Figure 
4f), histamine or vascular endothelial growth factor (VEGF) 
(Figure 4g) stimulated permeability. Since we showed that 
LNA was able to down-regulate the endogenous expression 
of miR23a/b and also to enhance EC tube formation, the LNA 
was indeed functional. Therefore, the lack of effectiveness in 
changing permeability is likely due to opposing roles of miR-
23a and b in regulating EC permeability.
The effect of the mimics on permeability in vivo was 
assessed by the Miles assay.10 Mice were injected intrader-
mally with 4 µg of the miR-23 mimics, LNA-23 or controls and 
24 hours later assessed for response to VEGF. Mir-23a mimic 
significantly inhibited both the basal permeability and the 
VEGF-induced increase in vascular permeability (Figure 4h). 
MiR-23b mimic actually increased permeability consistent 
with that seen in vitro (Figure 4d,e). LNA to miR-23 did not 
alter vascular permeability either basal or VEGF-stimulated 
permeability (Figure 4i). However, LNA to miR-27 inhibited 
VEGF-induced permeability as we have shown previously 
(Figure 4i).10 Thus, miR-23a and miR-23b inhibited perme-
ability in opposite manner as shown both in vitro and in vivo.
Figure 1  Regulation of predicted targets by miR-23-27-24 cluster. (a) Predicated and validated targets of miR-23~miR-27~miR-24 
clusters known to be present in tight and adherens junctions in ECs. miR-23 includes miR-23a and miR-23b. miR-27 includes miR-27a and 
miR-27b. Validated targets are in bold. (b) Relative mRNA expression of the predicted miR-23 targets JAM-C, VE-PTP, CCM2, ZO-1 and 
ZO-2 in HUVEC transfected with miR-23a or miR-23b mimic, LNA to miR-23 or controls. Expression levels were measured by qRT-PCR with 
results of mRNA normalized to β-actin. mean ± SEM; n = 3. *P < 0.05; **P < 0.005. LNA, locked nucleic acid; HUVEC, human umbilical vein 
endothelial cells; qRT-PCR, quantitative reverse transcriptase polymerase chain reaction.
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JAM-C and ZO-2 are direct targets of miR-23a and 
miR-23b
Our functional data shows that miR-23a and miR-23b regu-
late permeability and angiogenesis differently. In order to elu-
cidate the molecular basis of miR-23a/b-mediated regulation 
of EC function we chose to analyze the responses of endog-
enous ZO-2 and JAM-C to miR-23. These were chosen as 
the miR binding sites in their 3′UTR are of high affinity and 
conserved and these targets have been shown to influence 
angiogenesis and permeability.2,3
MiR-23 binding sites are the only miR binding sites in the 
3′UTR of JAM-C and one of the only two in ZO-2 3′UTR as 
predicted by Targetscan (see Supplementary Figure S3a,b). 
HUVECs were transfected with miR-23a, miR-23b, or control 
mimics and harvested for protein analysis 48 hours after. 
Overexpression of either miR-23a or miR-23b inhibited ZO-2 
to a similar extent (Figure 5a). Overexpression of miR-23a 
and miR-23b inhibited JAM-C expression although the extent 
of inhibition of JAM-C by miR-23a mimic was consistently and 
significantly greater than that seen by miR-23b (Figure 5b). 
The difference became greater when the transfection dose 
decreased from 15 nmol/l to 1.5 nmol/l (see Supplemen-
tary Figure S4a). The miR-23a/b complementary target 
site in JAM-C and ZO-2 3’UTR are different between human 
and mouse (see Supplementary Figure S3a,b). However, 
mouse and human EC had a similar pattern of response to 
miR23a and miR-23b in target preference. Overexpression 
of either miR-23a or miR-23b in mouse brain microvascular 
ECs inhibited zo-2 mRNA to a similar extent, but miR-23a 
inhibited jam-c expression to a greater extent especially at 
lower doses (see Supplementary Figure S4b) similar to 
that in human ECs (Figure 1b). Thus, miR-23a/b regulate 
Figure 2 Expression pattern of miR-23a and miR-23b during angiogenesis. (a) Expression of miR-23a and (b) miR-23b in EC during 
in vitro 3D collagen angiogenesis assay measured by microarray. (c) Confirmation of microarray by real-time PCR. C = nonangiogenic, 
3D = in vitro 3D collagen angiogenesis assay. mean ± SEM; n = 2. (d) Morphology of EC either before wounding (0 hour) and 0.5 and 
24 hours after wounding. Representative of three experiments. Scale bar = 100 µm. Quantification of miR-23a (e) and miR-23b(f) after scratch 
(mean ± SEM; n = 3). Data is compared with the levels in the confluent cells. Expression levels were measured by qRT-PCR with results of 
microRNA normalized to U48. *P < 0.05; ***P < 0.001; ****P < 0.0001 by unpaired two-tailed t-test. qRT-PCR, quantitative reverse transcriptase 
polymerase chain reaction.
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Figure 3 Mir-23b but not and miR-23a regulates EC tube formation. (a) LNA-23 increased HUVEC tubule formation on Matrigel. 
(b) Over-expression of miR-23b but not miR-23a inhibits tubule formation on Matrigel. Cells were monitored and photos taken every hour, for 
7 hours. Representative images all taken at the same time point for each experiment are shown with a scale bar = 100 µm. Images analysis 
and quantification were performed by Wimasis software (Wimasis GmbH). Graphs of tube length, number and branching points show the 
mean ± SEM. *P < 0.05; **P < 0.005; ****P < 0.0001 by unpaired two-tailed t-test. n = 3 independent EC lines. (c) Angiogenic effects of miR-
23a and miR-23b in mice. Mice received subcutaneous injection of 0.5 ml of a Matrigel mixture containing FGF-2, Heparin, and mimics. The 
animals were killed and gels dissected 2 weeks later. 5 µm sections were stained for CD31 (n = 3–4 for each plug) and a representative image 
is shown. Pixel histogram quantitation of percentages of vessel area (CD31 positive staining) and average vessel size with miR-23a, miR-23b 
or control mimic is shown. Each group contained 3–4 animals. Scale bar = 200 µm, *P < 0.05, **P < 0.01. NS = not significant. LNA, locked 
nucleic acid; HUVEC, human umbilical vein endothelial cells.
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Figure 4 MiR-23a inhibits and miR-23b enhances EC permeability. Cells were stimulated with 0.1–0.2 U/ml of thrombin, 10 µmol/l 
of histamine or 50 ng/ml of human VEGF165 for 30 minutes as indicated for in vitro experiments. (a) 48 hours after 1.5 or 15 nmol/l of 
miR-23a or miR-23b mimic treatment, HUVEC were stained for VE-cadherin (green). White arrows = examples of changed adherens junctions 
(VE-cadherin-staining). (b,d) Permeability measured in control or miR-23a (b) or miR-23b (d)-mimic–transfected cells without (N) or with 
thrombin stimulation (T). n = 4 experiments. (c,e) Permeability measured at basal level in control or cells transfected with 1.5 or 15 nmol/l miR-
23a-mimic (c) or miR-23b (e). n = 3 experiments, where values are normalized to control (C). (f,g) Permeability was measured without (N) or 
with thrombin (T, n = 6 experiments), histamine (H, n = 4 experiments) or VEGF (V, n = 5 experiments) stimulation in control or miR-23 LNA 
transfected EC. (h) The Miles assay was performed with 4 µg of control mimic or miR-23a or miR-23b mimic injected intradermally into the 
back of the mice. 24 hours later, 200 µl 0.5% Evan’s Blue was injected intravenously. After 30 minutes, 10 ng VEGF (V) or phosphate-buffered 
saline (N) was given into the same site as the mimic. Mice were sacrificed 30 minutes later and the dye was extracted from skin samples and 
quantified; # mice are: N+C, n = 10; N+23a, n = 6; N+23b, n = 5; V+C, n = 12, V+23a, n = 11; V+23b, n = 6. Representative photos of lesions 
are given. (i) The Miles assay was performed with 4 µg of control LNA, LNA-23 or LNA-27 without (N) or with VEGF stimulation (V) with set 
up given as in f above. # mice are: N+C, n = 16; N+23, n = 16; N+27, n = 8; V+C, n = 16, V+23, n = 16; V+27, n = 8. All graph represents 
mean ± SEM; *P < 0.05; **P < 0.01; ***P < 0.001, ****P < 0.0001 by unpaired two-tailed t-test. LNA, locked nucleic acid.
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Figure 5 MiR-23 directly target ZO-2 and JAM-C. (a) overexpression of miR-23a and miR-23b inhibited ZO-2 protein expression 
to a similar extent, n = 4 independent experiments.(b) overexpression of miR-23a inhibited JAM-C to a greater extent than miR-23b 
overexpression, n = 7 independent experiments. Representative Western blot is shown in upper panel and quantified by ImageJ as 
Pixel density. α-Tubulin was used as a loading control. (c) Putative miR-23 binding site and mutation within the ZO-2 and JAM-C 3′UTR. 
Nucleotides that were mutated are given in bold, underlined and italic ones in Mut. (d,e) Luciferase reporter assays, in which HEK293T 
cells were cotransfected with reporter constructs containing full length 3′UTR of the wild-type ZO-2, JAM-C mRNA (WT) or mutated 
miR-23 binding sites (Mut), together with miR-23a, miR-23b or control mimics. n = 3 independent experiments. (f) Schematic alignment 
between mature miR-23a/b and JAM-C 3′UTR shown at www.microrna.org. g, guide miRNA; t, target mRNA. Site t17 (in the rectangle) 
within WT1 was mutated to A (bold, italic and underlined) to become Mut3. (g) Luciferase reporter assays, in which HEK293T cells were 
cotransfected with reporter constructs containing full length 3′UTR of the wild-type JAM-C (WT), or single nucleotide mutation outside 
binding sites (Mut3), together with miR-23a, miR-23b or control mimics. n = 7 independent experiments. Data in all graph shown as 
mean ± SEM. *P < 0.05; **P < 0.01; ****P < 0.0001.
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in a similar fashion the expression of the proadhesive pro-
tein ZO-2, but miR-23a inhibits the propermeability protein 
JAM-C consistently and more significantly than miR-23b. 
Interestingly miR-23a overexpression inhibits permeability 
(Figure 4h) consistent with its inhibition of JAM-C. Although 
the degree of inhibition of target proteins was not high, the 
results are consistent with what we have previously observed 
for miR-27a targeting VE-cadherin10 and also consistent with 
the biology of EC junctions, where small changes in the junc-
tional proteins can have profound functional effects.
To confirm that ZO-2 and JAM-C were direct targets we 
constructed luciferase reporter plasmids containing the com-
plete wild-type 3′UTR of ZO-2 and JAM-C mRNA as well as 
mutants containing mutation sites in the predicted miR-23a/b 
binding sites (Figure 5c). These vectors were cotransfected 
into HEK293T cells with either miR-23a/b mimic or negative 
control. Firefly vector was also cotransfected as an internal 
control. Both miR-23a and miR-23b mimic significantly inhib-
ited ZO-2 (Figure 5d) and JAM-C (Figure 5e) compared with 
the negative control and mutation of the predicted binding 
sites reversed the loss of luciferase activity (Figure 5d,e). 
Collectively, our data suggested that miR-23a and miR-23b 
directly targeted JAM-C and ZO-2.
A single nucleotide difference outside the seed sequence 
of miR-23s is responsible for differential regulation of 
JAM-C
The inhibition of luciferase activity of ZO-2 is similar between 
miR-23a and miR-23b (Figure 5d). However, the inhibition 
of luciferase activity of JAM-C by miR-23a was significantly 
stronger than by miR-23b (Figure 5e). This is consistent with 
the greater inhibition of protein expression of JAM-C by miR-
23a compared with miR-23b (Figure 5b). Furthermore, this 
difference was maintained even after the mutation of the two 
most conserved binding sites (1,044 and 2,415), suggesting 
the difference did not arise from miR-23 seed sequence bind-
ing (Figure 5e). An increase in the dose of mimic (miR-23a 
or miR-23b) still showed miR-23a has a more pronounced 
inhibitory effect than miR-23b on JAM-C (not shown).
Since nucleotide g19 (guide strand19) is the only differ-
ence between miR-23a and miR-23b, we examined the effect 
this difference had on binding characteristics. The miR-23a/
ZO-2 alignment is the same as miR-23b/ZO-2 alignment 
on the conserved 366 site, with an identical mirSVR score 
of −0.9603 (www.microrna.org). However, the miR-23a/
JAM-C alignment is different to miR-23b/JAM-C alignment 
on the well-conserved 2415 site (WT1) with mirSVR scores 
of −0.1507 versus −0.1398 respectively. This suggests that 
miR-23a has a better base-pair binding than miR-23b to 
JAM-C 3′UTR. Indeed, as shown in Figure 5f, g19 “A” in 
miR-23b pairs with t17 “U”, with an accompanying loop-out of 
residues g9 and g10 to allow an additional pairing of t9 and 
t10 with g11 and g12. This altered configuration of miR-23b/
JAM-C spanning nucleotides 9–12 is likely to cause topologi-
cal constraints within its nucleic acid-binding binding channel 
of Ago2. The extension of complete pairing beyond the seed 
region has been shown, in structural studies, to cause major 
changes in Kd.37 To examine whether these differences con-
tributed to stronger effects of miR-23a on JAM-C, we mutated 
t17“U” in JAM-C 3′UTR site to “A” (Figure 5f). The mutation 
(Mut3) abolished the difference in binding to JAM-C 3′UTR 
between miR-23a and miR-23b, although both miR-23a 
and miR-23b still significantly inhibited the luciferase activ-
ity (Figure 5g). Thus together, these experiments show that 
seed sites are not the only sequences contributing to target 
repression, with nucleotides outside the seed sequence also 
contributing additional affinity.
Physiological regulation of miR-23 paralogues
Since miR-23a and miR-23b potentially can have differ-
ent targets, it may suggest that they will show different 
patterns of regulation during the different stages of angio-
genesis. Therefore, we measured endogenous expression 
of miR-23a/b, JAM-C, and ZO-2 in HUVECs under different 
conditions. When HUVECs were grown to confluence, miR-
23a was significantly and consistently up-regulated on day 
3 and 4 whereas miR-23b was down-regulated (Figure 6a). 
Figure 6 Physiological regulation of miR-23 paralogues. 
(a) Expression of miRNA-23a and miR-23b in 3–4 days postseeding. 
Data are normalized to levels on Day 1 after seeding, which did not 
differ from Day 0. (b) Expression of miR-23a, miR-23b, and mRNA 
for JAM-C and ZO-2 24 hours after seeding at different density. 
Density 1, 2, and 3 corresponds to 1 × 105, 2 × 105, and 3 × 105 HUVECs per well of six-well plate. Expression levels were measured 
by qRT-PCR, with the results of microRNA normalized to U48 and 
mRNA normalized to β-actin. Graph represents mean ± SEM; n = 5 
independent experiments. *P < 0.05, **P < 0.01. (c) Schematic of 
proposed function of miR23a and miR-23b in the regulation of EC 
function. LNA, locked nucleic acid; HUVEC, human umbilical vein 
endothelial cells; PCR, polymerase chain reaction.
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In contrast both showed a parallel up-regulation when cells 
were plated at different densities (Figure 6b). The increase in 
miR-23a and miR-23b upon plating at different densities was 
accompanied by a decrease of JAM-C but not of ZO-2 (Fig-
ure 6b). Thus, both miR-23a and miR-23b and their targets 
ZO-2 and JAM-C are differentially regulated in expression 
depending on context.
Discussion
The tight control of vascular permeability is one of the chief 
functions of the endothelial lining of blood vessels. Abnor-
mal vascular leakage contributes to many pathophysiological 
events including all forms of ischemia, trauma, inflamma-
tory and degenerative diseases.10,38–40 EC–EC junctions are 
formed by at least 17 proteins, uniting in either adherens or 
tight junctions. These in turn are controlled by intracellular 
signals generated by agonists such as histamine, VEGF and 
thrombin, by the balance of expression of proadhesive and 
antiadhesive proteins and by the macromolecular assem-
bly of the components. It has been anticipated that such a 
complex cellular system is subject to fine tuning and over-
all orchestration by microRNAs, since they are known to 
have special roles in complex cellular and developmental 
systems.5,11,20–22
The miR-23-27-24 cluster has been noted to have a 
diverse set of effects on the cardiovascular system and been 
linked to individual targets of single miRs in this cluster.18,41 
While this has been a significant advance, an additional 
challenge is to understand how this highly conserved cis-
tron orchestrates these cardiovascular effects. We and oth-
ers have noted that bioinformatics analysis has revealed a 
highly significant concentration of targets related to adherens 
junctions, tight junctions and transendothelial migration, of 
members of the cistron.13 We have previously validated VE-
cadherin being a target of miR-27a10 and now we show that 
an additional five junctional proteins are regulated by miR-
23. Two of these five proteins are confirmed to be direct tar-
gets of miR-23. In total, 3 of 17 major junctional molecular 
(18%) and 8 of 35 junctional regulating proteins (23%) are 
validated. Statistical analysis demonstrated that this enrich-
ment in EC junctional related genes was extremely unlikely 
to have accumulated by chance (P = 2.87 e−6, q = 5.31 e−3), 
thus suggesting very strongly that this conserved group of 
miRs has evolved to orchestrate (among other things) the 
function of EC junctions. The paradoxical situation however 
arises, as the proteins regulated often have opposing effects. 
For example, VE-cadherin and ZO-2 keep junctions intact,1,2 
while JAM-C and SEMA-6A have repulsive properties.3,12 
Thus, questions arise as to how the balance between these 
influences is regulated, and indeed whether individual miRs 
can be therapeutic targets having opposing functional tar-
gets. We have previously addressed the latter issue where 
we used the novel Blockmir technology to specifically and 
successfully target miR-27a-VE-cadherin interaction.10
With an identical seed sequence, it was somewhat surpris-
ing that the two miRs demonstrated robust differences on 
two important EC functions, angiogenesis and vascular leak. 
A similar difference between these isoforms was also noted 
in their effect on cytotoxic T cells where only miR-23a sup-
pressed function although miR-23a and miR-23b had similar 
expression pattern.25 We have observed a difference in the 
effect of miR-27a/b on VE-cadherin (data not shown), and 
others have of the miR-126a/b-Pak1 interaction.24 The com-
plexity of miR effects arises not only because the same miR 
can target genes with opposing functional effects, but also 
because some targets (or long noncoding RNAs) can also 
act as decoys altering the availability of miRs42–45 and in some 
instances the star strand (with a complementary sequence 
to the miR) can become functional.46–49 We have here inves-
tigated the molecular basis of these differences in miR-23 
on the vascular system by choosing two of its predicted tar-
gets, the attractive protein ZO-2 and repulsive protein JAM-C. 
The choices were based on the tightness of binding of miR-
23 to the 3′UTR of these genes (both bound at least 7/8 of 
the seed region in both human and mouse Supplementary 
Figure S3), the uniqueness of binding (being either the only 
(JAM-C) or one of two miRs (ZO-2) and the fact that these 
targets have been linked to regulation of angiogenesis and 
permeability.2,3 We confirmed that JAM-C and ZO-2 are direct 
targets of miR-23a/b, but miR-23a had more significant effects 
on JAM-C expression than did miR-23b  (Figure 5). The sin-
gle difference predicted a differential pairing  (Figure 5f) with 
a loop out in the original residue 9 and 10, and thus extend-
ing complementarity to t9 and 10 (with now g11 and 12). A 
point mutation in JAM-C changing g19 from A to U abolished 
the difference in function between the two miRs, whereas 
mutating the seed region reversed the effect of miR-23b, 
while maintaining the differential effect of miR-23a and miR-
23b. These results are consistent with recent structural and 
functional studies37 showing contributions from nonseed 
sequences in miR function and affinity for Ago2. The comple-
mentary target site in mouse and human differs by several 
nucleotides outside the seed region. However, g19 is the criti-
cal nucleotide in this region to confer target selection as dem-
onstrated by mutations at this site. We also show that the two 
paralogues can be expressed differentially. As EC approach 
confluence there is an increase in expression of miR-23a but 
a decrease of miR-23b, and there is also a divergence in the 
expression of the two targets JAM-C and ZO-2. In other cells 
and stimulation the paralogues are differentially expressed49 
and in a number of normal tissue (miRGator v3.0) and 
tumors.13 Thus, these experiments demonstrate that these 
two miRs can preferentially target different genes, that they 
can have different functional consequences depending on 
their target genes and that this differential target specificity, 
together with a differential expression of the miRs may have 
a major role in their functional effects (schematic of proposed 
functions is given in Figure 6c). Such differences are likely 
to have general applicability across many miR paralogues. 
Thus, therapeutic manipulation may need to address these 
issues.
Materials and Methods
Cell culture. HUVECs were isolated and cultured as previ-
ously described10 and used between passage two and four. 
The umbilical cords were anonymous (donors nonidentifiable) 
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and informed consent was given for their use. HEK293T were 
maintained in Dulbecco’s modified essential medium (Life 
technologies. Carlsbad, CA) supplemented with 10 % fetal 
calf serum. The mouse brain EC line MVEC/B3 cell line was 
cultured in Roswell Park Memorial Institute 1640 (RPMI) 1640 
(Life technologies) supplemented with 10% fetal calf serum.50 
HCMEC/D3 cell line was kept in Endothelial Basal Medium 
supplemented by bullet kit (Lonza, Basel, Switzerland).
Transfection with miRNA mimics and LNA. HUVECs were 
seeded at 3 × 105 cells per 25 cm2 flask and grown over-
night. Prior to performing all in vitro experiments, we have 
confirmed the high level of transfection efficiency (>90%) by 
using microRNA mimic transfection control- Dy547 labeled 
(Thermo Scientific Dharmacon) and fluorescence labeled 
LNA inhibitor (Exiqon, Vedbaek, Denmark). Mimics or control 
(miRIDIAN microRNA mimics, Dharmacon, Lafayette, CO) of 
miR23a or miR23b were transfected at final concentration of 
15 or 1.5 nmol/l for in vitro functional assays. LNA-modified 
antisense oligonucleotide miRNA inhibitor or scramble con-
trol (Exiqon) were used for inhibition of miR23a/b at final con-
centration of 15 nmol/l. All transfections were performed with 
HiPerFect transfection reagent (Qiagen, Hilden, Germany) 
following the manufacturer’s instructions.
Scratch assay. HUVEC cells were grown to 100% confluency 
on gelatin-coated six-well plates. Scratches across the HUVEC 
monolayer were then made using a 200 µl pipet tip. Cells were 
harvested for RNA extraction during an indicated time course.
In vitro permeability assay. In vitro permeability assay was 
performed in a 24-well tissue culture plate with 12 cell cul-
ture inserts as previously described. In brief, 24 hours after 
transfection, transfected HUVECs were plated onto fibronec-
tin-coated 0.3-µm pores inserts (Transwell; Corning Costar, 
Acton, MA) at 1 × 105 cells per insert in HUVEC medium. The 
cell monolayer formed in 24 hours. Cells were stimulated 
with 0.1–0.2 U/ml thrombin (Sigma, St. Louis, MO), 10 µmol/l 
histamine (Sigma), or 50 ng/ml human VEGF165 (R&D sys-
tems, Minneapolis, MN) for 30 minutes if required. FITC-
conjugated dextran was added to the upper chamber, and 
medium was taken from the lower chamber (20 µl) over the 
following 60 minutes. The amount of fluorescence was mea-
sured using a POLARstar Omega microplate reader (BMG 
Labtech, Ortenberg, Germany) at an excitation wavelength of 
485-12 and emission wavelength of 520P. The FITC-dextran 
fluorescence intensity over that of controls was used as a 
measure of the permeability of EC monolayers.
Miles assay for in vivo permeability measurement. Miles 
assay was employed for measuring in vivo permeability.10 In 
brief, 4 µg of the miR-23a mimic or LNA-23 or corresponding 
control was injected intradermally into the back of 8 week-old 
C57BL/6J-Tyrc-2J/J mice. During intradermal injection, mice 
were anaesthetized using isoflurane/oxygen (induced at 4% 
and maintained at 1–2% isoflurane vaporizer during treatment). 
After 24 hours, 200 µl of 0.5% Evans blue dye was injected 
intravenously, followed by injection of phosphate-buffered saline 
or 10 ug of VEGF (R&D systems) intradermally into the same 
site as the mimic 30 minutes later. After another 30 minutes, 
mice were sacrificed by cervical dislocation. For measurement, 
a biopsy of the injection site was taken, the dye eluted in for-
mamide overnight at 56°C with shaking. After centrifugation, 
the amount of dye was measured at 620 nm using a POLAR-
star Omega microplate reader (BMG Labtech).
In vitro 3D collagen angiogenesis assay. This was similar to 
that described elsewhere.51 HUVEC were isolated from umbili-
cal cords and cells were cultured under normal conditions. 
Cells were then detached and stimulated with an anti-α2β1 
antibody (AC11) for 7 minutes and then with  phorbol-12- 
myristate-13-acetate (PMA) for 1 minute. Cells were plated 
onto 3D collagen for the appropriate time. Capillary tube for-
mation occurred over the following 24 hours.
In vitro Matrigel capillary tube formation assay. The tube forma-
tion capability of ECs was evaluated by the Matrigel angiogen-
esis assay.10 Briefly, HUVECs (3.5 × 104 cells per well for mimic 
treated cells; 2.5 × 104 cells for LNA experiments in order to 
see inhibition and enhancement respectively) were plated in a 
96-well plate precoated with 100 µl Matrigel (BD Biosciences, 
Bedford, MA) per well 48 hours post-transfection. Cells were 
monitored and photos were taken every hour, for 7 hours and 
then repeated after 18 hours. Image analysis and quantification 
was performed using the WimTube software (Wimasis GmbH, 
Munich, Germany) to evaluate the generation of new vessels 
base on parameters including total tubes, tube length and total 
branching points. The result was normalized to control.
In vivo Matrigel plug angiogenesis assay. The Matrigel plug 
assay was performed as we have previously described.10 
Six to eight week-old female C57BL/6 mice were injected 
subcutaneously with 500 µl of Matrigel (BD) premixed with 
60 U/ml heparin and 400 ng/ml FGF-2 (Sigma), 15 µg con-
trol or miR-23a or miR-23b mimic. After 14 days, the mice 
were killed, the Matrigel plugs were isolated, resected and 
fixed in 10% paraformaldehyde. 4 µm cross-sections were 
stained with CD31 monoclonal Ab (mAb, Caltag Medsys-
tems, Buckingham, UK) to detect ECs of blood vessels in 
the Matrigel by using immunohistochemistry. The extent of 
angiogenesis was quantified as the blood vessel density by 
visually counting the total number of CD31-positive vessels 
per microscopic field.
Immunofluorescence and confocal microscopy. Localization 
studies were performed as we have previously described.10 In 
brief, 1.5 × 104 HUVECs were plated onto fibronectin coated 
labtek slides, LabTek slides (Thermo Fisher Scientific, Roch-
ester, NY) for 24 hours, followed by treated with miR23a/b 
mimics or control as described in the method of transfection. 
48 hours later, cells were fixed with a 50–50 mixture (v/v) of 
−20°C acetone – methanol for 20 minutes. Cells were then per-
meabilized by application of 0.1% Triton X-100 in 2% bovine 
serum albumin (Sigma). Incubation with the primary antibody 
(VE- cadherin, goat anti rabbit, Santa Cruz Biotechnology, 
Santa Cruz, CA) was followed by a secondary antibody Alexa 
594 donkey anti goat, Life technologies). Localization of VE-
cadherin was viewed under a Leica SP5 confocal microscopy 
(Leica Microsystems, Wetzlar, Germany). Images were ana-
lyzed by using Fiji software (Version 2.2.2-rc-34/1.50a).
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Luciferase reporter assay. HEK293T cells were transfected 
with Renilla luciferase reporter constructs containing miR-23 
binding sites (JAM-C 3′UTR WT or mutated sites, Switchgear 
genomics, Carlsbad, CA), along with pGL3 control vector, 
which contained the firefly luciferase reporter gene (Promega, 
Madison, WI) and 30 nmol/l of miR-23a/b mimics or control. 
Luciferase activity was quantitated 24 hours later using Dual-
Luciferase Reporter Assay System (Promega) on a POLAR-
star Omega microplate reader (BMG Labtech) according to 
the manufacturer’s recommendations. Three independent 
experiments were performed and assayed in triplicate per 
group. Data represent the S.E for three experiments. Relative 
luciferase activity (Renilla/firefly) was expressed in relative 
luminescence units and plotted.
RNA preparation and quantification of gene expression using 
quantitative Reverse Transcription PCR. Total RNA, includ-
ing small RNA fraction was extracted from ECs using Trizol10 
For validation of miR-23 family expression from microarray, 
HUVEC were harvested, stimulated with PMA and AC11 and 
lysed (as control) or replated after stimulation onto a 3D colla-
gen gel (3D) for 30 minutes. RNA was isolated for each condi-
tion and two steps real-time PCR was used to measure miRs. 
First, 1 µg of RNA was reverse transcribed using microRNA-
specific primers from Applied Biosystems. Second, real-time 
PCR was performed in combination with predesigned prim-
ers for miR-23a/b and RNU48 or RNU6 small nuclear RNA 
(snRU48 and snRNU6B reference gene). For mRNA quanti-
fication, cDNA were made by using reverse transcription kit 
followed by TaqMan probe based real-time PCR (Life tech-
nologies). The relative RNA amount was calculated with the 
2-∆∆CT method. All reactions were performed in quadruplicates 
and repeated in three biological replicates using Applied Bio-
systems 7900HT machine (Life technologies).
Preparation of cell extracts and Western blotting. Western blot 
analysis was performed as previously described.10 Whole-
cell lysates were prepared using lysis buffer (1 mol/l TrisHCl, 
pH 7.5, with 1% NP-40, 5 mol/l NaCl, 200 mmol/l EGTA, 500 
mmol/l NaF,100 mmol/l Na4P2O7 containing 1× protease 
inhibitor cocktail (Sigma)). We used NP-40, a milder, non-
ionic detergents in the lysis buffer for isolating cytoplasmic 
proteins although it does not lyse nuclear membranes. Pro-
teins concentrations were quantified using Bradford reagent 
(BioRad, Hercules, CA) and bovine serum albumin as stan-
dards. Equal amounts of protein were loaded onto a 4–15% 
precast polyacrylamide gel (BioRad) and separated by elec-
trophoresis in the running buffer, and then transferred to 
PVDF (polyvinyl difluoride) membranes in transferring buffer, 
blocked with 5% skim milk powder in PBS-Tween 20 (0.05%). 
The membranes were probed with a JAM-C antibody (mouse 
monoclonal antihuman, Santa Cruz), ZO-2 (Cell Signaling, 
Danvers, MA), β -actin, α-tubulin (Santa Cruz) overnight 
at 4 °C or for 1 hour at room temperature, followed by cor-
responding HRP-conjugated antibody (1:5,000; Amersham, 
UK) for 1 hour at room temperature. Proteins were visualized 
using ECL or ECL Plus Western blotting Detection Reagents 
(GE Healthcare, Little Chalfont, UK) on ChemiDoc MP sys-
tem (Bio-rad). Densitometric analysis was performed using 
ImageJ version 1.48, NIH, USA software.
Target prediction. The predicted targets of individual members 
of the miR-23-27-24 cistron were analyzed by TargetScan 
(Release 6.2). Modified gene set enrichment analysis (GSEA) 
was used to assess functional significance at the level of sets 
of genes as previous described.52 All of these potential tar-
gets were compared with the “c2_all” collection of curated 
gene sets from the Molecular Signatures Database (GSEA 
Version 2.0.14 Broad Institute, Cambridge, MA), consisting 
of 1,077 genesets corresponding to BIOCARTA, KEGG, and 
REACTOME biological pathways. The False Discovery Rate 
q-values is deemed significant value at < 0.05.
Statistical analysis. Data were presented as mean ± SEM 
and plotted using GraphPad Prism 5 software. For statisti-
cal comparison of two groups, unpaired, two-tailed Student’s 
t-test was used. A value of P < 0.05 was considered statisti-
cally significant.
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Supplementary material
Table S1. Targetscan 6.2 or Diana predicated targets of miR-
23~miR-27~miR-24 clusters known to be present in KEGG 
adherens junctions pathway.
Figure S1. Quantification of miR-23a and its predicated tar-
gets in human cerebral microvascular endothelial cell line 
treated with  miR-23a mimic and LNA to miR-23.
Figure S2. Quantification of miR-23a/b in ECs treated with 
microRNA mimics and LNAs.
Figure S3. TargetScan 6.2 predictions of interactions be-
tween microRNA and 3′-untranslated region of the JAM-
C (JAM3) or ZO-2 (TJP2) mRNA. Only conserved sites for 
miRNA families broadly conserved among vertebrates were 
considered for prediction.
Figure S4. Differential regulation of JAM-C and ZO-2 by miR-
23a and miR-23b.
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Table S1. Targetscan 6.2 or Diana predicated targets of miR-23~miR-27~miR-24 
clusters known to be present in KEGG adherens junctions pathway. 
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Figure S1. Quantification of miR-23a and its predicated targets in human cerebral 
microvascular endothelial cell line treated with miR-23a mimic and LNA to miR-23 
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Figure S2. Quantification of miR-23a/b in ECs treated with microRNA mimics and 
LNAs. 	
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Figure S3. TargetScan 6.2 predictions of interactions between miRNA and 3′-
untranslated region of the JAM-C (JAM3) or ZO-2 (TJP2) mRNA. Only conserved 
sites for miRNA families broadly conserved among vertebrates were considered for 
prediction. 
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Figure S4. Differential regulation of JAM-C and ZO-2 by miR-23a and miR-2b
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INTRODUCTION 
Chapter 2 shows the miRNAs that have the same seed sequence may have different 
target genes and biological functions in the same cell. Conventional antagomiRs 
cannot discriminate between miRNA paralogues. This is one of the reasons why 
miRNA inhibitors currently have limited clinical use. An alternate strategy is to 
design inhibitors that binds to the binding site on a miRNA target, rather than the 
conventional binding to miRNAs to inhibit function, thus leading to more specific 
regulation.  
We have developed a target site blocker, CD5-2, using the Blockmir technology 
developed by our collaborator Ranger Therapeutics in Denmark. BlockmiR CD5-2 
specifically prevents miR-27a binding to the VE-cadherin 3’UTR, leading to increase 
in VE-cadherin expression.  
Cerebral Cavernous Malformations (CCM) are featured by abnormal vascular 
integrity with decreased VE-cadherin expression in the affected lesions. At present 
there is no effective treatment for patients with CCM other than surgical resection. 
Indeed, a number of CCM downstream signalling pathways have been reported to be 
orchestrated by VE-cadherin. This makes using BlockmiR CD5-2 a novel therapeutic 
to target VE-cadherin for treatment of CCM. In this chapter, the effect of CD5-2 on 
CCM development has been investigated.  
The data generated from this chapter is presented as the manuscript format submitted 
to Plos Biology. 
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Abstract    
Cerebral cavernous malformations (CCMs) are vascular lesions predominantly 
developing in the central nervous system, with no effective treatments other than 
surgery. Loss of function mutation in CCM1/KRIT1, CCM2 or CCM3/PDCD10 
causes lesions that are characterized by enhanced permeability. VE-cadherin, a major 
regulator of endothelial cell junctional integrity is strongly disorganized in endothelial 
cells lining the CCM lesions. MiR-27a, a negative regulator of VE-cadherin is 
elevated in endothelial cells isolated from mouse brains developing early CCM lesions 
and following CCM depletion in vitro. Further, we show miR27a acts downstream of 
KLF2/4, two known key transcription factors involved in CCM lesion development.  
The novel drug Blockmir CD5-2, which prevents the miR-27a/VE-cadherin mRNA 
interaction rescues VE-cadherin expression in CCM1 or CCM2-depleted endothelial 
cells, reduces monolayer permeability and restores dermal vessel	barrier	function	in	
Ccm1	heterozygous mice. In a neonatal mouse model of CCM disease, CD5-2 reduces 
vascular leakage in the hindbrain, inhibits the development of large lesions and 
significantly reduces the size of established lesions in the hindbrain. In the retina, 
CD5-2 also inhibits CCM lesion growth. These studies suggest that restoration of VE-
cadherin expression through CD5-2 treatment is a potential novel therapy for CCM. 
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Significance Statement 
 
Cerebral cavernous malformations (CCM) are leaky vascular lesions that result in 
hemorrhagic stroke. There are no effective drugs available. VE-cadherin is strongly 
disorganized in the endothelial cells lining the CCM lesions. CD5-2 is a drug that 
specifically inhibits the interaction between microRNA-27a and VE-cadherin, 
resulting in upregulation of VE-cadherin. Here we provided evidence for the 
beneficial effects of CD5-2 on CCM lesions. In a neonatal mouse model of CCM 
disease, CD5-2 increases VE-cadherin expression in the lesions, inhibits the size of 
lesions and the vascular leak associated with lesion development in the brain. Further, 
CD5-2 inhibits the inflammatory phenotype associated with lesions. Our findings 
showed VE-cadherin as a novel target in CCM and demonstrated VE-cadherin target 
therapy rescues CCM lesions.  
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Introduction 
Cerebral cavernous malformations (CCM) are vascular malformations mostly 
occurring in the central nervous system (CNS) [1]. CCM lesions are formed by 
abnormal dilated blood capillaries. One of the key features of CCM is the existence of 
gaps between EC lining the lesions [2], which are leaky and can cause hemorrhagic 
stroke and seizure [3-5]. Currently there is no treatment for CCM other than surgery, 
which is limited by size and depth of the lesions.  
Familial CCM in humans are a result of loss-of-function mutation in either one of 3 
genes, CCM1 (KRIT1), CCM2 and CCM3 (PDCD10)[6]. Mice with postnatal loss of 
Ccm genes in endothelial cells (EC) develop similar brain vascular lesions as seen in 
human CCM patients. In both humans and mice, loss of CCM1 or CCM2 leads to 
similar defects in vascular integrity, morphology and burden of CCM lesions, with 
CCM3 deletion giving a more severe phenotype [7-10]. Nevertheless all mutations 
have similarly abnormal blood vessels with increased permeability in both established 
lesions and in other vascular structure such as in skin and lung. 
The molecular pathways involved in CCM development include the KLF2/4 pathway, 
endothelial-to-mesenchymal transition, RhoA/ROCK, and more recently, TLR4 
signaling through gut microbiome composition [3, 9, 11-14]. Although the clinical 
course of CCM disease is highly variable , a common feature is the disruptive EC–EC 
junctions and enhanced permeability [2, 4, 11, 15], which likely explains the 
hemorrhage and inflammatory response in CCM. Consistent with this, key endothelial 
junction molecules, including VE-cadherin, ZO-1 and claudin-5, are decreased or 
disorganized in lesions [10, 16]. Therapies that restore the expression of key junctional 
molecules and in particular the ‘hub’ of junctional molecules, VE-cadherin and act to 
reduce vascular leak could have a profound impact on CCM disease [17]. Indeed, the 
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RhoA kinase inhibitor fasudil, and to a lesser extent, simvastatin decreased CCM 
lesions through restoring vascular integrity in mice [9, 18]. 
MicroRNAs are key regulators of gene expression and generally act to inhibit protein 
expression [19]. We have developed a new type of microRNA inhibitor, an 
oligonucleotide-based drug, BlockmiR CD5-2, that specifically inhibits miR-27a 
binding to the 3’UTR of VE-cadherin and as a consequence, CD5-2 results in 
elevation of endogenous VE-cadherin expression and restoration of vascular integrity 
in peripheral and cancer vessels [20, 21].  Our previous findings suggested that CD5-2 
may have a therapeutic benefit in CCM and our study herein explores this possibility 
in vitro and in vivo using Ccm1 and Ccm2 EC specific knockout mice.  
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Results  
Key downstream signaling of CCM gene  
We first examined the in vitro effects of CCM1 or CCM2 depletion in EC function. 
Depletion of CCM1 or CCM2 with siRNA in both primary human umbilical vein 
endothelial cells (HUVEC) and in the brain microvascular endothelial cell line, 
hCMEC/D3 (SI Fig. S1A) resulted in a significant decrease in the expression of the 
key junctional molecules, VE-cadherin and claudin-5 (SI Appendix Fig. S1B). EC-EC 
junctions exhibited a disrupted phenotype as evidenced by weaker and discontinuous 
VE-cadherin staining (SI Appendix Fig. S1C). Knockdown of CCM1 or CCM2 also 
increased RhoA activity, shown by increased phospho-myosin light chain (pMLC), a 
feature also known to contribute to disruptive vascular integrity [12] (SI Appendix Fig. 
S1C). The disrupted junctions induced by either CCM1 or CCM2 depletion, were 
confirmed by the increased permeability of FITC-dextran through EC monolayers (SI 
Appendix Fig. S1D). Thus, the effects on permeability and RhoA activity by CCM1 
and CCM2 siRNAs were largely in line with previous reports, although in our case, 
CCM1 knockdown gave a stronger effect than the deletion of CCM2. Since the 
knockdown of CCM1 or CCM2 by specific siRNAs was > 90% (SI Appendix Fig. 
S1A), the difference is likely due to the factors other than the difference in knockdown 
efficiency. Nevertheless, in the animal models we used in the present study, there was 
no significant difference in the CCM lesions formed between Ccm1ECKO and 
Ccm2ECKO [8].  We therefore chose Ccm2ECKO mice for further investigations. 
Effect of BlockmiR CD5-2 on CCM downstream signaling in vitro 
MicroRNAs in general play an important role in regulating vascular integrity by 
targeting EC junctional molecules [22], with VE-cadherin being one of the direct 
targets of miR-27a [20]. Depletion of CCM1 or CCM2 in EC increased miR-27a (Fig. 
CHAPTER 3 	
	 100	
1Ai). Since CCM-depletion-induced elevation of KLF2 and KLF4 is a key causal 
factor for CCM development [3, 14] we hypothesized that elevated miR-27a may be 
due to higher KLF2/4 expression. Knockdown of KLF2 or KLF4 by siRNA partially 
inhibited the CCM2-depletion-induced miR-27a upregulation in cultured EC. 
Knockdown of both KLF2 and KLF4 completely rescued miR-27a upregulation (Fig. 
1Aii). These studies reveal that loss of CCM2 increases miR27a at least partially 
through upregulating KLF2/4 expression.  
Since CD5-2 blocks the interaction between miR-27a and VE-cadherin resulting in an 
increase in VE-cadherin expression and a restoration of vascular integrity [20, 21], we 
tested whether CD5-2 could reverse the effects of CCM depletion.  Indeed, CD5-2 
restored VE-cadherin and also claudin-5 expression [23], a key downstream junction 
molecule regulated through VE-cadherin (Fig. 1B) [21]. CCM lesions are also 
characterized by increased inflammation including up-regulation of the adhesion 
molecule ICAM-1, which may be due to an increase in NF-κB activity mediated by 
loss of CCM gene [11, 24, 25]. CD5-2 treatment significantly inhibited the 
upregulations of ICAM-1 expression and NF-κB activity as measured by phospho-p65 
expression, indicating an inhibition of inflammation (Fig. 1C, D).  Further, CD5-2 
decreased the elevated pMLC, in the CCM1 or CCM2 depleted EC, as visualized by 
immunofluorescence staining, suggesting an inhibition of the RhoA/ROCK activity 
(Fig. 1E). Although KLF2/4 overexpression is critical for CCM development [3, 14], 
CD5-2 had no effect on the expression of KLF2/4 suggesting that the CCM-induced 
up-regulation of KLF2/4 is VE-cadherin independent (Fig. 1F). To examine whether 
VE-cadherin is involved in the regulation of KLF2/4 expression in EC, we measured 
KLF2/4 expression in VE-cadherin null EC [26]. Upon depletion of Ccm2, KLF2/4 
expression in VE-cadherin null EC is still significantly upregulated (Fig. 1G), 
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suggesting that the CCM2-induced up-regulation of KLF2/4 is VE-cadherin 
independent.  
BlockmiR CD5-2 restores CCM1 haploinsufficiency induced vascular barrier 
dysfunction 
CD5-2 reversed the EC monolayer permeability induced upon CCM depletion (Fig. 
2A) consistent with its effects to inhibit pMLC activation and to restore VE-cadherin 
levels. , To assess the anti-permeability effects of CD5-2 in vivo, we used adult Ccm1 
heterozygous (Tie2Cre, Ccm1fl/+) mice since these mice have been shown to exhibit 
increased basal vascular leak[9]. The mice were injected intradermally with CD5-2 or 
control Blockmir. 24 hours later they received a further intradermal injection of PBS 
or vascular endothelial cell growth factor (VEGF) to the same site as the 
oligonucleotide injection. They showed a strong response to VEGF, as measured by 
the intensity of Evans blue dye in the skin, in line with previous reports [9, 12] (SI 
Appendix Fig. S1Ei,ii). CD5-2 treatment inhibited the permeability under both basal 
conditions and after VEGF stimulation (Fig. 2B, SI Appendix Fig. S1Eiii, iv, v).  
BlockmiR CD5-2 reduces the size of CCM lesion and the number of large CCM 
lesion 
The 4-OH tamoxifen-inducible endothelial–specific Ccm1 (Ccm1ECKO) or Ccm2 
(Ccm2ECKO) loss-of-function mice have been used as a model system for CCM. 
Ccm2ECKO mice develop lesions in both brain and eye (SI Appendix Fig. S2A, B) with 
numerous lesions presented by P12 [3, 27]. In line with previous reports [11, 27], the 
vascular lesions in the cerebellum of Ccm2ECKO mice at P12 showed abnormal 
vascular integrity with weak and discontinuous VE-cadherin expression (SI Appendix 
Fig.  S2Aii). This is similar to CCM lesion from human patients, where VE-cadherin 
expression is also disrupted [16] (SI Appendix Fig. S2C)  
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To investigate whether elevated miR-27a is an early event in CCM development, we 
measured its expression in the ECs extracted from P5 and P8 CcmECKO mouse brains. 
Compared to the levels seen in the control mice, miR-27a is approximately 70% 
higher in Ccm1ECKO and Ccm2ECKO at P8 (Fig. 2C) and 25% higher in EC from P5 
Ccm2ECKO mice (SI Appendix Fig. S2D), a time prior to the appearance of CCM 
lesions at P6 [3]. This is consistent with the report showing miR-27a is highly 
upregulated in the brain tissues from human CCM patients [28]. These results indicate 
that elevated miR-27a may contribute to CCM lesion formation possibly by targeting 
the EC junctional molecule, VE-cadherin.  
We then evaluated the effect of CD5-2 on CCM formation by treating animals, as 
indicated in SI Appendix Fig. S2C, at P6 and P8, and assessed lesions at P12. CD5-2 
was delivered to Ccm2ECKO mice through i.p injection and 6 h later was localized to 
brain EC, as assessed by in situ hybridization (Fig. 2D). A single treatment of CD5-2 
at P6 was able to inhibit vascular leakage in Ccm2ECKO mice (Fig. 2E). CD5-2 
delivered at P6 and P8 significantly reduced the vascular lesion burden, as shown, for 
3 representative mice (Fig. 3A). Lesion size was reduced as assessed morphologically 
in hindbrain sections by H&E staining and by CD31 staining (SI Appendix Fig. S2E,F 
respectively). To precisely quantitate CCM lesions we then imaged P12 hindbrains 
using contrast-enhanced, high-resolution X-ray micro-tomography (microCT) and 
measured lesion volumes using semi-automated software [3, 8] (Fig. 3B). Treatment 
of Ccm2ECKO mice with CD5-2 conferred more than 60% inhibition in both total CCM 
lesion volume and the size of the large lesions (Fig. 3Ci-iv). In addition, there was a 
trend for CD5-2 to reduce the total lesion numbers, although the difference was not 
statistically significant (Fig. 3D). However, when the lesions were classified into three 
groups according to their size, CD5-2 significantly reduced the large (>10-2 mm3) and 
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medium (10-3-10-2 mm3) lesions but not the small (<10-3 mm3) lesions (Fig. 3E). Large 
lesions	are more likely to have abnormal EC junctions shown by discontinuous VE-
cadherin staining (SI Appendix Fig. S2Aiii). The lesion size is correlated with vascular 
leak susceptibility and reflects the severity of CCM disease [27, 29]. Of note, the 
larger CCM lesions in humans are those that are more prone to hemorrhage, and which 
therefore are more likely to need surgical intervention [18]. 
BlockmiR CD5-2 normalises endothelium in CCM  
CD5-2 markedly increased VE-cadherin expression in EC lining CCM lesions (Fig. 
4A). This is in line with the results of scanning electron microscope (SEM), where 
CD5-2 treated animals have improved vascular integrity with clear EC junctions and a 
flattened morphology indicative of less-activated cell (Fig. 4B). CD5-2 reduced 
ICAM-1 expression (Fig. 4C) and consistent with the role of this adhesion molecule in 
inflammation, CD5-2 treatment resulted in a reduction in the CD11b subpopulation of 
leukocyte associated with the vessel wall in the lesions (SI Appendix Fig. S2G). 
Importantly, CD5-2-treated wild-type animals showed no notable differences in the 
appearance and vasculature of brain and retina, and total hindbrain volume at P12 (SI 
Appendix Fig. S3A,B). 
 BlockmiR CD5-2 reduces size of late stage CCM lesion in the hindbrain and 
retina 
These results suggested that CD5-2 has the ability to inhibit the growth of newly 
forming lesions. Perhaps of more clinical relevance is whether CD5-2 can affect 
existing lesions, especially the large lesions. To address this possibility, we treated 
mice at P12 and P14 (rather than at P6 and P8), a time when most of the CCM lesions 
were established and numerous large lesions presented, as is seen in Fig 3A [27]. 
Brains were then dissected at P19 (SI Appendix Fig. S3C). CD5-2 was able to 
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significantly reduce the volume of CCM lesions in the brain (Fig. 5A,B). Although, as 
before, CD5-2 did not affect overall lesion numbers (SI Appendix Fig. S3D), it 
significantly reduced the number and size of the very large, the large and the medium 
sized lesions (Fig. 5C,D). Similar to the effect on P12, CD5-2 did not affect the overall 
volume of the hindbrain analyzed at P19 (SI Appendix Fig. S3E). 	
In the retina of Ccm2ECKO mice, venous malformations developed at the periphery of 
vascular plexus, as visualized by isolectin B4 staining (SI Appendix Fig. S2Bii) and as 
previously reported [11, 27]. In both early (P6 and P8) and late stage (P12 and P14) 
treated animals, CD5-2 inhibited the lesions in the retina (Fig. 6A,B).  
Discussion 
CCM lesions are characterized by the existence of abnormal EC junctions seen in both 
CCM neonatal mouse models and CCM human patients[11]. VE-cadherin is critical in 
the maintenance of vascular integrity [30] and decreased VE-cadherin expression is 
seen in many diseases where vascular leak is central to the pathology [11, 21, 31]. VE-
cadherin is linked to a number of pathways altered in CCM development. For example, 
VE-cadherin regulates the actin cytoskeleton through RhoA [32] and also claudin-5, a 
key protein in tight junctions, which are prominent in the CNS [23, 33]. In addition, it 
is a critical endothelial regulator of TGFβ signaling [34]. Thus, VE-cadherin serves as 
an appealing target for CCM, since RhoA, claudin 5 and TGFβ are all deregulated in 
this disease [9, 11, 12, 27] and are linked to vascular permeability changes. However, 
VE-cadherin levels and localization would need to be increased and there are limited 
technologies for increasing the endogenous expression of proteins especially in vivo. 
MicroRNA targeting offers one alternative but the nature of microRNAs having large 
numbers of targets some with disparate functions may be a limitation for their 
therapeutic use in some circumstances [22]. The Blockmir technology, which 
CHAPTER 3 	
	 105	
generates an inhibitor of a miRNA with a specific mRNA target, is therefore attractive.  
BlockmiR CD5-2 was designed to specifically block the interaction between miR-27a 
and VE-cadherin.  
MiR-27a is increased in EC with depletion of CCM1 or CCM2 and in EC isolated 
from Ccm2ECKO neonatal mice (Figs1A, 2C). In addition, miR-27a is the most 
upregulated microRNA in CCM patients, making the application of CD5-2 in CCM 
disease more rational [28]. Intriguingly, miR-27a is also upregulated in the plasma 
from patients with hereditary hemorrhagic telangiectasia (HHT), a vascular 
malformation also characterized by abnormal vascular integrity and fragile lesions [17, 
35]. Thus, miR-27a could be a common regulator of vascular integrity and CD5-2 may 
be beneficial for more broad vascular malformation diseases.  
KLF2 and KLF4 are causal factors in CCM formation [3, 14, 36]. We show here that 
the increased miR-27a expression is at least partially mediated through KLF2/4 
(Fig1A). This regulation maybe transcriptional [37, 38] since there are at least 3 
putative KLF2/4 binding sites in the promoter of  miR-27a [38]. Two of these are 
conserved between human and mouse, suggesting a mechanism for the KLF2/4 
regulation of miR-27a. KLF2/4 is not downstream of VE-cadherin since CD5-2 has no 
effect on KLF2/4 expression and depletion of CCM2 in VE-cadherin null EC still 
induces KLF2/4 overexpression. Collectively, these results indicate the existence of 
CCM1/2-KLF2/4-miR-27a-VE-cadherin pathway in CCM pathology.  
In brain capillary-venous, where CCM lesions develop, the EC express the lowest 
levels of KLF2/4 in the human body (Data ref: Gene expression for KLF2 
ENSG00000127528.5, KLF4 ENSG00000136826.10, GTEx Analysis Release V7, 
dbGaP Accession phs000424.v7.p2). Loss of function mutation of CCM genes result 
in increased expression of KLF2/4. Since KLF2/4 are responsive to shear stress [39] 
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the protective range of KLF2/4 levels will vary depending on the vascular bed. For 
example, in arterials, KLF2/4 are normally highly expressed and associated with 
vascular stability and lack of inflammation [40, 41]. In disease such as arteriovenous 
malformations (AVMs), Alk1 or endoglin (two key genes for AVMs) depletion 
induced higher-than-normal KLF2/4 expressions, and these increased levels were non-
protective [42].  
In vivo, early CD5-2 treatment inhibited the total volume of lesions, especially the size 
of the large lesions in Ccm2ECKO mice indicating that CD5-2 is able to inhibit lesion 
growth.  CD5-2 also showed strong inhibition on established large lesions and 
suggests CD5-2 may promote the regression of the lesion or, at least, be able to 
stabilise established lesions and to inhibit their growth throughout the timeframe of the 
experiment. The fact that CD5-2 showed strong inhibition on both the number and size 
of the established large lesions would suggest that it maybe therapeutically beneficial, 
since large lesions have more severe disruptive inter-endothelial junctions as shown by 
disorganized VE-cadherin staining and indeed, in humans, these are the lesions more 
likely to hemorrhage[5, 18]. It is difficult to judge whether CD5-2 directly improved 
the organization of VE-cadherin in CCM lesions, or whether the change in VE-
cadherin localisation is a consequence of the reduction in lesion size, as smaller 
lesions tend to have better VE-cadherin localisation. Further, since we did not see 
significant changes in the number of small lesions upon CD5-2 treatment, CD5-2 may 
not influence lesion initiation. Alternately, the small lesions may reflect EC with low 
levels of miR-27a such that VE-cadherin is not regulated. In this situation, CD5-2 will 
not be functional as it inhibits the miR-27a/VE-cadherin interaction rather than having 
a direct effect on VE-cadherin in the absence of miR-27a.  These possibilities require 
further investigations.   
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Inflammation is associated with increasing vascular permeability and infiltration of 
immune cells, both key features of CCM lesions and both controlled by VE-cadherin 
[11, 31, 43]. CD5-2 limits CCM-depleted inflammation evidenced by decreased 
ICAM-1 and NF-κB activation in vitro and reduced ICAM expression and numbers of 
CD11b cells associated with lesions. We have previously shown CD5-2 exhibits 
selectivity on the inflammatory infiltrate, inhibiting the CD11b/Gr1hi population of 
cells into tumors, while promoting CD8+ T cells [21]. The mechanism underlying this 
selectivity is currently being investigated.  
A key question remains for CD5-2 is its specificity. We have previously shown that 
CD5-2 did not regulate other known targets of miR-27a, including SEMA6A and 
PPARγ [20].  CD5-2 regulates VE-cadherin downstream interacting pathways, TIE-2 
and claudin 5 but only when VE-cadherin is expressed [20, 21]. RNA-seq analysis has 
shown CD5-2 induced changes in 141 genes (fold change >2, p < 0.05, FDR < 0.005) 
in EC where VE-cadherin is abundant but in VE-cadherin null EC, no genes were 
differently expressed between control and CD5-2-treated EC when using the same cut-
off criteria suggesting a high specificity for the miR-27a-VE-cadherin axis. The Gene 
Set Enrichment Analysis revealed the regulated genes are highly enriched in cytokine 
signalling pathways, consistent with our data showing CD5-2 treated endothelium 
regulates immune cell trafficking [21]. In addition to the miR-27a binding site in the 
3’UTR region of VE-cadherin, in silico study shows that there are two other possible 
CD5-2 binding sites in the human and mouse genome. One is in the 3’ UTR region of 
ORC4; the other one is located within an exon region of FXR1. To further improve the 
specificity of CD5-2, we have designed CD5-2 analogs that are predicted to only bind 
to VE-cadherin 3’UTR in the human and mouse genome. These analogs are currently 
under investigations.  
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The results herein confirm VE-cadherin as an important potential therapeutic target 
and secondly, CD5-2 has potential as a drug in CCM. Since multiple pathways are 
activated with loss of CCM function, our results raise the possibility of combination 
therapy in CCM disease. Indeed, recently an increase in TSP1, a downstream target of 
KLF2/4, was shown to limit CCM lesions [44] suggesting the possibility that targeting 
both the VE-cadherin and the KLF2/4-TSP1 pathways together maybe synergistically 
beneficial.  Other combinations, such as drugs that are Rho or TLR directed or 
targeting other miRNAs involved in vascular integrity, such as miR-132 [45] may 
exert further additive or synergistic effects.  
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Materials and Methods  
Short interference RNAs (siRNA) against CCM1, CCM2, KLF2, KLF4 or scrambled 
control were used for the in vitro knockdown experiments in HUVECs or Human 
cerebral microvascular endothelial cell line hCMEC/D3. Transwell permeability assay 
was employed to measure the effect of CD5-2 on EC monolayer permeability after 
CCM1 or CCM2 was silenced. Miles assay was used for assessment of CD5-2 on 
dermal vascular leakage in Ccm1fl/+;Tg(Tie2-Cre) mice and wild type (WT) littermates 
[20, 22]. 
To evaluate CD5-2 on the mice with CCM lesions, Cdh5-CreErt2;Ccm1fl/fl  (Ccm1ECKO) 
or Cdh5-CreErt2;Ccm2fl/fl (Ccm2ECKO) mice were employed as previously described 
[3]. Animals were randomly assigned to receive either BlockmiR control or CD5-2 at 
P6 and P8 (early stage treatment) or P12 and P14 (late stage treatment). A 30mg/kg 
dose of BlockmiR at 7.5mg/ml was intraperitoneally injected to	Ccm2ECKO mice and 
wild type (WT) littermates. Pups were euthanized at P12 or P19. Tissues were 
dissected immediately and fixed in 4% PFA at 4°C for downstream measurement. 10-
µm frozen sections were prepared for histology study.  
CCM lesions were analyzed by scanning electron microscope and the number and size 
of the lesions were quantified by X-ray microCT as previously reported [8]. CD5-2 
localisation into CCM lesions was confirmed by in situ hybridization with the FAM-
probe specific for CD5-2.  
Human patients samples were paraffin-embedded and cut to 4-µm sections for 
downstream staining for VE-cadherin.  
Data are expressed as mean ± SEM for the indicated number of observations. P values 
were calculated as indicated in figure legends using an unpaired, two-tailed Student’s 
t-test or one-way ANOVA with Tukey correction for multiple comparisons. A P value 
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of less than 0.05 was considered significant.	For further methodological details, please 
consult SI Appendix 
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Figure Legends  
Figure 1. BlockmiR CD5-2 inhibits loss-of-CCM induced downstream signaling.  
A  (i) qPCR analysis reveals increased miR-27a in human umbilical vein endothelial 
cells (HUVEC) with CCM1 or CCM2 depleted by siRNAs (n=3). (ii) siRNA 
knockdown of KLF2 or KLF4 or both in HUVEC blocks loss-of-CCM2 induced 
expression of miR-27a (n = 4).  
B, C, D Western blot analysis of VE-cadherin and claudin-5 (B) or ICAM-1 (C) and 
phospho-p65 (D) in brain microvascular endothelial cells (hCMEC/D3) treated with 
10 nM siRNAs for scramble control (Ctrl), CCM1 or CCM2 for 4 h, followed by 
transfection of 15 nM BlockmiR CD5-2 or controls then cultured overnight. 
Molecular weights in kilodaltons are shown. Representative blots are shown (n=3-4) 
with α-tubulin or β-actin rabbit used as loading control. E.  HUVEC were treated with 
10nM siRNAs for scramble control, CCM1 or CCM2 (si-Ctrl, si-CCM1, si-CCM2) 
for 4 h, followed by transfection of 15nM BlockmiR CD5-2 or control (Ctrl) then 
cultured for 48 h. Immunostaining was performed to measure pMLC. Representative 
images are shown. Intensity of staining quantified from 3-5 images per treatment, n=3 
experiments. Bar, 60µm.  F.  mRNA levels of KLF2 and KLF4 following CD5-2 or 
control treatment in CCM1 or CCM2 depleted EC, analysed by real-time PCR 
analysis. n=3 experiments. G.  Measurement of KLF2 and KLF4 in VE-cadherin null 
EC with CCM2 depleted by si-RNAs (n=3). Quantification of immunoblots was by 
NIH Fiji ImageJ software. Data represents mean ± SEM *P < 0.05, **P < 0.01, ***P 
< 0.001, ****P < 0.001	determined by one-way ANOVA with Tukey correction. 
 
Figure 2. BlockmiR CD5-2 rescues the loss-of-CCM induced vascular 
permeability.  
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A.  CCM1 or CCM2 in hCMEC/D3 was depleted by siRNAs. Cells were then 
transfected with control BlockmiR (Ctrl) or CD5-2. Endothelial monolayer 
permeability to FITC-dextran (40KDa) was determined by measurement of 
absorbance at 490 nm (A490)(n=3). B.  Miles assay of dermal permeability in 
heterozygous Ccm1 (Tie2-Cre, Ccm1 fl/+) mice in response to PBS or VEGF after 
pretreatment with control Blockmir or CD5-2 (n=6). C.  miR-27a was up-regulated in 
EC isolated at P8 from the WT (n=9), Ccm1ECKO (n=6) and Ccm2ECKO (n=4) mice. D. 
in situ detection of CD5-2 in the blood vessels in the hindbrain of P6 Ccm2ECKO 
animal, 6 h after i.p injection of CD5-2,. The image without CD5-2 probe was used as 
background control (top). CD5-2 was detected as the color of Cyan (bottom) with EC 
stained with CD31. Bar: 50 µm (left); 10 µm (right). E.  Hindbrains photographed 
after fluorescent cadaverine injection. Bright field (top) and fluorescence image with 
555/60 nm excitation and 610/75 nm emission (bottom). Animal without cadaverin 
Alexa 555 injection was used as background (i,ii); Fluorescence from BlockmiR 
control (Ctrl) and CD5-2 treated animals was measured by stereo microscope (iii-vi) 
and quantified by Fiji imageJ software (vii). Ctrl n=5; CD5-2 n=4 from 2 litters. Bar 2 
mm.  
Values are shown as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 
0.001, determined by Student’s t test or one-way ANOVA with Tukey correction. 
 
Figure 3. BlockmiR CD5-2 rescues CCM lesions in the hindbrain of Ccm2ECKO 
mice. 
A.  Visual appearance of CCM lesions in the hindbrain of representative three P12 
Ccm2ECKO mice treated with control BlockmiR or CD5-2. Bar 1mm. B.  Composite 
microCT images of the same hindbrains shown in (A). Bar 1mm. CCM lesions are 
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shown in red. C.  Quantitation of CCM lesion by (i) total lesion volume and (ii) the 
largest lesion volume and (iii) the mean value of the largest 5 or  (iv) 20 lesions. D.  
Quantitation of lesion number. Control: 186.6 ± 26.31; CD5-2: 127.3 ± 18.44. E.  
Lesions were classified into three groups according to volume size (large: >10-2 mm3; 
medium: 10-3-10-2 mm3;	small:	<10-3 mm3). Large, control: 12.9 ± 1.6; CD5-2: 5.6 ± 
1.3; medium, control: 39 ± 4.9; CD5-2: 26.3 ± 3.5; small, control: 134.7 ± 24.0; CD5-
2: 95.1 ± 15.4 n=7 mice for control BlockmiR treated group, and n=9 mice for CD5-2 
treated group. Mice are from 4 different litters.  
Values are shown as mean ± SEM, N.S, not significant, *P < 0.05, **P < 0.01, ***P 
< 0.001, determined by Student’s t test. 
 
Figure 4. BlockmiR CD5-2 normalises CCM lesion structure in Ccm2ECKO mice. 
A  CD5-2 increases VE-cadherin expression in EC lining CCM lesion. Bar,12µm. B.		
Sample scanning electron micrographs of the blood vessels in hindbrain from mice 
that received BlockmiR Ctrl (top) and CD5-2 (bottom). Images were taken from 
multiple vessels. Two magnifications are shown: Magnification 1, approximately 
2000x, bar 10 µm; magnification 2, approximately 5000x, top bar 5 µm, bottom bar 2 
µm. (EC junctions are indicated by red arrow). C.  CD5-2 effects on ICAM-1 
expression in CCM lesion. Sections were triple-stained for DAPI (blue) or CD31 
(green), ICAM-1 (red). n=3 mice were utilized for each condition. Representative 
sections are shown. Bar, 8µm.   
Values are shown as mean ± SEM. N.S, not significant, *P < 0.05, **P < 0.01, ***P 
< 0.001, determined by Student’s t test. 
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Figure 5. BlockmiR CD5-2 decreases established CCM lesions in the hindbrain 
of Ccm2ECKO mice.  
A.  Visual appearance of CCM lesions in the hindbrain of representative three P19 
Ccm2ECKO animals treated with control BlockmiR or CD5-2. Bar, 1mm. B.  microCT 
images of the hindbrains from two mice shown in (A). CCM lesions are shown in red. 
C.  Quantitation of CCM lesion volume (normalised to 1.0 for mice that received 
control Blockmir) by total lesion volume and mean size of the largest 5 lesions. D.  
Number of lesions per brain within different size ranges.  
Values are shown as mean ± SEM. *P < 0.05, **P < 0.01, determined by Student’s t 
test. n=4. 
 
Figure 6. BlockmiR CD5-2 rescues CCM lesions in the retina of Ccm2ECKO mice. 
Representative images of whole mount retina isolated from Blockmir control and 
CD5-2 treated littermates stained with isolectin-B4.  
A.  Mice were treated at P6 and P8. Retinas were dissected at P12. Images are 
representative of 6 retinas from 3 mice (3 litters) for each treatment. Bar, 200µm. 
Quantification is given as the percentage of the marked condensed vascular plexus at 
the leading edge against the total area of the retinal vasculature. B.  Mice were treated 
at P8 and P12. Retinas were dissected at P19.  Images are representative of 10 retinas 
from 5 mice (3 litters) for each treatment. Bar, 200µm.  
Values are shown as mean ± SEM. **P < 0.01, ***P < 0.001, determined by 
Student’s t test. 						
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THE	ROLE	OF	FLUID	SHEAR	STRESS	IN	
THE	DEVELOPMENT	OF	CEREBRAL	
CAVERNOUS	MALFORMATIONS 
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INTRODUCTION 
In humans, CCM genes are ubiquitously expressed, however the development of 
CCM lesions is confined primarily to the CNS, where blood velocity is extremely 
low. The underlying mechanism responsible for the development of CCM lesions at 
selective locations remains one of the major unresolved questions in CCM pathology. 
Blood flow induced haemodynamic forces is another major factor to regulate vascular 
permeability by remodelling endothelial cell–cell junctions and the cytoskeleton. This 
suggests FSS may contribute to the pathology of CCM. In this chapter, the role of 
FSS in the CCM signalling pathways was investigated. The data generated from this 
Chapter is presented as the manuscript format submitted to BBA Molecular Basis of 
Disease 
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Abstract 
Cerebral cavernous malformations (CCMs) are vascular malformations that cause 
hemorrhagic stoke. CCMs can arise from loss-of-function mutations in any one of 
CCM1(KRIT1), CCM2 or CCM3 (PDCD10). Despite the mutation being in all 
endothelial cells the CCM lesions develop primarily in the regions with low fluid shear 
stress (FSS). Whether blood flow induced FSS contributes to CCM development is 
largely unknown. Here we investigated the role of FSS in the signalling pathways 
associated with loss of function of CCM1 or CCM2 genes.   CCM1 or CCM2-silenced 
endothelial cells were subjected to various FSS.   The results showed 1382 genes were 
deregulated under low FSS, whereas only 29 genes were deregulated under high FSS. 
Key CCM downstream signalling pathways, including increased KLF2/4 expression, 
actin cytoskeleton reorganisation and TGF-β and toll-like receptor signalling pathways 
were all highly upregulated but only under low FSS. We also show that the key known 
phenotypes of CCM lesions, such as disrupted endothelial cell junctions, increased 
inflammatory response and actin cytoskeleton reorganisation, are only exhibited in 
monolayers of CCM-silenced endothelial cells subjected to low FSS. Our data 
establish that shear stress acts as a previously unappreciated but important regulator 
for CCM gene function and may determine the site of CCM lesion development. 
 
Key Words: Cerebral cavernous malformations; Endothelial cells; Fluid hear stress; 
Inflammation; RNA sequencing,  
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Introduction 
Cerebral cavernous malformations (CCM) are vascular malformations mostly 
occurring in the areas in the central nervous system (CNS)1. Unlike brain 
arteriovenous malformations (AVMs), whish are high blood flow, the abnormal blood 
vessels in CCM have sluggish blood flow in both patients and animal models2-4. CCM 
lesions are prone to leakage, often leading to hemorrhagic stroke. Loss-of-function 
mutation in either one of 3 genes that form the CCM complex, CCM1 (KRIT1), 
CCM2, and CCM3 (PDCD10), results in the familial forms of the disease5. The CCM 
complex is essential to control vascular integrity6-8.  
One of the major unresolved questions in CCM pathology is the underlying 
mechanism for the selective locations of CCM lesions. In humans, although CCM 
genes are ubiquitously expressed, the development of CCM lesions is confined 
primarily to the CNS. In animal models mimicking human CCM disease, despite pan-
EC Ccm gene ablation, lesions form predominantly in the post-venous capillaries in 
the brain and eye, regions where blood flow is low5. These are regions with sluggish 
blood flow and low fluid shear stress (LSS). Thus LSS may be an important secondary 
event in the induction of CCM lesions9.  
Shear stress is caused by the drag force of blood flow, and plays an important role in 
the control of blood vessel growth and endothelial cell (ECs) functions10. Intriguingly, 
many of CCM downstream pathways, including KLF2/4, RhoA-ROCK and TGF-β1, 
are activated by LSS11-13. In the present study, we investigated whether shear stress 
impacts on the signalling pathways induced by CCM1 or CCM2 depletion in EC. Our 
results indicate that LSS is a prerequisite for CCM depletion-induced key downstream 
signalling pathways.    
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Materials And Methods 
Mice  
Cdh5Cre Ccm2fl/fl animals have been previously described14. Ccm2 EC specific 
knockout mice (Ccm2iECKO) were obtained by crossing Cdh5Cre  and Ccm2fl/fl mice. To 
induce ccm2 gene EC specific deletion in neonatal mice, 40µg of 4-hydroxytamoxifen 
(4OHT, Sigma Aldrich) dissolved in corn oil was injected intragastrically to pups at 
P1. The Sydney local hospital district animal welfare committee approved all animal 
protocols.  
Cell culture  
HUVECs were isolated and cultured as previously described15. The umbilical cords 
were anonymous (donors non-identifiable) and informed consent was given for their 
use. The human cerebral microvascular endothelial cell line hCMEC/D3 were 
maintained in Endothelial Cell Basal Medium-2 (Lonza, Switzerland) supplemented 
by SingleQuots Kit (Lonza)16. Cells were cultured at 37 oC in a 5% CO2 humidified 
atmosphere.  
Knockdown CCM1 and CCM2 in ECs by siRNAs  
1.1.1.1. E
Cs were seeded at 2.0 x 105 cells in gelatin-coated 6-well plate wells or 4.0x104 cells 
in fibronectin-coated straight or Y-shape IBIDI Slide (IBIDI GmbH, Germany) 
overnight. Lipofectamine:siRNA (Thermo scientific) complexes were formed by 
mixing 1.5 µL of Lipofectamine RNAiMax (Thermo scientific), diluted in 150 µL 
OptiMEM (Thermo scientific), and 1.5 µL of 10 µmol/L siRNA to control, CCM1 or 
CCM2, diluted in 150 µL OptiMEM, for 10 min. The complexes were added to 
1.2mL EBM-2 medium, and then added to cells on a plate or slide.  Cells were 
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incubated overnight, after which the medium was replaced with corresponding culture 
medium.  
In vitro Fluid shear stress 
HUVEC grew to confluence on strait or Y-shape IBIDI slides 48 h after seeding. The 
ECs were then either kept under static or exposed to various shear stress conditions 
using IBIDI pump system (IBIDI GmbH). For RNA extraction, EC were harvested 2-
24hrs after various shear stress treatments.  
Neutrophil adhesion assay 
The live-cell microscopy flow model has been described17, 18. Neutrophils were 
isolated as previously reported. Confluent endothelial monolayers with or without 
CCM1 knockdown were stimulated with 5 ng/mL TNF-α (R&D system) for 2 h prior 
to shear stress treatment. Imaging was acquired using an inverted phase-contrast 
microscope (Nikon Eclipse TE2000), connected to a Nikon Digital Sight camera. 
Neutrophils (106 cells/mL in culture medium) were infused into the Y-shape IBIDI µ-
Slide and allowed to settle for 10 min. Cells were imaged 10 min after introduction of 
2 dyn/cm2 constant shear stress. A gentle wash was given 20 min after application of 
shear stress.  Images were then taken from different spots. Neutrophils per field were 
counted by Fiji ImageJ version 2.0.0-rc-34/1.50a. 
Immunofluorescence and confocal microscopy 
For immunofluorescence stain, cells were fixed for 15 min with 4% paraformaldehyde 
at room temperature or 50/50 (v/v) methanol/acetone at -20 °C, then permeabilised for 
10 min with 0.1%Triton X-100 in Ca2+/Mg2+ phosphate-buffered saline (PBS) 
followed by 2 h blocking with 2% bovine serum albumin (BSA) before probing with 
various antibodies. Primary antibodies used were: goat polyclonal anti-VE-cadherin 
(Santa Cruz Biotechnology), rhodamine phalloidin (Life Technologies), rabbit 
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phospho-Myosin Light Chain 2 (Ser19) (Cell Signalling) and rabbit phospho-
VEGFR2 Y1175 (Cell Signalling). Secondary antibodies included anti-rabbit Alexa 
Fluor 488, anti-goat Alexa Fluor 594 (Invitrogen). Cells were mounted with ProLong 
Gold Antifade Reagent (Invitrogen). Microscopy was performed with a Leica SP5 
confocal microscopy (Leica Microsystems, Wetzlar, Germany). Images were analysed 
by using Fiji software. (Version: 2.2.2-rc-34/1.50a, NIH). 
RNA sequencing 
Total RNA was extracted from ECs using RNeasy Plus Mini Kit (Qiagen). RNA-Seq 
libraries for mRNA profiling were prepared from 1.5-5  µg total RNA using the 
NEBNext® UltraTM RNA Library Prep Kit for Illumina® (NEB, USA) following 
manufacturer’s recommendations. Library fragments were purified with AMPure XP 
system (Beckman Coulter, Beverly, USA). Library quality was assessed on the 
Agilent Bioanalyzer 2100 system. Library preparations were sequenced on an 
Illumina Hiseq4000 platform and 150 bp paired-end reads were generated. Reference 
genome and gene model annotation files were downloaded from genome website 
browser (NCBI/UCSC/Ensembl) directly. Indices of the reference genome were built 
using Bowtie (v2.2.3) and paired-end clean reads were aligned to the reference 
genome using TopHat (v2.0.12). We then used HTSeq (v0.6.1) to count the read 
numbers mapped of each gene, followed by calculation of RPKM (Reads Per 
Kilobase of exon model per Million mapped reads) of each gene based on the length 
of the gene and reads count mapped to that gene. Differentially expressed genes were 
then determined using DESeq R package (v1.12.0). The resulting P-values were 
adjusted using the Benjamini and Hochberg’s approach for controlling the False 
Discovery Rate (FDR). Genes with an adjusted P-value <0.05 and FDR<0.005 were 
assigned as differentially expressed. 
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Gene set enrichment and protein-protein interaction analysis   
Modified gene set enrichment analysis (GSEA) was used to assess functional 
significance at the level of sets of genes as previous described19. All of these potential 
targets were compared with the “c2_all” collection of curated gene sets from the 
Molecular Signatures Database (v6.1), consisting of 1077 gene sets corresponding to 
BIOCARTA (217), KEGG (186) and REACTOME (674) biological pathways. Heat 
maps were generated using the Multiple Array Viewer MeV_4_8 (version 10.2). 
Protein-protein interaction analysis of differentially expressed genes was processed by 
the web-based STRING analysis (v10.5), which contained known and predicted 
Protein-Protein Interactions. We constructed the networks by extracting the target 
gene lists from the database. 
RNA isolation and Quantification of Gene Expression Using Quantitative 
Reverse Transcription PCR 
Total RNA, including small RNA fraction was extracted from ECs using miRvana 
RNA isolation kit of Trizol15. RNA was isolated for each condition and two steps 
real-time RCR was used to measure miRNAs.  First, 1 µg of RNA was reverse 
transcribed to cDNA by using reverse transcription kit, followed by 
TaqMan probe based real time PCR (Life technologies). The relative RNA amount 
was calculated with the 2-ΔΔCT method19. All reactions were performed in 
quadruplicates and repeated in three biological replicates using Biorad real-time PCR 
machine (Biorad). 
Preparation of cell extracts and Western blotting  
Western blot analysis was performed as previously described15 Whole-cell lysates 
were prepared using lysis buffer (1 mol/L Tris.HCl, pH 7.5, with 1% NP-40, 5 mol/L  
NaCl, 200 mmol/L EGTA, 500 mmol/L NaF,100 mM Na4P2O7 containing 1x 
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protease inhibitor cocktail (Sigma). Equal amounts of protein were loaded onto a 4-
15% precast polyacrylamide gel (BioRad) and separated by electrophoresis in a 
running buffer, and then transferred to PVDF (polyvinyl difluoride) membranes in 
transferring buffer, blocked with 5% skim milk powder in PBS-Tween 20 (0.05%). 
The membranes were probed with ICAM-1 rabbit (1:1000, 4915, Cell Signaling) and 
α-tubulin (Santa Cruz) overnight at 4 °C or for 1 h at room temperature, followed by 
corresponding HRP-conjugated antibody (1:5000; Amersham, UK) for 1 h at room 
temperature. Proteins were visualized using ECL Western blotting Detection Reagents 
(GE Healthcare, Little Chalfont, UK) on ChemiDoc MP system (Bio-rad). 
Densitometric analysis was performed using ImageJ (Version 1.48, NIH, USA) 
software. 
Statistics  
All experiments were not assessed blindly. Sample size determination was based on 
previous experience with similar studies. The researchers were not blinded to the 
treatment groups when performing experiments and data assessment. Data are 
expressed as mean ± standard deviation (SD) for the indicated number of observations. 
P values were calculated as indicated in figure legends using an unpaired, two-tailed 
Student’s t-test or one-way ANOVA with Tukey correction for multiple comparisons. 
A P value of less than 0.05 was considered significant. 
Study approval 
Human umbilical cords were collected under approval from the New South Wales 
Local Sydney Health District Ethics Committees. This study was conducted in 
accordance with the Declaration of Helsinki. 	
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Results   
CCM lesions in retina occur in regions of low blood flow	 (I	 am	still	 thinking	we	may	need	this	in	vivo	data	even	though	it’s	not	novel) 
In the retina of 1-week-old P1-ablated Ccm2 endothleial specific knockout mice, 
CCM malformations present at the vein and periphery of venous plexus in retinas 5, 
20(Figure. 1). These are regions where blood flow and FSS is the low in the retina 
vasculature20-22. The arteries, where blood flow is higher, were thin and normal (Fig. 
1). Thus, loss of Ccm2 results in the abnormal vascular remodelling specifically in 
regions of low blood flow.  
CCM2-depletion induced KLF2/4 upregulation is dependent of shear stress 
magnitude  
KLF2/4 act as downstream in the CCM pathway and are essential in the development 
of CCM lesions14, 23. KLF2/4 are also widely reported as FSS induced genes12, 13.To 
investigate how FSS affects CCM-depletion induced signalling pathways, we first 
examined KLF2/4 expression in CCM2-silenced EC subjected to various FSS from 0 
to 15 dyn/cm2. HUVECs were used for this investigation as they have been widely 
used to explore the effect of FSS on ECs and loss-of-CCM induced signalling 
pathways12, 23-27. Consistent with previous reports23, 28, with CCM2 depletion, KLF2/4 
were significantly increased under static conditions (Figure 2A). Under LSS (3.5 
dyn/cm2), KLF2/4 expression were also increased although to a lesser extent than that 
under static condition (Figure 1B). There was no significant upregulation of KLF2/4 
with CCM2 depletion in cells under High FSS (HSS 15 dyn/cm2). In control ECs, FSS 
linearly induced KLF2/4 expression. In CCM2-silenced cells, maximum levels of 
KLF2/4 were induced under LSS, and the levels were not changed with a further 
increase in FSS (Figure 2C,D). This is different to the case in the high flow vascular 
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malformation disease: hereditary hemorrhagic telangiectasia, where KLF2/4 are 
significantly higher under both static and HSS22.  These results suggest a hyper-
responsiveness of KLF2/4 expression to flow in the absence of CCM2.  
Silencing of CCM2 in the context of different FSS results in distinct 
transcriptomic profiling  
The above results suggested that CCM gene loss may allow an inappropriate 
expression of genes under LSS. To test this hypothesis, we applied RNA-seq based 
transcriptomic analysis for control or CCM2-silenced EC, subjected to either LSS or 
HSS. 
As anticipated there was a marked difference in the gene expression pattern of control 
ECs between LSS and HSS conditions (comparison 1) (Figure 3A), with 1189 genes 
increased and 32 genes decreased. The regulated genes included those increased in 
ECs by HSS such as SIRT129, ITGB130 and HMGB131, and decreased in ECs 
subjected to HSS such as IGFBP732. These genes are important for proper vascular 
functions29-32. Thus, our model was detecting flow and the cells were responding in the 
anticipated manner.  
The pattern was also strikingly different between control and CCM2-silenced cells 
under LSS (Comparison 2 Figure 3A) with 1382 genes (≥2-fold change) differentially 
expressed (Figure 3B). In sharp contrast, under HSS, only 29 were differentially 
expressed (Comparison 3, Figure 3A and Figure 3C). Since KLF2 is higher in CCM2-
silenced cells under LSS but not HSS (Figure 2), the possibility existed that the 
deregulated genes under CCM2-silenced LSS maybe KLF2-regulated genes. To 
exclude this possibility, we performed a cross-validation with 373 deregulated genes 
induced by KLF2 overexpression in EC12. Of these 373 genes, only 16 of these were 
also induced under LSS (Figure 3D). This would suggest that KLF2 is not a major 
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regulator of the differentially expressed genes under LSS. Overall, these data 
demonstrates that shear stress plays a critical role in the gene profiles conferred by 
loss-of-CCM2.  
Effects of FSS on key CCM2-depletion induced pathways 
We then investigated signalling pathways for the dysregulated genes under LSS. Of 
the 1382 genes that were differentially expressed under LSS (Comparison 2), 1281 
genes were upregulated, whereas only 9 genes were up under HSS (Comparison 3) 
(Figure 4Ai). Those upregulated genes, including ROCK1/2, TGFB2, TGFBR1, 
MYCBP, ITGB1 and AKT3, are involved in CCM related pathways, such as actin 
cytoskeleton, WNT, TGFβ and VEGF signalling pathways (based on KEGG, Kyoto 
Encyclopedia of Genes and Genomes analysis) (Figure 4Ai,ii, Supplemental Table 1,2 
and Supplemental Figure 1A-C) 6, 7, 23, 33-35.  
Our approach also allowed us to discover potential pathways associated with CCM 
development. A notable result was that a large number of genes were enriched in gene 
sets involved in host-defence and inflammatory responses (Figure 4Aiii). Among these 
gene sets are Toll-like receptors, NOD-like receptors and RIG-I-like receptors 
signalling pathways, which are crucial for sensing microbiota-derived pathogens 
peptidoglycan (PGN) fragments and endogenous danger-associated molecules in the 
bloodstream36, 37; Endocytosis signalling pathway facilitating PGN across endothelial 
host barriers37; Nuclear factor κB (NF-κB) and MAPK signalling pathways involved in 
the transcriptional upregulation of pro-inflammatory and host-defence genes. These 
results are in line with a recent report showing gut microbiome contributes to CCM 
pathology where TLR4 was involved34 (Supplemental Figure 1D). Our screen has also 
identified a large number of genes that have previously not been implicated in CCM 
pathology, including the NF-κB activators TBK1 and TANK 38; XIAP, BIRC2 and 
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TAB2 involved in NOD like receptor signalling pathway for gene activation37 (Figure 
4Aiii). We have validated some of the genes identified in our screen and known to be 
involved in CCM development, including RhoA, HIF1α, TLR4 and TGFβ1 (Figure 
4B), thus confirming the validity of our screen.  
Whilst the downregulated gene numbers were less impressive there were some 
interesting changes.  101 of 1382 altered genes were downregulated under LSS (Figure 
3, Comparison 2) whereas under HSS only 20 (Figure 3, Comparison 3), with 13 genes 
in common between these two data sets (Figure 4Ci). Gene set analysis of the 101 
downregulated genes showed an enrichment in genes involved in vascular 
development and angiogenesis under both LSS and HSS (Figure 4Cii) suggesting 
CCM2 is required for vascular development regardless of the FSS magnitude. This is 
consistent with that CCM2 is required for proper assembly of head, heart and 
intersomitic vasculature 28. Further, of the 101 genes downregulated under LSS, some 
are involved in the pathways that contribute to CCM pathology, such as NOTCH1 20 
and its downstream target, HES439. In line with the loss of claudin-5 and decreased 
pericyte coverage in the EC lining CCM lesion, SOX18, a transcription factor 
regulating Claudin-5 expression40, and PDGFB, a key molecule involved in pericyte-
endothelial interaction41 are both down-regulated (Figure 4Ciii, D).  
CCM2-depletion induced RhoA-ROCK activity and actin reorganization is 
dependent on shear stress magnitude  
To further confirm FSS as an important component of the CCM-depletion induced 
phenotypes, we investigated, under different FSS, the regulation of the hallmark of 
CCM development, the increase in RhoA/ROCK activity6, 14. The RhoA-ROCK 
pathway was evaluated by staining for pMLC and evaluating stress fibre content. In 
line with previous reports6, 14, CCM2 depletion resulted in higher levels of pMLC 
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under static condition (Figure 5Aiv vs. i, and 5C). Under LSS conditions (3.5 
dyn/cm2), there was the anticipated increase in pMLC (Figure 5Aii vs. i, 5C) in 
control cells.  CCM2-silenced cells showed similar elevated levels of pMLC when the 
cells were under LSS for either 1.5 or 24hrs (Figure 5Av vs. ii, vi vs. iii, 5C). 
However, this difference disappears when cells were subjected to HSS for either 1.5 or 
24hrs (Figure 5B), with the level of pMLC staining in CCM2-silenced EC reducing to 
a level similar to control EC (Figure 5Bv, vi, 5C). Thus the changes, due to CCM2 
depletion, are only observable under LSS. Similar effects were seen for F-actin stress 
fibres (Figure 5D). Under static conditions, CCM2-depletion increased the formation 
of F-actin stress fibres (Figure 5Div vs. i)6 with the differences disappearing under 
HSS (Figure 5Dv vs. ii, vi vs. iii, 5C). Thus, HSS rescues the effects on F-actin stress 
fibres caused by CCM depletion (Figure 5Dvii), confirming the vascular protective 
effects of HSS42. 
CCM2-depletion induced ECs junction disruption and inflammatory reaction is 
dependent of shear stress magnitude  
We also investigated the other hallmarks of CCM including ECs junctional 
reorganization20, 33 and inflammation33. On the Y shape slide, FSS varies with position, 
with LSS seen in area1 and HSS in area 2 on the same slide43 (Figure 6A). In CCM2-
silenced cells under static conditions there was a weaker and disorganized ECs 
junction as shown by VE-cadherin staining (Figure 6A iv vs. i). In the LSS region 
(Area 1, predicted FSS is 0-5 dyn/cm2), the CCM2-silenced cells show wide and open 
zipper–like staining for VE-cadherin (Figure 6Av), whereas control cells show a 
smoother and continuous VE-cadherin staining, indicative of tightly apposed junctions 
(Figure 6Aii).  In contrast, in the HSS (Area 2, 15 dyn/cm2) region, both control and 
CCM2-silenced ECs showed less disruption in VE-cadherin junctional staining and 
   CHAPTER 4 
	 155	
fewer gaps (Figure 6Aiii and vi), consistent with the known effect of HSS42. Taken 
together, the results show that CCM2 is required for ECs to form tight junctions under 
LSS.  
Depletion of CCM1 or CCM2 in ECs resulted in a significant upregulation of ICAM-1 
(Figure 6B), an inflammation marker known to facilitate neutrophil adhesion and also 
regulated by FSS18. We investigated neutrophil adhesion in CCM1-silenced cells as 
knockdown of CCM1 resulted in more upregulation than CCM2 (Figure 6B), In area i 
FSS continuously increased from left to right43, and neutrophils preferentially attached 
to the CCM1-silenced ECs (Figure 6C).  In Areas ii and iii uniform laminar flow is 
seen in both areas but FSS in area ii is twice the FSS in area iii43.  ECs in HSS regions 
(area ii) captured similar numbers of neutrophils between control and CCM1-silenced 
ECs (Figure 6D). However, in LSS region (area iii), there was a significant increase in 
the number of neutrophils adherent to CCM1-silenced ECs (Figure 6D). Thus, LSS 
predisposes CCM-silenced ECs to enhanced neutrophil adhesion following stimulation 
with the inflammatory cytokine, TNF.  
Loss of CCM2 enhances mechanotransduction sensitivity under LSS 
FSS selectively upregulates ICAM-1 and downregulates VACAM-144,45. Depletion of 
CCM2 also regulates ICAM-1 and VCAM-1 in the same trend, together with KLF2/4 
(Figure 7A). Thus, there is a similarity of response in ECs to FSS and to CCM2 
depletion. Indeed, under LSS, CCM2-silenced ECs have highly comparable 
transcriptomic profiling with only 1 gene significantly differently expressed (P-value 
<0.05; FDR<0.005; ≥2-fold change) to the control ECs under HSS (Figure 3A, 
Comparison 4).  In the abnormal vessels in the lesions, the ECs are subjected to LSS. 
Thus, in the absence of CCM2, the response to LSS by the ECs are similar as if they 
are under HSS, which will be inappropriate. Since ECs sense FSS via a range of 
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molecular mechanosensors, these results indicate that loss-of-CCM may cause an 
alteration in the mechanosensing apparatus.   
FSS sensors in ECs include integrins10, PECAM1 and VEGFR246, 47, and Tie248.  Loss 
of CCM2 activated integrin β123. We then measured VEGFR2 and Tie2, to CCM2 
deletion. Under static and LSS conditions, CCM2-depletion resulted in a significantly 
increased expression of VEGFR2 and Tie-2 (Figure 7B). Although HSS further 
increase genes expression in control ECs, there was much less change in CCM2-
silenced ECs. These results indicate that CCM2 depletion may increase ECs sensitivity 
to LSS via altering mechanosensor gene expression. Acute flow treatment also triggers 
fast activation and nuclear translocation of the VEGFR2 tyrosine kinase as a response 
of ECs 49. This reaction is critical to mediate the transduction of shear-stress signals 
into ECs49. In line with increased expression of VEGFR2 (Figure 7B), CCM2-
depletion also translocated Tyr1175 VEGFR2 to the nucleus (Figure 7C), suggesting 
loss of CCM2 in ECs may sensitize the endothelium to FSS through increasing the 
levels and activity of mechanosenory complex genes.  
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Discussion 
CCM lesions occur in the brain and retina, regions of low blood flow9. Despite recent 
progress in our understanding of CCM, only a limited number of pathways have been 
identified which are involved in the development of CCM lesions 6, 14, 23, 27, 33, 34, 50, 51. 
Further, the understanding of the site-restricted development of the CCM lesions has 
not been explained. We propose that shear stress contributes to the site restricted 
development of lesions in conditions of CCM loss-of-function. In support of this, we 
demonstrate, by RNA-sequence transcriptomic analysis, that CCM-depletion under 
LSS but not under HSS induces genotypic changes consistent with CCM lesion 
development. We further show that the disrupted junctions and an enhanced neutrophil 
adhesion following CCM depletion occurred only under LSS but not under HSS. 
Finally LSS under CCM depletion facilitated changes in the expression of key 
molecules previously described in the response to flow in EC. Mechanistically, loss of 
CCM alters the expression of genes known to be mechanosensors, thus suggesting that 
the endothelium inappropriately responds to the FSS in the vessels within the regions 
of low blood flow. Our data demonstrates a new model, that loss of CCM sensitize EC 
response to LSS in the capillary-venous vessels in retina and brain52, 53.  In accordance 
with our findings, CCM1 has been shown to control the sensitivity of endothelial cells 
to hemodynamic forces during cardiovascular development. We further suggest that 
LSS is a major determinant of the development of the CCM lesions in the CNS. , 
Depletion of CCM2 in EC placed under HSS did not lead to a significant change in 
gene expression compared to control cells. This was demonstrated, under HSS, by lack 
of morphological changes in the state of the junctions and by there being only 29 
genes differently expressed between control and CCM2-silenced ECs (>2.0 fold 
change). Even when we used ≥1.5-fold change as a cut-off, there were still only 92 
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genes changed under HSS. In contrast CCM2 depletion under LSS resulted in loss of 
junctional integrity and 2034 genes were differentially regulated (>1.5 fold). Thus, in 
the loss-of-function of CCM the effect on the endothelium will be site specific, at least 
partially governed by the FSS. In arteries, where FSS is high, we predict that loss of 
CCM will not cause major phenotypic changes. In contrast, EC in brain capillaries, 
being subjected to LSS, CCM2 is essential to exert its protective effect.  
Our in vitro flow model also offers an unique tool to identify new pathways 
contributing to CCM development. Firstly, GSEA analysis (Supplementary Figure 3) 
revealed 116 of 1281 upregulated genes are involved in immune system gene set, 
suggesting a broader involvement of the immune response than previously 
considered1. Indeed, pathogen-infection and inflammation related signalling pathways 
are highly enriched in CCM2-silenced EC under LSS but not under HSS. Recently, the 
gut-bacterial triggered signalling, including but not limited to LPS-TLR4 signalling 
pathways, was shown to be a critical driver of CCM formation34. Our results suggest 
that under LSS, CCM2-depletion itself can trigger a pathogen-infection-like response 
in EC, or at least prime the endothelium towards such a response. Signals from the gut 
microbiome may then act as a second hit to strengthen the pathogen-infection like 
response in LSS areas, such as the CNS, to trigger or accelerate CCM development.   
Secondly, CCM lesions are characterised by dilated capillaries14. The RNA-seq data 
showed upregulation in the CCM2-silenced cells under LSS of many genes associated 
with outward remodelling or negative regulation of vasoconstriction, namely NOS3, 
MMP9, TWF1, HIF1A, and LEPR54-56. In contrast, PDGFB, shown to induce inward 
remodelling 57, was significantly downregulated. This could also explain the loss of 
pericyte coverage in CCM lesions since PDGFB expression contributes to the 
recruitment of pericytes to vessels41, 58, 59, 60.  
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Lastly, other pathways, including the insulin, WNT, mTOR and c-MET pathways 
were also highly regulated in CCM2-silenced ECs under LSS but not under HSS 
suggesting their involvement in CCM mediated signalling. Further studies to confirm 
these pathways and also the scope of the immune response in CCM pathologies are 
required. 
Collectively, our data demonstrates that depletion of CCM may reset the response of 
ECs to LSS in part through altering the mechanosensory complex. Indeed, the CCM 
complex has been shown to be directly linked to key mechanosensory complex 
molecules such as VE-cadherin and VEGFR28, 61. We would argue that CCM2 is 
essential for this complex to fine-tune its activity and respond appropriately to the LSS 
that is seen in the capillary-venous vessels in retina and brain52, 53. Thus, our results 
suggest that the LSS that is seen in the CNS, in the absence of a functional CCM 
complex, contributes to the site-restricted development of CCM lesions. 
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Legend 
Figure 1. Effects of blood flow on the development of retinal CCMs under 
impaired Ccm2 signaling.  
Representative images of P12 retinas stained with isolectin B4 to identify blood 
vessels in control (WT) and Ccm2iECKO  mice after tamoxifen treatment at P1.	 A: 
artery, V: vein. CCM lesions are the areas marked by red circles. Shear stress is higher 
in the area close to the optic nerve and decreases towards the periphery of the vascular 
plexus. Scale bars, 100 µm. 
 
Figure 2. Upregulation of KLF2/4 is dependent of shear stress magnitude. (A) 
KLF2 and KLF4 expression were significantly higher in CCM2-silenced EC under 
static and low FSS but not under high FSS. Expression levels were compared with the 
levels of control EC under indicated FSS. n=4-5 independent experiments.  (B) KLF2 
and (C) KLF4 expression in control (si-Ctrl) and CCM2-silenced EC (si-CCM2) at 
different FSS condition. Expression was normalized to the level in control EC under 
static condition. n=4-5 independent experiments with a representative experiment 
shown in (B) and (C). Data in (A) represents mean ± SD *P < 0.05, **P < 0.01, ***P 
< 0.001, N.S: not significant, determined by one-way ANOVA with Tukey correction 
 
Figure 3. Silencing of CCM2 under different FSS results in distinct 
transcriptomic profiling. (A) Heatmap representing gene expression level. Red 
denotes genes with high expression levels, and blue denotes genes with low expression 
levels. (B and C) Cuffdiff analysis showing the differentially expressed genes 
between control and CCM2-silenced EC under LSS (B) and HSS (C). Green, red, and 
blue correspond to genes with >2 log2-fold differential expression, >1 log2-fold 
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differential expression, and <1 log2-fold differential expression, respectively. The x-
axis shows the fold change in gene expression between different samples, and the y-
axis shows the statistical significance of the differences. Significantly up and down 
regulated genes are highlighted in red and green, respectively. Genes that were similar 
in expression between treatment group and control group are in blue. (D) Venn 
diagram of differentially expressed genes in common between genes induced by KLF2 
overexpression and by CCM2 depletion under LSS. The numbers in each circle is the 
total number of genes expressed within a group, and the overlap represents the genes 
expressed in common between groups.  
 
Figure 4. Pathways and genes deregulated in CCM2-silenced EC. (A) Venn 
diagrams showing the number of genes upregulated under LSS and HSS (i). Hallmark 
gene sets/pathways enriched for upregulated mRNAs in CCM2-silenced EC under 
LSS(ii, iii).  (B) The mRNA expression of RhoA, HIFa, TLR4 and TGFBR1 was 
quantified by real-time PCR.  (C) Venn diagrams showing the number of genes 
downregulated under LSS and HSS(i). Common hall-mark gene sets enriched in 
CCM2-silenced EC under both LSS and HSS (ii). Key downregulated genes under 
LSS. (D) PDGFB mRNA and protein expression in CCM2-silenced EC under 
static/LSS and HSS condition.  
 
Figure 5. CCM2-depletion induced RhoA activity is dependent on shear stress 
magnitude. RhoA activity as shown by staining of pMLC under LSS (A) or HSS (B). 
(C) Quantification of phospho-MLC intensity in (A) and (B). (D) Phalloidin staining 
for cellular actin fibers after static or HSS treatment. Results are representative of 
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three independent experiments. Scale bars, 60 µm. Data represents mean ± SD *P < 
0.05, **P < 0.01, N.S: not significant, determined by Student’s t test. 
 
Figure 6. CCM2-silenced induced disruptive EC junctions and CCM1-silenced 
enhanced inflammation are dependent on shear stress magnitude. 
(A) ECs with or without CCM2 depletion were plated on Y-shape slide. Area 1 and 2 
show areas that are LSS and HSS, respectively. VE-cadherin was used as an indicator 
of EC junctional integrity. Results are representative of 3 independent experiments. 
Scale bars, 60 µm. (B) Western blot analyses of ICAM-1 expression. Quantification of 
n=4 independent experiments. (C) Microscopic images at the 45 degree branching area 
(area i) showing neutrophils adhering to hCMEC/D3 with CCM1-silenced as assessed 
by in vitro adhesion assay. Red circle indicates neutrophils. (D) Neutrophil adhesion 
was quantified by number of adherent neutrophils per field of view at uniform laminar 
but at 100% (area ii) and 50% (area iii) flow velocity region in ibidi flow chambers. 
Scale bars, 60 µm. Means ± SD of 3 experiments reflect neutrophil counts from 5 
fields per well. **P < 0.01, ***P < 0.001, N.S: not significant, determined by 
Student’s t test. 
 
Figure 7. Loss of CCM2 gene modulates molecular mechanosensor and enhances 
mechanotransduction sensitivity under LSS. (A) Genes are similarly regulated by 
CCM2-depletion and FSS. (B) qPCR measurement of TIE-2 and VEGFR2 in control 
and CCM2-silenced EC under low and high FSS. (C) p-VEGFR2 staining in ECs 
treated with siRNA to control and CCM2. Scale bars, 60 µm. Representative images 
are presented. n=3 independent experiments. Data represent mean ± SD.  *P < 0.05, 
**P < 0.01, determined by Student’s t test. 
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Supplementary Legends 
S-Figure 1. String analysis of upregulated genes in CCM2-depleted ECs under 
LSS. 
Analysis reveals interaction among genes involved in regulation of actin cytoskeleton, 
VEGF signaling pathway, TGFβ and Toll like receptor signaling pathway. 
S-Table 1. GSEA analysis of differently expressed gene sets/pathways in CCM2- 
depleted ECs under LSS. 
S-Table 2. Dysregulated genes between control and CCM2-depleted ECs 
under LSS. 
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Vascular integrity is essential for the vasculature development and homeostasis1. It is 
finely tuned by a large number of factors comprising extracellular mediators like fluid 
shear stress2, 3, inflammatory4 and angiogenic factors5, and intracellular signalling 
including contractile forces generated by actinomyosin6, 7 and signallings triggered by 
phosphorylation and cleavage of EC junction molecules5, 8-11. These factors affect 
vascular integrity majorly though affect EC behaviour and function, especially 
alteration of vascular permeability via disrupting endothelial junctions. Recently 
miRNAs are emerging as a new regulator of vascular integrity through regulating 
aforementioned factors, of particular interest in this thesis, EC junction molecule12-20.  
The current work explored the role of miRNA and shear stress in the regulation of 
vascular integrity and developed novel miRNA-based therapeutics for cerebral 
cavernous malformation, a disease associated with abnormal vascular integrity.  
Chapter 2 of this thesis included my investigations into the role of miR-23-27-24 
cluster in the regulation of vascular integrity. We previously showed this cluster is 
down regulated in the early stage of angiogenesis21.  The results in this chapter 
indicate their predicted targets were enriched in EC junction molecules. We have 
focused on two of these miRNAs, miR-27a, where we have shown it directly targeted 
VE-cadherin to regulate vascular integrity21. The role of miR23 in the regulation of 
vascular integrity was then explored here. MiR-23 includes miR-23a and miR-23b, 
which share an identical seed region with a single nucleotide difference at g19 (No.19 
nucleotide from 5’end). Conventional theory suggests miRNAs recognise their target 
through the seed region22, 23 and thus the paralogues of the miRNA which have the 
identical sequence should have the same target specificity. Surprisingly, miR-23a and 
miR-23b functioned differently in the regulation of vascular permeability and 
angiogenesis. MiR-23a preferentially targeted JAM-C to regulate angiogenesis, while 
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miR-23b preferentially targeted ZO-1 to regulate vascular permeability. There is now 
increasing evidence in a number of different systems, with a number of different 
miRNA that miRNAs with identical seed region have different functions24, 25. MiRNA 
recognises and binds to the target mRNA via the seed region. However, nucleotides at 
the 3’-end of the miRNA may also contribute to target recognition and binding 
through partial complementarity 22, 26. Luciferase reporter assay showed that miR-23a 
mimic had more inhibition on JAM-C 3’UTR reporter activity than miR-23b, 
suggesting the binding between miR-23a and JAM-C was stronger than that between 
miR-23b and JAM-C.	 The	 difference	 could	 be	 due	 to	 a loop out, caused by this 
single nucleotide difference, between miR-23b and its binding site in the 3UTR of 
JAM-C, since mutating g19 binding site of miR-23b in the 3UTR of JAM-C 
restores identity. Thus, a single nucleotide difference between miR-23a and miR-23b 
outside the seed region leads to different affinities between miR-23a or miR-23b and 
their target. These results are consistent with recent structural and functional studies27 
showing contributions from nonseed sequences in miRNA function and affinity for 
Ago2.  
The three important points from this chapter and the paper published in Mol Ther 
Nucleic Acids. 2016 Aug 23;5(8):e354.  
1. The miR23-27-24 cluster may function in endothelial cells as a major 
junctional “operon”  
2. MiRNAs that have the same seed sequence do not necessarily have the same 
target genes in the same cell. It is also possible that the individual miRNAs may 
switch targets based on the cellular context. 
3. Two paralogues of miRNAs can be differentially regulated. 
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There is strong evidence to show these are important considerations given that 
miRNAs, especially miRNA inhibitors, are being developed as therapeutics. One of 
the ways to overcome this complexity that may impact on the efficacy of therapeutics 
is to develop miRNA specific inhibitors, which can distinguish miRNAs with single 
nucleotide differences outside the seed region. However, antagomiRs such as LNA, 
and as a general rule regardless of the miRNA, cannot discriminate between the 
paralogues. An alternate inhibitor is a target site blocker, that rather than binding to 
miRNA to inhibit function, binds to the binding site on a miRNA target. 
Consequently, these inhibitors block the interaction between a miRNA and a specific 
target, leading to more restricted regulation. Such an inhibitor is our Blockmir, CD5-2. 
MiR-27 has been confirmed to target VE-cadherin, a major adherens junction 
molecule that plays a critical role in the regulation of vascular integrity28, 29. We have 
developed a target site blocker, using the Blockmir technology developed by our 
collaborator, MirrX Therapeutics in Denmark. BlockmiR CD5-2 specifically prevents 
miR-27a binding to the VE-cadherin 3’UTR. CD5-2 also fails to engage the RISC and 
thus prevents VE-cadherin degradation.  When miR-27 is expressed in endothelial 
cells, CD5-2 prevents its interaction with VE-cadherin, and thus increases VE-
cadherin expression21.  
Cerebral Cavernous Malformations (CCM) are featured by abnormal vascular integrity 
in the affected lesions. At present there is no effective treatment other than surgery, 
which is restricted by the size and depth of the lesions. Indeed, a number of CCM 
downstream signalling pathways are reported to be orchestrated by VE-cadherin. This 
makes VE-cadherin a potential target and BlockmiR CD5-2 a novel therapeutic for the 
treatment of CCM. 
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Chapter 3 explored the possibility that BlockmiR CD5-2 could be used to treat CCM. 
We noted a reciprocal expression of miR-27a and VE-cadherin. VE-cadherin was 
decreased and delocalised in the EC lining of CCM lesions whereas miR-27a was 
upregulated in the ECs isolated from neonatal CCM mice brain. In vitro experiments 
showed that increasing VE-cadherin expression in CCM2-depleted ECs rescued 
vascular permeability, inflammatory response and RhoA activity. Application of 
BlockmiR CD5-2 in CCM neonatal mice inhibited nascent lesions and most 
importantly for the potential of CD5-2 to be a therapeutic, it also inhibited existing 
lesions. Consistent with the target of CD5-2 and the importance of it in lesion 
development, CD5-2 resulted in an increase in VE-cadherin expression and interrupted 
a subset of signalling pathways in CCM.  
Delivering drugs to the CNS is difficult since they must cross the blood–brain 
barrier30. However, PS-oligonucleotides have been used to modulate CNS proteins, 
with the ability to cross the BBB31, 32.. Nevertheless, a drug for CCM that targets the 
endothelium and is not required to pass the BBB to take effect is beneficial. Recent 
reports suggested that CCM formation is driven by the signalling on the luminal, blood 
side of the blood–brain barrier (BBB)33. CD5-2 increases VE-cadherin in EC lining 
CCM lesions and functions without the need to actually cross the BBB. Our study 
further supports this idea since VE-cadherin is only expressed in ECs, the lining of the 
luminal side of blood vessel. Thus, this study opens the possibility of the development 
of combinations of therapeutics that target the endothelial cells providing better 
efficacy. Such a combination could be CD5-2 in combination with drugs that directly 
regulate targets other than EC junctions for the treatment of CCM34 for example RhoA 
kinase inhibitors and TSP1 reconstitution.  
Overall this chapter provided increased evidence of the potential utility of microRNA-
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based drugs for the treatment of diseases associated with abnormal vascular integrity 
such as CCM. There are three important points: 
1. Loss of VE-cadherin orchestrates a number of key CCM downstream 
signalling pathways.  
2. BlockmiR CD5-2 is able to rescue key CCM downstream signalling and inhibit 
existing as well as nascent lesions through increasing VE-cadherin expression. Thus 
VE-cadherin is a ‘druggable’ target for CCM disease. 
3. MicroRNA-based drugs possess unique advantages for the treatment of disease 
with abnormal vascular integrity. 
Increased vascular permeability is a hallmark for many vascular diseases. The effect of 
CD5-2 on inhibiting vascular permeability and restoring vascular integrity suggest it 
may have potential to benefit other disease with abnormal vascular integrity. 
In diabetic retinopathy, blood-retinal barrier is breakdown. To explore its potential 
efficacy for diabetic retinopathy, CD5-2 has been tested in three mouse models of 
retinal dysfunction (Ting et al In press. Diabetologia 2018). Our results show that 
CD5-2 is able to penetrate the vasculature of the eye in these animal models and 
enhance expression of VE-cadherin, resulting in reduction in vascular leak and 
improvement in pericyte coverage of retinal vasculature. These results indicate that 
CD5-2 has the potential to be used in a broad range of diseases with abnormal 
vascular integrity 
In the current study, BlockmiR CD5-2 was given to animals through i.p. injection 
without formulation. Although the pharmacological effect of CD5-2 is promising, at 
present we have only limited information about its toxicity and PK/PD. VE-cadherin 
is widely expressed in all blood vessels. One would argue whether CD5-2 has an 
effect on normal blood vessels and compromise their function. At least in the case of 
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CCM, wild type mice treated with CD5-2 show no obvious change in the blood vessel 
density in the brain and retina. We have not checked the other organs. However, it 
could be argued that CD5-2 will be ineffective unless miR-27a is present. Studies for 
our work and through the literature suggest that miR-27a is expressed at very low 
levels in homeostasis but is highly upregulated during disease. This would suggest 
that CD5-2 may only be functional during disease. Commercial development of CD5-
2 will require toxicity studies involving multiple doses and long-term treatment.  
To translate CD5-2 into the clinic, future studies will focus on:  
1. Investigating the biodistribution of CD5-2 
2. Alternative oligonucleotide design of CD5-2 to achieve better uptake in vivo 
and lower renal and hepatic toxicity. 
3. Exploration of other routes for injection such as local administration to the 
CNS. This could increase local drug concentration in the CCM lesion area, avoid 
toxicity to other organs and tissues and minimise potential immunostimulatory effects.  
In humans, although CCM genes are ubiquitously expressed, the development of CCM 
lesions is confined primarily to the CNS, where blood velocity is extremely low35. 
Blood flow induced haemodynamic forces is another major factor to regulate vascular 
permeability by remodelling endothelial cell–cell junctions and the cytoskeleton36. 
This suggests FSS may contribute to the pathology of CCM. 
Chapter 4 investigated how FSS affects CCM signalling pathways. An in vitro flow 
system was established to mimic the high and low blood flow areas of the body. Under 
LSS, depletion of CCM2 induced over 1,300 genes differently expressed compared 
with control ECs. These deregulated genes were enriched in known key genes in 
pathways critical for CCM development. In comparison, under HSS, there were less 
than 30 genes deregulated. These results strongly support the idea that LSS is required 
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for CCM loss-of-function mutation to induce the effect in ECs. In addition to the effect 
on gene expression, FSS also affects the key phenotypes caused by CCM gene 
mutation including cytoskeleton reorganisation, disruptive EC-EC junction and 
increasing inflammatory response. Further studies indicate loss of CCM2 induced 
similar response in EC to that induced by FSS. These effects were initiated through 
regulation and activation of mechanosensory complex molecules.  
CCM proteins are important for maintenance of vascular integrity37, 38. Since junction 
molecules are used by EC to sense flow, one would imagine that loss of CCM might 
disrupt the endothelial respond to flow. Our model suggests that loss of CCM actually 
enhances EC response to FSS via multiple pathways. Indeed, acute increases in FSS 
disrupts EC junctions, whereas prolonged FSS protects vascular integrity 39, 40. On the 
other hand, loss of CCM activates EC and makes them respond to FSS as if they are 
under constantly changed FSS. This may lead to vessel dilation. Under normal 
structural conditions, blood vessels are able to maintain their response to flow. 
However, with loss of CCM, the structural changes such as loss of pericyte renders the 
vessels fragile, vessel dilation is compromised, ultimately leading to vascular leak. 
FSS on EC modulates mechanical tension across VE-cadherin and PECAM-1 to 
trigger intracellular signalling41. My work suggests that CCM2 is required for EC to 
correctly sense LSS. To further this study the ideal system would be to use FRET-
based tension sensors for VE-cadherin and PECAM-142 to determine whether deletion 
of CCM2 alters the mechanical tension across VE-cadherin and PECAM-1 in ECs 
under LSS but not under HSS stimulation.  
Overall this chapter revealed a previously unappreciated role for FSS in CCM 
pathology. However mechanistic studies of the influence of shear stress on the 
endothelial barrier function and other loss-of-CCM behaviour of ECs have been 
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challenging in vivo43. A three-dimensional biomimetic vascular model has been used 
as an alternative way to investigate how FSS influences EC function including 
angiogenesis, barrier integrity and interaction with pericytes43-46. They showed HSS is 
beneficial for barrier integrity and promotes pericyte coverage. In addition, there is a 
FSS threshold for angiogenic sprouting to take place. This 3D vascular model of 
perfused microvessels would be ideal in order to confirm the following effects exerted 
by steady perfusion at higher flow rates on CCM1 or CCM2 depleted ECs: 
1. Whether flow promotes the establishment of a functional vascular barrier with 
more stable AJs, which are resistant to leakage and sensitive to known permeability 
factors like VEGF43. 
2. Whether flow promotes adhesive interactions between endothelial and mural 
cells and impacts on vascular barrier function44.  
3. Whether flow inhibits angiogenic sprouting. 
Further, since BlockmiR CD5-2 was shown to inhibit CCM lesions, it would be of 
interest to determine whether CD5-2 mimics such flow effects in the 3D vascular 
model. 
Summary: 
Collectively the studies in this thesis have demonstrated that the poly-cistronic miR-
23-27-24 complex targets endothelial cell junctions with differential functional and 
molecular effects of miR-23a and miR-23b. Blocking interaction between miR-27 and 
VE-cadherin restores endothelial junctional integrity to rescue cerebral cavernous 
malformation. In addition, LSS was shown to play a previously unappreciated role in 
CCM pathology. 
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